Aung T, Churei H, Hayashi K, Tsuchiya K, Sasaki K, Tanabe G, Ueno T, Fueki K. Development of a device for continuous salivary pH measurement at two locations in the oral cavity. Journal of prosthodontic research. 2026.07; 70 (3): 414-423. ( PubMed, DOI )

Tanaka K, Shimomura A, Ishitobi M, Yamanaka T, Tsukioki T, Iwata H, Hara F, Fujisawa T, Sasaki K, Sadachi R, Kajikawa R, Sakai T, Sagara Y, Shigematsu H, Ozaki Y, Nozawa K, Sudo K, Naito Y, Terata K, Ishiba T, Fukuda H, Shien T. Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017. Breast cancer (Tokyo, Japan). 2026.07; 33 (4): 829-838. ( PubMed, DOI )

Tachibana H, Matsuura K, Onimaru R, Yoshida D, Kobayashi T, Ueda T, Nakahira M, Ohkoshi A, Omura G, Mukaigawa T, Katagiri K, Asakage T, Shinomiya H, Ito F, Asada Y, Beppu T, Fujii T, Hirayama Y, Tsukahara K, Saito Y, Ichikawa K, Uemura H, Tahara M, Hanai N, Kiyota N, Iwamoto S, Sasaki K, Mizusawa J, Fukuda H, Homma A, JCOG Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG). Superselective intra-arterial chemoradiotherapy for maxillary sinus squamous-cell carcinoma: results from the T4bN0M0 cohort of JCOG1212. ESMO open. 2026.07; 11 (8): 108336. ( PubMed, DOI )

Kanehira S, Ota Y, Sonobe K, Ichimura N, Okamoto K, Gu Y, Sasaki K, Saito R. Draft genome sequence of a multidrug-resistant Streptococcus agalactiae sequence type 1665 strain isolated from ascitic fluid. Microbiology resource announcements. 2026.06; e0041226. ( PubMed, DOI )

Nguyen D, Kantarjian HM, Bidikian A, Manuel CM, Qiao W, Ning J, DiNardo CD, Kadia TM, Daver N, Borthakur G, Jabbour E, Yilmaz M, Maiti A, Sasaki K, Montalban-Bravo G, Chien K, Hammond D, Pierce S, Andreeff M, Ravandi F, Short NJ, Garcia-Manero G, Issa GC. Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026.06; ( PubMed, DOI )

Duan C, Yu Z, Li X, Sakai M, Maejima Y, Shimomura K, Furuyashiki T, Kikuchi S, Kobayashi N, Sasaki K, Matsuki T, Komatsu H, Hino M, Kunii Y, Kasahara T, Ishikuro M, Murakami K, Orui M, Abe T, Nagami F, Fuse N, Ogishima S, Kinoshita K, Yamamoto M, Nakaya N, Hozawa A, Obara T, Kuriyama S, Tomita H. Sex differences in the risk of autistic-related traits in toddlers born to mothers with perinatal depression: Evidence from human cohort and mouse study. Molecular psychiatry. 2026.06; 31 (6): 3229-3242. ( PubMed, DOI )

Myelodysplastic syndrome with concomitant SF3B1 mutation and deletion of chromosome 5 long arm: outcomes and response to treatment. 2026.05; ( PubMed, DOI )

Outcomes of patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia following solid organ transplantation. 2026.05; ( PubMed, DOI )

Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL. 2026.05; ( PubMed, DOI )

Takada R, Fujita H, Sasaki K, Iwase T, Sakurai T, Oura H, Morishima T, Nishisaka F, Shibanuma N, Kadowaki M, Katayama N, Otsuka H. Incidence of periprosthetic femoral fracture after total hip arthroplasty using the exeter stem: A retrospective multicenter cohort study in Japan. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association. 2026.05; ( PubMed, DOI )

Sasaki K, Ishiba T, Nishibuchi I, Hara F, Sekino Y, Machida R, Shibata T, Kawahara D, Sagara Y, Naito Y, Terata K, Ozaki Y, Shimomura A, Sakai T, Shigematsu H, Sudo K, Nozawa K, Yoshimura M, Shikama N, Mizowaki T, Shien T. A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110). Japanese journal of clinical oncology. 2026.05; 56 (5): 659-665. ( PubMed, DOI )

Ishitobi M, Tanaka K, Shimomura A, Yamanaka T, Tsukioki T, Iwata H, Hara F, Fujisawa T, Sasaki K, Kajikawa R, Sakai T, Sagara Y, Shigematsu H, Ozaki Y, Nozawa K, Sudo K, Naito Y, Terata K, Ishiba T, Fukuda H, Shien T. Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized clinical trial. The British journal of surgery. 2026.05; 113 (5): ( PubMed, DOI )

Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis. 2026.04; 101 (7): 1717-1722. ( PubMed, DOI )

Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trial 2026.04; ( PubMed, DOI )

Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms. 2026.04; 40 (4): 841-844. ( PubMed, DOI )

Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. 2026.04; 40 (4): 856. ( PubMed, DOI )

A Case Report of Tyrosine Kinase Inhibitor Interruption in a Patient with Multilineage Philadelphia Positive Acute Lymphoblastic Leukemia. 2026.03; 1-8. ( PubMed, DOI )

Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes 2026.03; 16 (1): ( PubMed, DOI )

Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis. 2026.03; 26 (5): e678-e682.e1. ( PubMed, DOI )

Shigematsu H, Fujisawa T, Hara F, Iwata H, Ishiba T, Ozaki Y, Sakai T, Sagara Y, Shimomura A, Sudo K, Terata K, Naito Y, Nozawa K, Sasaki K, Mitome N, Sadachi R, Shibata T, Shien T. Clinical complete response and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy aimed at omission of surgery: an exploratory analysis of the JCOG1806 trial. International journal of clinical oncology. 2026.03; 31 (3): 528-536. ( PubMed, DOI )

BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. 2026.02; 40 (2): 304-313. ( PubMed, DOI )

Corrigendum to "Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group" [Modern Pathology. 2024;37(2):100406]. 2026.02; 39 (2): 100952. ( PubMed, DOI )

Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor. 2026.02; 147 (23): 2809-2820. ( PubMed, DOI )

Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. 2026.01; 10 (1): e70289. ( PubMed, DOI )

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia 2026.01; 147 (5): 547-556. ( PubMed, DOI )

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. 2026.01; 40 (1): 262. ( PubMed, DOI )

Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia 2026.01; 67 (1): 220-224. ( PubMed, DOI )

Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia. 2025.12; 9 e2500494. ( PubMed, DOI )

Araki J, Mori K, Yasunaga Y, Nakagawa M, Onitsuka T, Yurikusa T, Kimata Y, Sakuraba M, Higashino T, Hyodo I, Ishida K, Miyamoto S, Takanari K, Sasaki K, Arikawa M, Umezawa H, Kadota H, Matsumoto H, Tanaka K, Fujii M, Hamahata A, Kubo T, Yanagisawa D, Kurosawa K, Umekawa K, Iida T, Sarukawa S, Migita H. Functional Outcomes after Subtotal/Total Glossectomy with Microsurgical Reconstruction: A Multicenter Prospective Observational Study in Japan. Annals of surgical oncology. 2025.11; 32 (12): 9198-9213. ( PubMed, DOI )

Sasaki K, Sasaki T, Yamamoto A, Sekiguchi T, Wakabayashi Y. Functional Recovery of Posterior Interosseous Nerve Injury Treated With a Nerve Conduit: A Case Report. Cureus. 2025.05; 17 (5): e83303. ( PubMed, DOI )

Nozawa H, Ito S, Sasaki K, Murono K, Emoto S, Yokoyama Y, Yamauchi S, Kinugasa Y, Ajioka Y, Ishihara S. Role of Adjuvant Chemotherapy After Surgical Resection of Paraaortic Lymph Node Metastasis from Colorectal Cancer-A Multicenter Retrospective Study. Annals of surgical oncology. 2025.04; 32 (4): 2282-2291. ( PubMed, DOI )

Shinomiya H, Matsuura K, Onimaru R, Ohkoshi A, Saito Y, Tachibana H, Shiga K, Ueda T, Asada Y, Uemura H, Beppu T, Seto A, Yasumatsu R, Nakahira M, Omura G, Asakage T, Minami S, Fujii T, Hirayama Y, Yoshida D, Nakamura K, Sasaki K, Mizusawa J, Fukuda H, Homma A, Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG). Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy for locally advanced maxillary sinus cancer (JCOG1212): final analysis. International journal of clinical oncology. 2025.03; 30 (3): 489-496. ( PubMed, DOI )

Fueki K, Manabe Y, Sasaki K, Kimoto K, Hashimoto M, Ueda T, Utsumi K, Ishikawa T, Baba K, Ikeda M, Kuboki T. Medical-dental collaboration on an exploratory research project on the correlation between cognitive and oral function: The ECCO project. Journal of prosthodontic research. 2025.01; 69 (1): 1-3. ( PubMed, DOI )

Causes of death in patients with myelodysplastic syndrome and spliceosome mutations. 2024.11; 147 107612. ( PubMed, DOI )

Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial. 2024.10; 20 (38): 1-11. ( PubMed, DOI )

Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients 2024.02; 65 (3): 378-382. ( PubMed, DOI )

Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. 2024.02; 11 (3): e186-e195. ( PubMed, DOI )

Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups 2024.02; 99 (4): 792-796. ( PubMed, DOI )

Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax 2024.02; 30 (7): 1319-1326. ( PubMed, DOI )

Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial 2024.02; 99 (5): 836-843. ( PubMed, DOI )

Outcomes of Patients with<i> IDH1</i>-Mutated Myeloid Neoplasms Treated with Olutasidenib 2024; 26 (2): e223-e228.e3. ( PubMed, DOI )

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission 2024; 143 (5): 417-421. ( PubMed, DOI )

Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: a Report From the BCR::ABL1 Pathology Group. 2023.12; 37 (2): 100406. ( PubMed, DOI )

Early mortality after chemotherapy as a quality indicator—the leukemia perspective 2023.12; 13 (1): 176. ( PubMed, DOI )

Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes. 2023.12; 79 (2): 297-306. ( PubMed, DOI )

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression 2023.12; 38 (3): 545-556. ( PubMed, DOI )

Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes. 2023.11; 10 (11): e872. ( PubMed, DOI )

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era 2023.10; 98 (10): 1619-1626. ( PubMed, DOI )

Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure 2023.10; 98 (10): E281-E284-E284. ( PubMed, DOI )

Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants 2023.09; 98 (11): 1780-1790. ( PubMed, DOI )

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation 2023.09; 98 (9): 1383-1393. ( PubMed, DOI )

The role of therapy in the outcome of patients with myelofibrosis 2023.09; 129 (18): 2828-2835. ( PubMed, DOI )

Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. 2023.09; 129 (23): 3805-3814. ( PubMed, DOI )

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. 2023.09; 13 (1): 148. ( PubMed, DOI )

Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia 2023.08; 23 (12): 905-910. ( PubMed, DOI )

Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results 2023.08; 23 (11): e369-e378-e378. ( PubMed, DOI )

FIGURE 1 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma 2023.08; 3 (8): 1435-1446. ( PubMed, DOI )

Myeloid lineage switch in <i>KMT2A-</i>rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies. 2023.08; 109 (1): 293-297. ( PubMed, DOI )

Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. 2023.08; 29 (21): 4352-4360. ( PubMed, DOI )

Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia 2023.08; 203 (4): 581-592. ( PubMed, DOI )

Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia. 2023.07; 142 (19): 1647-1657. ( PubMed, DOI )

ROS1 alterations as a potential driver of gliomas in infant, pediatric, and adult patients. 2023.07; 36 (11): 100294. ( PubMed, DOI )

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. 2023.06; 7 (11): 2378-2387. ( PubMed, DOI )

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results 2023.05; 37 (5): 1048-1059. ( PubMed, DOI )

Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results 2023.05; 23 (10): 742-748. ( PubMed, DOI )

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. 2023.05; 10 (6): e433-e444-e444. ( PubMed, DOI )

Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution 2023.05; 99 (2): 329-330. ( PubMed, DOI )

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. 2023.05; 16 (1): 44. ( PubMed, DOI )

Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in <i>ABL</i> Class Rearrangements. 2023.05; 7 e2200707. ( PubMed, DOI )

Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements. 2023.04; 98 (4): E91-E94-E94. ( PubMed, DOI )

Management of chronic myeloid leukemia in 2023 – common ground and common sense 2023.04; 13 (1): 58. ( PubMed, DOI )

Optimizing Treatment Options for Newly Diagnosed Acute Myeloid Leukemia in Older Patients with Comorbidities 2023.04; 15 (8): ( PubMed, DOI )

PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia 2023.04; 127 107044. ( PubMed, DOI )

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. 2023.03; 37 (3): 617-626. ( PubMed, DOI )

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). 2023.03; 108 (9): 2331-2342. ( PubMed, DOI )

Association between bariatric surgery and outcomes in chronic myeloid leukemia. 2023.03; 129 (12): 1866-1872. ( PubMed, DOI )

Early Caffeine Therapy on the Prevention of Severe Hyperkalemia in Preterm Infants. 2023.03; 65 (1): e15526. ( PubMed, DOI )

Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. 2023.03; 98 (3): 493-501. ( PubMed, DOI )

Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. 2023.03; 129 (12): 1856-1865. ( PubMed, DOI )

Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. 2023.03; 7 (13): 3284-3296. ( PubMed, DOI )

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. 2023.03; 7 (6): 933-942. ( PubMed, DOI )

A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. 2023.02; 129 (4): 560-568. ( PubMed, DOI )

Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring 2023.02; 64 (3): 746-749. ( PubMed, DOI )

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. 2023.01; 29 (1): 115-126. ( PubMed, DOI )

Current Understanding of DDX41 Mutations in Myeloid Neoplasms. 2023.01; 15 (2): ( PubMed, DOI )

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1 2023; 37 (6): 1336-1348. ( PubMed, DOI )

Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations 2023; 37 (6): 1397-1400. ( PubMed, DOI )

Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib 2023; 26 (1): 915-923. ( PubMed, DOI )

The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors 2023; 98 (4): 658-665. ( PubMed, DOI )

Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor 2023; 98 (4): 639-644. ( PubMed, DOI )

Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia 2023; 129 (7): 1017-1029. ( PubMed, DOI )

A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies 2022.11; 140 11830-11832. ( DOI )

Aplastic anemia following the severe acute respiratory syndrome coronavirus-2 vaccine. 2022.11; 4 (1): 288-90. ( PubMed, DOI )

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. 2022.11; 36 (11): 2729-2733. ( PubMed, DOI )

A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA 2022.11; 140 6739-6741. ( DOI )

A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph plus ) Acute Myeloid Leukemia (AML) 2022.11; 140 3880-3882. ( DOI )

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia 2022.11; 140 3253-3255. ( DOI )

A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow- 2022.11; 140 9005-9007. ( DOI )

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure 2022.11; 140 6206-6208. ( DOI )

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI) 2022.11; 140 6784-6786. ( DOI )

Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1 2022.11; 140 5860-5861. ( DOI )

Homologous Recombination DNA Repair Deficiency Score Is Independent Prognostic Variable in Myelodysplastic Syndrome/ Acute Myeloid Leukemia with Complex Karyotype 2022.11; 140 1353-1354. ( DOI )

Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results 2022.11; 140 3250-3252. ( DOI )

Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53 2022.11; 140 8807-8808. ( DOI )

Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS) 2022.11; 140 6952-6954. ( DOI )

Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia 2022.11; 140 1493-1494. ( DOI )

Incidence of Central Nervous System Toxicity and Cytokine Release Syndrome in Leukemia Patients Treated with Blinatumomab 2022.11; 140 11663-11665. ( DOI )

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study 2022.11; 140 11698-11701. ( DOI )

More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia 2022.11; 140 3897-3899. ( DOI )

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study 2022.11; 140 8966-8968. ( DOI )

Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome 2022.11; 140 9793-9795. ( DOI )

Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. 2022.11; 115 44-53. ( PubMed, DOI )

Venetoclax Added to Cladribine (CLAD) plus Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study 2022.11; 140 9041-9043. ( DOI )

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) 2022.11; 140 9050-9053. ( DOI )

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia 2022.11; 140 2007-2009. ( DOI )

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia 2022.11; 140 ( DOI )

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data 2022.11; 140 ( DOI )

Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy 2022.11; 140 8652-8654. ( DOI )

Outcomes of Chronic Myeloid Leukemia with No Major Molecular Response within 2 Years of Tyrosine Kinase Inhibitor Therapy 2022.11; 140 9626-9628. ( DOI )

Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis 2022.11; 140 ( DOI )

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients 2022.11; 140 4042-4044. ( DOI )

Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. 2022.11; 97 (11): 1443-1452. ( PubMed, DOI )

Combined Structural Variant and Mutation Profiling for Comprehensive Characterization of Chromoanagenesis and TP53 Mutations in Myelodysplastic Syndromes with Complex Karyotype 2022.11; 140 7844-7845. ( DOI )

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML 2022.11; 140 ( DOI )

Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies 2022.11; 140 6328-6330. ( DOI )

Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia 2022.11; 140 1427-1429. ( DOI )

Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia 2022.11; 140 3895-3896. ( DOI )

Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression 2022.11; 140 ( DOI )

A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia 2022.10; 22 S239-S240. ( DOI )

Acute Lymphoblastic Leukemia Following Multiple Myeloma Therapy: A Single-Center Experience With 9 Patients 2022.10; 22 S201-S202. ( DOI )

Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial 2022.10; 22 S300. ( DOI )

Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration 2022.10; 22 S233-S234. ( PubMed, DOI )

Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After.2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update 2022.10; 22 S295-S296. ( DOI )

Impact of ASXL1 Mutations on Prognosis of Chronic Phase Chronic Myeloid Leukemia 2022.10; 22 S291. ( DOI )

The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34) 2022.10; 22 S258. ( DOI )

Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 2022.10; 22 S204. ( DOI )

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. 2022.10; 12 (10): 144. ( PubMed, DOI )

Prognostic Implication of the Molecular Profiles of Patients With Hypocellular Myelodysplastic Syndrome 2022.10; 22 S310. ( DOI )

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. 2022.09; 63 (9): 2161-2170. ( PubMed, DOI )

Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia 2022.09; 117 (1): 24-29. ( PubMed, DOI )

High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance 2022.09; 36 (9): 2306-2316. ( PubMed, DOI )

Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. 2022.09; 35 (9): 1212-1219. ( PubMed, DOI )

Low-dose decitabine versus low-dose azacitidine in lower-risk MDS 2022.09; 1 (10): ( DOI )

Therapeutic Advances in Immunotherapies for Hematological Malignancies. 2022.09; 23 (19): ( PubMed, DOI )

Real‐life incidence of thrombotic events in leukemia patients treated with ponatinib 2022.09; 97 (9): E350-E352-E352. ( PubMed, DOI )

Transcatheter arterial embolization for hemothorax caused by spinal fracture without arterial injury: a case report and review of the literature. 2022.09; 16 (1): 332. ( PubMed, DOI )

Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis 2022.08; 97 (11): 1413-1418. ( PubMed, DOI )

TP53 ‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis 2022.08; 97 (8): 1005-1012. ( PubMed, DOI )

Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. 2022.08; 97 (8): 1035-1043. ( PubMed, DOI )

Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. 2022.07; 97 (7): 885-894. ( PubMed, DOI )

Prediction of survival with intensive chemotherapy in acute myeloid leukemia 2022.07; 97 (7): 865-876. ( PubMed, DOI )

A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy 2022.06; 97 (9): 1127-1134. ( PubMed, DOI )

Acute myeloid leukemia with KMT2Ar and association with risk of bleeding and early mortality. 2022.06; 40 (16):

A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL). 2022.06; 40 (16):

A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL). 2022.06; 40 (16):

Blinatumomab Is Associated with Favorable Outcomes in Patients With B-cell Lineage Acute Lymphoblastic Leukemia and Positive Measurable Residual Disease at a Threshold of 10^-4 and Higher. 2022.06; 97 (9): 1135-1141. ( PubMed, DOI )

Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after >= 2 prior tyrosine kinase inhibitors (TKIs): Week 96 update. 2022.06; 40 (16):

Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia 2022.06; 98 (1): E11-E14-E14. ( PubMed, DOI )

Treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) following the discontinuation of tyrosine kinase inhibitors. 2022.06; 40 (16):

Outcomes of patients with newly diagnosed acute myeloid leukemia (AML) and hyperleukocytosis. 2022.06; 40 (16): E19029. ( DOI )

Phase 2 study of azacitidine (AZA) and venetoclax (VEN) as maintenance therapy for acute myeloid leukemia (AML) patients in remission. 2022.06; 40 (16): E19018.

Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia 2022.06; 374 (33): 3848-3857. ( PubMed, DOI )

Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects. 2022.05; 14 (10): ( PubMed, DOI )

Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. 2022.05; 12 (5): 77. ( PubMed, DOI )

Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. 2022.05; 9 (5): e350-e360-e360. ( PubMed, DOI )

Improved survival of patients with myelofibrosis in the last decade: Single‐center experience 2022.04; 128 (8): 1658-1665. ( PubMed, DOI )

Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia 2022.04; 63 (7): 1-4. ( PubMed, DOI )

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification 2022.03; 97 (3): 329-337. ( PubMed, DOI )

Major and minor complications of the pancreas after transcatheter arterial embolization using n-butyl-2-cyanoacrylate for acute bleeding from pancreatic arteries. 2022.03; 40 (3): 308-317. ( PubMed, DOI )

Treatment‐Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors 2022.03; 97 (7): 856-864. ( PubMed, DOI )

Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab 2022.03; 97 (6): E201-E204-E204. ( PubMed, DOI )

Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib 2022.02; 36 (5): 1253-1260. ( PubMed, DOI )

Characteristics and Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Frontline HCVAD 2022.01; 6 (10): 3027-3035. ( PubMed, DOI )

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c) 2022.01; 12 (1): 5. ( PubMed, DOI )

Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy 2022.01; 97 (1): 68-78. ( PubMed, DOI )

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia. 2022; 12 1021662. ( PubMed, DOI )

Efficacy of superselective transcatheter arterial embolization for intractable postpartum hemorrhage due to genital tract trauma after vaginal delivery. 2021.12; 28 (6): 1127-1133. ( PubMed, DOI )

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. 2021.12; 35 (12): 3421-3429. ( PubMed, DOI )

Prediction for sustained deep molecular response for treatment-free remission. 2021.12; 63 (1): 5-6. ( PubMed, DOI )

A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission 2021.11; 138 ( DOI )

A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study 2021.11; 138 ( DOI )

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive BCell Acute Lymphoblastic Leukemia 2021.11; 138 ( DOI )

Association between Bariatric Surgery and Outcomes in Patients with Chronic Myeloid Leukemia Treated with Oral Tyrosine Kinase Inhibitors 2021.11; 138 ( DOI )

Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study 2021.11; 138 ( DOI )

General Characteristics and Association of Myeloid Neoplasm with Thyroid Cancer 2021.11; 138 ( DOI )

Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML 2021.11; 138 ( DOI )

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First -in -Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after >= 2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks 2021.11; 138 ( DOI )

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia 2021.11; 138 ( DOI )

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and PostHypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) 2021.11; 138 ( DOI )

NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) 2021.11; 138 ( DOI )

The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors 2021.11; 138 ( DOI )

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. 2021.11; 106 (11): 2853-2858. ( PubMed, DOI )

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial 2021.11; 138 ( DOI )

Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML 2021.11; 138 ( DOI )

Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 2021.11; 138 ( DOI )

Disease Characteristics of Multiple Myeloma Involving BRAF Mutations 2021.11; 138 ( DOI )

Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents 2021.11; 138 ( DOI )

Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVADBased Chemotherapy 2021.11; 138 ( DOI )

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML 2021.11; 138 ( DOI )

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy 2021.11; 138 ( DOI )

Clinical and Pathological Characteristics of Hypocellular Myelodysplastic Syndrome : A Single-Center Retrospective Study 2021.11; 138 ( DOI )

Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups 2021.11; 138 ( DOI )

Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) 2021.11; 138 ( DOI )

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. 2021.11; 138 (18): 1733-1739. ( PubMed, DOI )

Clinical Outcomes of Patients with Newly Diagnosed Myelodysplastic Syndrome with MLL Aberrations 2021.11; 138 ( DOI )

Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. 2021.10; 127 (19): 3552-3565. ( PubMed, DOI )

Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. 2021.10; 127 (19): 3541-3551. ( PubMed, DOI )

A Simplified Three-Marker Panel for Myelodysplastic Syndrome Prognostic Outperforms the Well-Established Revised International Prognostic Scoring Systems (IPSS-R) 2021.09; 21 S351.

Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. 2021.09; 127 (18): 3381-3389. ( PubMed, DOI )

Improved Survival of Patients with Primary Myelofibrosis in the Last Decade at a Large Single Academic Center 2021.09; 21 S361.

Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia 2021.09; 21 S291.

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. 2021.09; 39 (25): 2768-2778. ( PubMed, DOI )

Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. 2021.09; 127 (17): 3113-3124. ( PubMed, DOI )

Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. 2021.09; 62 (14): 3501-3505. ( PubMed, DOI )

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. 2021.09; 11 (9): 162. ( PubMed, DOI )

A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs. 2021.08; 138 (21): 2031-2041. ( PubMed, DOI )

Ibrutinib plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial 2021.08; 7 (8): 1213-1219. ( PubMed, DOI )

Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. 2021.08; 127 (15): 2641-2647. ( PubMed, DOI )

Clinical and molecular characterization of myeloid sarcoma without medullary leukemia 2021.08; 62 (14): 3402-3410. ( PubMed, DOI )

Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. 2021.08; 127 (15): 2648-2656. ( PubMed, DOI )

Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts. 2021.07; 194 (2): 414-422. ( PubMed, DOI )

Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. 2021.07; 127 (14): 2489-2499. ( PubMed, DOI )

Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. 2021.07; 127 (20): 3772-3781. ( PubMed, DOI )

Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. 2021.07; 194 (1): 61-68. ( PubMed, DOI )

Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). 2021.07; 96 (7): E246-E249-E249. ( PubMed, DOI )

Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. 2021.06; 96 (6): 650-658. ( PubMed, DOI )

Impact of frontline treatment approach on outcomes of myeloid blast phase CML. 2021.06; 14 (1): 94. ( PubMed, DOI )

Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. 2021.06; 127 (12): 2025-2038. ( PubMed, DOI )

De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. 2021.06; 127 (12): 2049-2061. ( PubMed, DOI )

Nakamura, F; Arai, H; Nannya, Y; Ichikawa, M; Furuichi, S; Nagasawa, F; Takahashi, W; Handa, T; Nakamura, Y; Tanaka, H; Nakamura, Y; Sasaki, K; Miyano, S; Ogawa, S; Mitani, K. Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy INTERNATIONAL JOURNAL OF HEMATOLOGY. 2021.06; 113 (6): 936-940. ( PubMed, DOI )

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. 2021.05; 35 (5): 1494-1499. ( PubMed, DOI )

Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. 2021.05; 39 (15): ( DOI )

Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. 2021.05; 96 (5): 589-598. ( PubMed, DOI )

Samra, B; Kantarjian, HM; Sasaki, K; Alotaibi, AS; Konopleva, M; O'Brien, S; Ferrajoli, A; Garris, R; Nunez, CA; Kadia, TM; Short, NJ; Jabbour, E. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant ACTA HAEMATOLOGICA. 2021.05; 144 (3): 285-292. ( PubMed, DOI )

Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. 2021.05; 96 (5): E154-E157-E157. ( PubMed, DOI )

Current status and novel strategy of CML. 2021.05; 113 (5): 624-631. ( PubMed, DOI )

Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. 2021.05; 21 (5): 338-344. ( PubMed, DOI )

Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). 2021.05; 39 (15): ( DOI )

Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. 2021.04; 106 (4): 1097-1105. ( PubMed, DOI )

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. 2021.04; 5 (8): 2173-2183. ( PubMed, DOI )

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. 2021.04; 5 (7): 1876-1883. ( PubMed, DOI )

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. 2021.03; 11 (3): 52. ( PubMed, DOI )

Maiti, A; Qiao, W; Sasaki, K; Ravandi, F; Kadia, TM; Jabbour, EJ; Daver, NG; Borthakur, G; Garcia-Manero, G; Pierce, SA; Montalbano, KS; Pemmaraju, N; Naqvi, K; Ohanian, M; Short, NJ; Alvarado, Y; Takahashi, K; Yilmaz, M; Jain, N; Kornblau, SM; Andreeff, M; Bose, P; Ferrajoli, A; Issa, GC; Masarova, L; Thompson, PA; Rausch, CR; Ning, J; Kantarjian, HM; DiNardo, CD; Konopleva, MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality AMERICAN JOURNAL OF HEMATOLOGY. 2021.03; 96 (3): 282-291. ( PubMed, DOI )

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. 2021.03; 106 (3): 894-898. ( PubMed, DOI )

Shoukier, M; Kadia, T; Konopleva, M; Alotaibi, AS; Alfayez, M; Loghavi, S; Patel, KP; Kanagal-Shamanna, R; Cortes, J; Samra, B; Jabbour, E; Garcia-Manero, G; Takahashi, K; Pierce, S; Short, NJ; Yilmaz, M; Sasaki, K; Masarova, L; Pemmaraju, N; Borthakur, G; Kantarjian, HM; Ravandi, F; DiNardo, CD; Daver, N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent <i>FLT3</i>-ITD and <i>IDH</i> mutations CANCER. 2021.02; 127 (3): 381-390. ( PubMed, DOI )

Sasaki, K; Jabbour, EJ; Ravandi, F; Konopleva, M; Borthakur, G; Wierda, WG; Daver, N; Takahashi, K; Naqvi, K; DiNardo, C; Montalban-Bravo, G; Kanagal-Shamanna, R; Issa, G; Jain, P; Skinner, J; Rios, MB; Pierce, S; Soltysiak, KA; Sato, J; Garcia-Manero, G; Cortes, JE. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes AMERICAN JOURNAL OF HEMATOLOGY. 2021.02; 96 (2): 241-250. ( PubMed, DOI )

Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. 2021.02; 101 106511. ( PubMed, DOI )

Montalban-Bravo, G; Kanagal-Shamanna, R; Guerra, V; Ramos-Perez, J; Hammond, D; Shilpa, P; Naqvi, K; Sasaki, K; Jabbour, E; DiNardo, C; Takahashi, K; Konopleva, M; Pemmaraju, N; Kadia, T; Ravandi, F; Daver, N; Borthakur, G; Estrov, Z; Khoury, JD; Loghavi, S; Pierce, S; Bueso-Ramos, C; Patel, K; Kantarjian, H; Garcia-Manero, G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia AMERICAN JOURNAL OF HEMATOLOGY. 2021.02; 96 (2): E52-E55. ( PubMed, DOI )

Yilmaz, M; Kantarjian, HM; Toruner, G; Yin, CC; Kanagal-Shamanna, R; Cortes, JE; Issa, G; Short, NJ; Khoury, JD; Garcia-Manero, G; Ravandi, F; Kadia, T; Konopleva, M; Wierda, WG; Jain, N; Estrov, Z; Sasaki, K; Pierce, S; O'Brien, SM; Jabbour, EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis LEUKEMIA & LYMPHOMA. 2021.01; 62 (1): 224-228. ( PubMed, DOI )

Sasaki, K; Nannya, Y; Nakamura, Y; Ichikawa, M; Ogawa, S; Mitani, K. Essential thrombocythaemia with aggressive megakaryocytosis after myelofibrotic transformation HEMATOLOGY. 2021.01; 26 (1): 594-600. ( PubMed, DOI )

Jang, JH; Tomiyama, Y; Miyazaki, K; Nagafuji, K; Usuki, K; Uoshima, N; Fujisaki, T; Kosugi, H; Matsumura, I; Sasaki, K; Kizaki, M; Sawa, M; Hidaka, M; Kobayashi, N; Ichikawa, S; Yonemura, Y; Enokitani, K; Matsuda, A; Ozawa, K; Mitani, K; Lee, JW; Nakao, S. Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study BRITISH JOURNAL OF HAEMATOLOGY. 2021.01; 192 (1): 190-199. ( PubMed, DOI )

Nakamura, F; Arai, H; Tokita, K; Furuichi, S; Sugita-Nagasawa, F; Takahashi, W; Handa, T; Iso, H; Tadokoro, J; Tsurumi, S; Nakamura, Y; Nakamura, Y; Sasaki, K; Seo, S; Ichikawa, M; Mitani, K. PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphoma LEUKEMIA & LYMPHOMA. 2021.01; 62 (1): 239-242. ( PubMed, DOI )

Sasaki, K; Montalban-Bravo, G; Kanagal-Shamanna, R; Jabbour, E; Ravandi, F; Kadia, T; Daver, N; Pemmaraju, N; Konopleva, M; Borthakur, G; Takahashi, K; Patel, K; Soltysiak, KA; Chien, KS; Sakurai, K; Pierce, S; Kantarjian, HM; Garcia-Manero, G. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3) AMERICAN JOURNAL OF HEMATOLOGY. 2020.12; 95 (12): E326-E329. ( PubMed, DOI )

Maiti, A; Franquiz, MJ; Ravandi, F; Cortes, JE; Jabbour, EJ; Sasaki, K; Marx, K; Daver, NG; Kadia, TM; Konopleva, MY; Masarova, L; Borthakur, G; DiNardo, CD; Naqvi, K; Pierce, S; Kantarjian, HM; Short, NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias ACTA HAEMATOLOGICA. 2020.12; 143 (6): 567-573. ( PubMed, DOI )

Major, CK; Kantarjian, H; Sasaki, K; Borthakur, G; Kadia, T; Pemmaraju, N; DiNardo, C; Short, NJ; Daver, N; Jabbour, E; Champlin, R; Garcia-Manero, G; Konopleva, M; Andreeff, M; Kornblau, S; Wierda, W; Pierce, S; Ravandi, F; Cortes, J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years LEUKEMIA & LYMPHOMA. 2020.11; 61 (13): 3120-3127. ( PubMed, DOI )

Morita, K; Kantarjian, HM; Bravo, GM; Sasaki, K; Daver, N; Jabbour, E; Alvarado, Y; Chien, KS; DiNardo, CD; Ravandi, F; Borthakur, G; Bose, P; Pemmaraju, N; Naqvi, K; Cortes, JE; Kadia, TM; Konopleva, M; Rausch, CR; Gasior, Y; Garcia-Manero, G. A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) BLOOD. 2020.11; 136 ( DOI )

Hammond, D; DiNardo, CD; Konopleva, M; Borthakur, G; Perez, JMR; Guerra, VA; Kanagal-Shamanna, R; Paul, S; Naqvi, K; Sasaki, K; Jabbour, E; Pemmaraju, N; Kadia, TM; Ravandi, F; Daver, N; Estrov, ZE; Pierce, SA; Kantarjian, HM; Garcia-Manero, G; Montalban-Bravo, G. Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation BLOOD. 2020.11; 136 ( DOI )

A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab 2020.11; 136 ( DOI )

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo plus Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response 2020.11; 136 ( DOI )

CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study 2020.11; 136 ( DOI )

Hochhaus, A; Boquimpani, C; Rea, D; Minami, Y; Lomaia, E; Voloshin, S; Turkina, AG; Kim, DW; Apperley, J; Cortes, JE; Abdo, A; Fogliatto, LM; Kim, DDH; Le Coutre, PD; Saussele, S; Annunziata, M; Hughes, TP; Chaudhri, NA; Chee, LCY; Gutierrez, VG; Sasaki, K; Aimone, P; Allepuz, A; Quenet, S; Bédoucha, V; Mauro, MJ. Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs BLOOD. 2020.11; 136 ( DOI )

Bravo, GM; Kanagal-Shamanna, R; Darbaniyan, F; Ganan-Gomez, I; Sasaki, K; Naqvi, K; Wei, Y; Yang, H; Soltysiak, KA; Chien, KS; Bueso-Ramos, CE; Kantarjian, HM; Garcia-Manero, G. Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS) BLOOD. 2020.11; 136 ( DOI )

Cherng, HJJ; Jammal, N; Paul, S; Wang, XM; Sasaki, K; Thompson, PA; Burger, JA; Ferrajoli, A; Estrov, ZE; O'Brien, SM; Keating, MJ; Wierda, WG; Jain, N. Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia BLOOD. 2020.11; 136 ( DOI )

Kanagal-Shamanna, R; Bravo, GM; Katsonis, P; Sasaki, K; Class, C; Benton, CB; Jabbour, E; Chien, KS; Luthra, R; Bueso-Ramos, CE; Kadia, TM; Andreeff, M; Short, NJ; Daver, N; Routbort, M; Khoury, JD; Patel, K; Ganan-Gomez, I; Wei, Y; Borthakur, G; Ravandi, F; Do, KA; Soltysiak, KA; Lichtarge, O; Medeiros, LJ; Kantarjian, HM; Garcia-Manero, G. Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis BLOOD. 2020.11; 136 ( DOI )

Rafei, H; Kantarjian, HM; Sasaki, K; Short, NJ; Ravandi, F; Huang, XL; Khoury, JD; Wang, SA; Jorgensen, JL; Yin, CC; Khouri, IF; Kebriaei, P; Jain, N; Takahashi, K; Dabaja, BS; Verstovsek, S; Kadia, TM; Paul, S; Rausch, CR; Garcia-Manero, G; Wierda, WG; DiNardo, CD; Daver, N; Montalban-Bravo, G; Yilmaz, M; Nasnas, P; Khouri, R; Kwari, M; Jacob, J; Rostykus, M; Garris, R; Konopleva, M; O'Brien, SM; Jabbour, E. Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study BLOOD. 2020.11; 136 ( DOI )

Sasaki, K; Jabbour, E; Bravo, GM; Short, NJ; Kanagal-Shamanna, R; Kadia, TM; Borthakur, G; Pemmaraju, N; Cortes, JE; Ravandi, F; Alvarado, Y; Chien, KS; Yang, H; Kantarjian, HM; Garcia-Manero, G. Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study BLOOD. 2020.11; 136 ( DOI )

Sasaki, K; Kantarjian, HM; Ravandi, F; Short, NJ; Kebriaei, P; Huang, XL; Jain, N; Konopleva, M; Garcia-Manero, G; Champlin, RE; Kadia, TM; Takahashi, K; Daver, N; Rafei, H; Khoury, JD; Jorgensen, JL; Wang, SA; Khouri, MR. Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial BLOOD. 2020.11; 136 ( DOI )

Morita, K; Bravo, GM; Sasaki, K; Bodden, KR; Wang, F; Bose, P; Alvarado, Y; Daver, N; Borthakur, G; Ravandi, F; Takahashi, K; Jabbour, E; DiNardo, CD; Pemmaraju, N; Kadia, TM; Ohanian, M; Pierce, SA; Azab, M; Kantarjian, HM; Garcia-Manero, G. Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) BLOOD. 2020.11; 136 ( DOI )

Perez, JMR; Kadia, TM; Montalban-Bravo, G; Faderl, S; Sasaki, K; Daver, N; DiNardo, CD; Masarova, L; Ferrajoli, A; Jabbour, E; Borthakur, G; Al Azzawi, H; Pemmaraju, N; Konopleva, M; Pierce, SA; Garcia-Manero, G; Andreeff, M; Kantarjian, HM; Ravandi, F; Alvarado, Y. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) BLOOD. 2020.11; 136 ( DOI )

Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia 2020.11; 136 ( DOI )

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML 2020.11; 136 ( DOI )

Bravo, GM; Jabbour, E; Kadia, TM; Ravandi, F; Estrov, ZE; Naqvi, K; Sasaki, K; Chien, KS; González, GMN; Dong, XQ; Faderl, S; Schneider, H; John, RB; Kantarjian, HM; Garcia-Manero, G. Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents BLOOD. 2020.11; 136 ( DOI )

Sasaki, K; Kantarjian, HM; Issa, GC; Garcia-Manero, G; Kadia, TM; Wierda, WG; Yilmaz, M; DiNardo, CD; Skinner, J; Khouri, R; Pemmaraju, N; Nasnas, P; Dellasala, SE; Pierce, SA; Cortes, JE; Jabbour, E. Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors BLOOD. 2020.11; 136 ( DOI )

Darbaniyan, F; Bravo, GM; Wei, Y; Kanagal-Shamanna, R; Sasaki, K; Yang, H; Soltysiak, KA; Chien, KS; Do, KA. Impact of Hemoglobin Level As a Continuous Variable in Calculating Prognosis in MDS: Incorporation into LSC4 and IPSS-R BLOOD. 2020.11; 136 ( DOI )

Kanagal-Shamanna, R; Bravo, GM; Sasaki, K; Bueso-Ramos, CE; Jabbour, E; Wei, Y; Darbaniyan, F; Routbort, M; Pierce, SA; Soltysiak, KA; Patel, K; Medeiros, LJ; Kantarjian, HM; Garcia-Manero, G. Only Hotspot <i>SF3B1</i> K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes BLOOD. 2020.11; 136 ( DOI )

Sasaki, K; Jabbour, E; Naqvi, K; Skinner, J; Anderson, K; Dellasala, SE; Yilmaz, M; Ferrajoli, A; Bose, P; Thompson, PA; Alvarado, Y; Jain, N; Garcia-Manero, G; Takahashi, K; Burger, JA; Borthakur, G; Pemmaraju, N; Khouri, R; Paul, S; Pierce, SA; Cortes, JE; Kantarjian, HM. The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis BLOOD. 2020.11; 136 ( DOI )

Bravo, GM; Darbaniyan, F; Kanagal-Shamanna, R; Ganan-Gomez, I; Sasaki, K; Naqvi, K; Wei, Y; Yang, H; Soltysiak, KA; Chien, KS; Bueso-Ramos, CE; Kantarjian, HM; Garcia-Manero, G. Transcriptomic Features and Deregulation of Genes Involved in Monopoiesis Influence Outcomes of Patients with Chronic Myelomonocytic Leukemia BLOOD. 2020.11; 136 ( DOI )

Jain, N; Keating, MJ; Thompson, PA; Ferrajoli, A; Burger, JA; Borthakur, G; Takahashi, K; Estrov, ZE; Sasaki, K; Fowler, NH; Kadia, TM; Konopleva, M; Alvarado, Y; Yilmaz, M; DiNardo, CD; Bose, P; Ohanian, M; Pemmaraju, N; Jabbour, E; Kanagal-Shamanna, R; Patel, K; Wang, W; Jorgensen, JL; Wang, SA; Garg, N; Wang, XM; Cruz, N; Ayala, A; Plunkett, W; Kantarjian, HM; Gandhi, V; Wierda, WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results BLOOD. 2020.11; 136 ( DOI )

Sasaki, K; Jabbour, E; Issa, GC; Garcia-Manero, G; Kadia, TM; Wierda, WG; Yilmaz, M; DiNardo, CD; Skinner, J; Khouri, M; Pemmaraju, N; Nasnas, P; Pierce, SA; Cortes, JE; Kantarjian, HM. Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors BLOOD. 2020.11; 136 ( DOI )

Guerra, V; Perez, JMR; Hammond, D; Chien, KS; Kanagal-Shamanna, R; Naqvi, K; Sasaki, K; Paul, S; Kadia, TM; DiNardo, CD; Konopleva, M; Daver, N; Ravandi, F; Pemmaraju, N; Short, NJ; Issa, GC; Takahashi, K; Estrov, ZE; Pierce, SA; Kantarjian, HM; Garcia-Manero, G; Bravo, GM. Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure BLOOD. 2020.11; 136 ( DOI )

Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression 2020.11; 136 ( DOI )

Morita, K; Kantarjian, HM; Ravandi, F; Sasaki, K; Jain, N; Konopleva, M; Short, NJ; Takahashi, K; Khouri, R; Nasnas, P; DiNardo, CD; Kadia, TM; Garcia-Manero, G; Daver, N; Bravo, GM; Issa, GC; Cortes, JE; Jabbour, E. Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib BLOOD. 2020.11; 136 ( DOI )

Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis 2020.11; 136 ( DOI )

Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib 2020.11; 136 ( DOI )

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse 2020.11; 136 ( DOI )

Rafei, H; Kantarjian, HM; Sasaki, K; Short, NJ; Ravandi, F; Huang, XL; Khoury, JD; Wang, SA; Jorgensen, JL; Khouri, IF; Kebriaei, P; Champlin, RE; Jain, N; Dabaja, BS; Issa, GC; Pemmaraju, N; Kadia, TM; Paul, S; Jammal, N; Garcia-Manero, G; Wierda, WG; DiNardo, CD; Daver, N; Montalban-Bravo, G; Khouri, R; Nasnas, P; Thompson, PA; Jacob, J; Rostykus, M; Garris, R; Konopleva, M; O'Brien, SM; Jabbour, E. Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study BLOOD. 2020.11; 136 ( DOI )

Guerra, VA; Alwash, Y; Yan, YQ; Perez, JMR; Richard-Carpentier, G; Alotaibi, AS; Ahaneku, HO; Samra, B; Raghunath, A; Jain, N; Short, NJ; Ravandi, F; Borthakur, G; Ferrajoli, A; Sasaki, K; Kornblau, SM; Estrov, ZE; Cortes, JE; Kantarjian, HM; Garcia-Manero, G; Jabbour, E; Kadia, TM. Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Lymphoblastic Leukemia (ALL) BLOOD. 2020.11; 136 ( DOI )

Perez, JMR; Guerra, VA; Hammond, D; Chien, KS; Kanagal-Shamanna, R; Naqvi, K; Sasaki, K; Paul, S; Kadia, TM; DiNardo, CD; Konopleva, M; Daver, N; Ravandi, F; Pemmaraju, N; Short, NJ; Takahashi, K; Estrov, ZE; Pierce, SA; Kantarjian, HM; Garcia-Manero, G; Montalban-Bravo, G. Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories BLOOD. 2020.11; 136 ( DOI )

Maiti, A; DiNardo, CD; Wang, SA; Jorgensen, JL; Kadia, TM; Daver, N; Short, NJ; Yilmaz, M; Pemmaraju, N; Borthakur, G; Bose, P; Issa, GC; Ferrajoli, A; Jabbour, E; Jain, N; Garcia-Manero, G; Ohanian, M; Takahashi, K; Montalban-Bravo, G; Masarova, L; Burger, JA; Thompson, PA; Verstovsek, S; Sasaki, K; Andreeff, M; Rausch, CR; Montalbano, K; Pierce, SA; Kantarjian, HM; Konopleva, M; Ravandi, F. Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia BLOOD. 2020.11; 136 ( DOI )

Bravo, GM; Kanagal-Shamanna, R; Guerra, V; Perez, JMR; Hammond, D; Paul, S; Naqvi, K; Sasaki, K; Jabbour, E; DiNardo, CD; Takahashi, K; Konopleva, M; Pemmaraju, N; Kadia, TM; Ravandi, F; Daver, N; Borthakur, G; Estrov, ZE; Khoury, JD; Loghavi, S; Pierce, SA; Bueso-Ramos, CE; Patel, K; Kantarjian, HM. Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia BLOOD. 2020.11; 136 ( DOI )

Reville, PK; González, GMN; Ravandi, F; Sasaki, K; Borthakur, G; Garcia-Manero, G; Daver, N; DiNardo, CD; Jabbour, E; Pemmaraju, N; Andreeff, M; Verstovsek, S; Ferrajoli, A; Jain, N; Ohanian, M; Pierce, SA; Estrov, ZE; Konopleva, M; Kantarjian, HM; Kadia, TM. Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort BLOOD. 2020.11; 136 ( DOI )

Phase II Study of Venetoclax Added to Cladribine plus Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) 2020.11; 136 ( DOI )

Bravo, GM; Kanagal-Shamanna, R; Sasaki, K; Masarova, L; Naqvi, K; Jabbour, E; DiNardo, CD; Takahashi, K; Konopleva, M; Pemmaraju, N; Short, NJ; Issa, GC; Kadia, TM; Ravandi, F; Daver, N; Borthakur, G; Estrov, ZE; Khoury, JD; Loghavi, S; Pierce, SA; Bueso-Ramos, CE; Patel, K; Verstovsek, S; Kantarjian, HM; Bose, P; Garcia-Manero, G. Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia BLOOD. 2020.11; 136 ( DOI )

Siddiqui, MT; Kanagal-Shamanna, R; Naqvi, K; Sasaki, K; Masarova, L; Jabbour, E; Pemmaraju, N; Kadia, TM; Ravandi, F; Daver, N; Borthakur, G; Pierce, SA; Verstovsek, S; Bose, P; Kantarjian, HM; Garcia-Manero, G; Montalban-Bravo, G. Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series BLOOD. 2020.11; 136 ( DOI )

DiNardo, CD; Maiti, A; Rausch, CR; Pemmaraju, N; Naqvi, K; Daver, NG; Kadia, TM; Borthakur, G; Ohanian, M; Alvarado, Y; Issa, GC; Montalban-Bravo, G; Short, NJ; Yilmaz, M; Bose, P; Jabbour, EJ; Takahashi, K; Burger, JA; Garcia-Manero, G; Jain, N; Kornblau, SM; Thompson, PA; Estrov, Z; Masarova, L; Sasaki, K; Verstovsek, S; Ferrajoli, A; Weirda, WG; Wang, SA; Konoplev, S; Chen, ZN; Pierce, SA; Ning, J; Qiao, W; Ravandi, F; Andreeff, M; Welch, JS; Kantarjian, HM; Konopleva, MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial LANCET HAEMATOLOGY. 2020.10; 7 (10): E724-E736. ( PubMed, DOI )

Masarova, L; Bose, P; Pemmaraju, N; Daver, NG; Zhou, LS; Pierce, S; Sasaki, K; Kantarjian, HM; Estrov, Z; Verstovsek, S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era CANCER. 2020.10; 126 (19): 4322-4331. ( PubMed, DOI )

Quesada, AE; Montalban-Bravo, G; Luthra, R; Patel, KP; Sasaki, K; Bueso-Ramos, CE; Khoury, JD; Routbort, MJ; Bassett, R; Hidalgo-Lopez, JE; Zhao, C; Lin, P; Loghavi, S; Ok, CY; Kadia, T; DiNardo, CD; Kantarjian, H; Garcia-Manero, G; Kanagal-Shamanna, R. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated <i>RUNX1</i> MODERN PATHOLOGY. 2020.09; 33 (9): 1678-1689. ( PubMed, DOI )

Sasaki, K; Jabbour, E; Naqvi, K; Skinner, J; Anderson, K; Dellasala, S; Yilmaz, M; Ferrajoli, A; Bose, P; Thompson, P; Alvarado, Y; Jain, N; Takahashi, K; Burger, J; Estrov, Z; Borthakur, G; Pemmaraju, N; Paul, S; Pierce, S; Cortes, J; Kantarjian, H. Low-Dose Dasatinib 50 mg Daily Versus Standard-Dose Dasatinib 100 mg Daily in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020.09; 20 S237.

Issa, G; Zarka, J; Sasaki, K; Short, N; Jabbour, E; Kadia, T; Borthakur, G; Garcia-Manero, G; Kantarjian, H; Ravandi, F. Predictors of Outcomes in AML with <i>MLL</i> Rearrangement CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020.09; 20 S202-S203.

Sasaki, K; Kantarjian, H; Samra, B; Short, N; Khoury, J; Kanagal, R; Konopleva, M; Jain, N; DiNardo, C; Khouri, R; Garcia-Manero, G; Kadia, T; Wierda, W; Tippett, N; Garris, R; Jeanis, V; Daver, N; Thompson, P; Yilmaz, M; Cortes, J; O'Brien, S; Ravandi, F; Jabbour, E. Outcomes of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Molecular Response at Three Months of Therapy CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020.09; 20 S164-S165.

Predictors of Outcomes in AML with MLL Rearrangement 2020.09; 20 S202-S203.

Jabbour, E; Richard-Carpentier, G; Sasaki, Y; Konopleva, M; Patel, K; Roberts, K; Gu, ZH; Wang, F; Huang, XL; Sasaki, K; Short, NJ; Jain, N; Ravandi, F; Daver, NG; Kadia, TM; Alvarado, Y; DiNardo, CD; Issa, GC; Pemmaraju, N; Garcia-Manero, G; Verstovsek, S; Wang, S; Khoury, JD; Jorgensen, J; Champlin, R; Khouri, I; Kebriaei, P; Schroeder, H; Khouri, M; Mullighan, CG; Takahashi, K; O'Brien, SM; Kantarjian, H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial LANCET HAEMATOLOGY. 2020.07; 7 (7): E523-E533. ( PubMed, DOI )

Sasaki, K; Kantarjian, H; Wierda, W; Ravandi-Kashani, F; Jorgensen, J; Wang, SA; Khoury, J; Daver, N; Burger, J; Di Nardo, CD; Jain, N; Short, NJ; Estrov, Z; Konopleva, M; Ohanian, M; Garcia-Manero, G; Kadia, T; Alvarado-Valero, Y; Yilmaz, M; Pierce, S; Garris, R; Ingram, A; Cortes, J; O'Brian, S; Jabbour, E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia AMERICAN JOURNAL OF HEMATOLOGY. 2020.07; 95 (7): 734-739. ( PubMed, DOI )

Montalban-Bravo, G; Kanagal-Shamanna, R; Class, CA; Sasaki, K; Ravandi, F; Cortes, JE; Daver, N; Takahashi, K; Short, NJ; DiNardo, CD; Jabbour, E; Borthakur, G; Naqvi, K; Issa, GC; Konopleva, M; Khoury, JD; Routbort, M; Pierce, S; Do, KA; Bueso-Ramos, C; Patel, K; Kantarjian, H; Garcia-Manero, G; Kadia, TM. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy AMERICAN JOURNAL OF HEMATOLOGY. 2020.06; 95 (6): 612-622. ( PubMed, DOI )

Zhou, J; Huang, X; Endou, H; Sasaki, K; Hooshangnejad, H; Han, D; Ding, K. Feasibility Study of a Curved Flexible Probe for Abdominal Imaging During Radiation Therapy MEDICAL PHYSICS. 2020.06; 47 (6): E620.

Short, NJ; Kantarjian, H; Kanagal-Shamanna, R; Sasaki, K; Ravandi, F; Cortes, J; Konopleva, M; Issa, GC; Kornblau, SM; Garcia-Manero, G; Garris, R; Higgins, J; Pratt, G; Williams, LN; Valentine, CC; Rivera, VM; Pritchard, J; Salk, JJ; Radich, J; Jabbour, E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment <i>ABL1</i> kinase domain mutations in Ph plus ALL BLOOD CANCER JOURNAL. 2020.05; 10 (5): 61. ( PubMed, DOI )

Sakurai, K; Kantarjian, HM; Sasaki, K; Jabbour, E; Ravandi, F; Konopleva, M; Borthakur, G; Wierda, WG; Daver, NG; Takahashi, K; Naqvi, K; Dinardo, CD; Bravo, GM; Issa, GC; Jain, P; Pierce, SA; Soltysiak, KA; Garcia-Manero, G; Tingen, MS; Cortes, JE. Geographic disparity of outcome in patients with cancer over decades: The surveillance, epidemiology, and end results. JOURNAL OF CLINICAL ONCOLOGY. 2020.05; 38 (15):

Chien, KS; Class, CA; Montalban-Bravo, G; Wei, Y; Sasaki, K; Naqvi, K; Ganan-Gomez, I; Yang, H; Soltysiak, KA; Kanagal-Shamanna, R; Do, KA; Kantarjian, HM; Garcia-Manero, G. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents LEUKEMIA & LYMPHOMA. 2020.05; 61 (6): 1493-1499. ( PubMed, DOI )

Dalle, IA; Ghorab, A; Patel, K; Wang, XM; Hwang, H; Cortes, J; Issa, GC; Yalniz, F; Sasaki, K; Chihara, D; Price, A; Kadia, T; Pemmaraju, N; Daver, N; DiNardo, C; Ravandi, F; Kantarjian, HM; Borthakur, G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3-mutant acute myeloid leukemia BLOOD CANCER JOURNAL. 2020.05; 10 (5): 48. ( PubMed, DOI )

Geographic disparity of outcome in patients with cancer over decades: The surveillance, epidemiology, and end results. 2020.05; 38 (15):

Lachowiez, CA; Loghavi, S; Kadia, TM; Daver, N; Borthakur, G; Pemmaraju, N; Naqvi, K; Alvarado, Y; Yilmaz, M; Short, N; Ohanian, M; Pierce, SR; Patel, KP; Qiao, W; Ning, J; Sasaki, K; Takahashi, K; Jabbour, E; Andreeff, M; Ravandi, F; Kantarjian, HM; Konopleva, M; DiNardo, CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens BLOOD ADVANCES. 2020.04; 4 (7): 1311-1320. ( PubMed, DOI )

Montalban-Bravo, G; Class, CA; Ganan-Gomez, I; Kanagal-Shamanna, R; Sasaki, K; Richard-Carpentier, G; Naqvi, K; Wei, Y; Yang, H; Soltysiak, KA; Chien, K; Bueso-Ramos, C; Do, KA; Kantarjian, H; Garcia-Manero, G. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes LEUKEMIA. 2020.03; 34 (3): 872-881. ( PubMed, DOI )

Montalban-Bravo, G; Kanagal-Shamanna, R; Benton, CB; Class, CA; Chien, KS; Sasaki, K; Naqvi, K; Alvarado, Y; Kadia, TM; Ravandi, F; Daver, N; Takahashi, K; Jabbour, E; Borthakur, G; Pemmaraju, N; Konopleva, M; Soltysiak, KA; Pierce, SR; Bueso-Ramos, CE; Patel, KP; Kantarjian, H; Garcia-Manero, G. Genomic context and <i>TP53</i> allele frequency define clinical outcomes in <i>TP53</i>-mutated myelodysplastic syndromes BLOOD ADVANCES. 2020.02; 4 (3): 482-495. ( PubMed, DOI )

Sasaki, K; Kanagal-Shamanna, R; Montalban-Bravo, G; Assi, R; Jabbour, E; Ravandi, F; Kadia, T; Pierce, S; Takahashi, K; Gonzalez, GN; Patel, K; Soltysiak, KA; Cortes, J; Kantarjian, H; Garcia-Manero, G. Impact of the variant allele frequency of <i>ASXL1</i>, <i>DNMT3A</i>, <i>JAK2</i>, <i>TET2</i>, <i>TP53</i>, and <i>NPM1</i> on the outcomes of patients with newly diagnosed acute myeloid leukemia CANCER. 2020.02; 126 (4): 765-774. ( PubMed, DOI )

Yilmaz, M; Kantarjian, H; Wang, XM; Khoury, JD; Ravandi, F; Jorgensen, J; Short, NJ; Loghavi, S; Cortes, J; Garcia-Manero, G; Kadia, T; Sasaki, K; Konopleva, M; Takahashi, K; Wierda, W; Jain, N; Verstovsek, S; Estrov, Z; Bose, P; Pierce, S; Garris, R; O'Brien, S; Jabbour, E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival AMERICAN JOURNAL OF HEMATOLOGY. 2020.02; 95 (2): 144-150. ( PubMed, DOI )

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. 2020; 10 582213. ( PubMed, DOI )

Montalban-Bravo, G; Class, C; Ganan-Gomez, I; Kanagal-Shamanna, R; Sasaki, K; Richard-Carpentier, G; Naqvi, K; Wei, Y; Yang, H; Soltysiak, K; Chien, KS; Bueso-Ramos, CE; Do, KA; Kantarjian, HM; Garcia-Manero, G. Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes BLOOD. 2019.11; 134 ( DOI )

Daver, NG; Garcia-Manero, G; Konopleva, MY; Alfayez, M; Pemmaraju, N; Kadia, TM; DiNardo, CD; Cortes, JE; Ravandi, F; Abbas, H; Basu, S; Jabbour, E; Pierce, SA; Estrov, ZE; Takahashi, K; Ning, J; Kornblau, SM; Sasaki, K; Masarova, L; Flores, W; Allison, JP; Sharma, P; Kantarjian, HM. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo plus Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study BLOOD. 2019.11; 134 ( DOI )

Cortes, J; Garcia-Manero, G; Sasaki, K; Naqvi, K; Alvarado, Y; Kadia, TM; Ravandi, F; Cortes, JE; Daver, NG; Takahashi, K; Jabbour, E; Borthakur, GM; Pemmaraju, N; Konopleva, MY; Pierce, SA; Bueso-Ramos, CE; Patel, KP; Kantarjian, HM; Bravo, GM. Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS) BLOOD. 2019.11; 134 ( DOI )

Cortes, J; Alfayez, M; Kadia, TM; Konopleva, MY; Ravandi, F; Cortes, JE; Jabbour, E; Garcia-Manero, G; Pierce, SA; Yilmaz, ME; Short, NJ; Sasaki, K; Masarova, L; Pemmaraju, N; Borthakur, GM; Kantarjian, HM; DiNardo, CD; Daver, NG. Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm) BLOOD. 2019.11; 134 ( DOI )

Guerra, VA; Kantarjian, HM; Cortes, JE; Garcia-Manero, G; Masarova, L; Pemmaraju, N; Jabbour, E; Kadia, TM; DiNardo, CD; Zhou, LS; Pierce, SA; Borthakur, GM; Wierda, WG; Ferrajoli, A; Sasaki, K; Takahashi, K; Naqvi, K; Alvarado, Y; Ohanian, MN; Jain, N; Bose, P; Ravandi, F; Konopleva, MY; Estrov, ZE; Verstovsek, S; Daver, NG. A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs) BLOOD. 2019.11; 134 ( DOI )

Rausch, CR; DiNardo, CD; Maiti, A; Jammal, N; Kadia, TM; Marx, K; Borthakur, GM; Savoy, JM; Pemmaraju, N; Dipippo, A; Daver, NG; Chew, S; Sasaki, K; Issa, GC; Naqvi, K; Ravandi, F; Kantarjian, HM; Konopleva, MY. Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia BLOOD. 2019.11; 134 ( DOI )

Kadia, TM; Cortes, JE; Konopleva, MY; Borthakur, GM; Pemmaraju, N; Daver, NG; Bravo, GM; Issa, GC; Naqvi, K; Short, NJ; DiNardo, CD; Bhalla, KN; Jabbour, E; Takahashi, K; Sasaki, K; Kornblau, SM; Malla, R; Pierce, SA; Wang, XM; Estrov, ZE; Andreeff, M; Garcia-Manero, G; Ravandi, F; Kantarjian, HM. Venetoclax Combined with Cladribine plus Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) BLOOD. 2019.11; 134 ( DOI )

Short, NJ; Kantarjian, HM; Ravandi, F; Huang, XL; Jain, N; Sasaki, K; Khouri, R; Daver, NG; Pemmaraju, N; Khoury, JD; Jorgensen, JL; Alvarado, Y; Konopleva, MY; Garcia-Manero, G; Kadia, TM; Yilmaz, ME; Borthakur, GM; Burger, JA; Kornblau, SM; Wierda, WG; DiNardo, CD; Ferrajoli, A; Jacob, J; Rostykus, M; Garris, R; Ward, M; Huang, BR; Encarnacion, C; Loiselle, C; O'Brien, SM; Jabbour, E. Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia BLOOD. 2019.11; 134 ( DOI )

Richard-Carpentier, G; Kantarjian, HM; Short, NJ; Ravandi, F; Ferrajoli, A; Schroeder, HM; Garcia-Manero, G; Bravo, GM; Cortes, JE; Kwari, M; Loiselle, C; Garris, R; Volter, N; Jain, N; Konopleva, MY; Takahashi, K; Sasaki, K; Wierda, WG; Jabbour, E. Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL) BLOOD. 2019.11; 134 ( DOI )

Short, NJ; Kantarjian, HM; Kanagal-Shamanna, R; Sasaki, K; Ravandi, F; Cortes, JE; Konopleva, MY; Issa, GC; Kornblau, SM; Garcia-Manero, G; Rivera, V; Garris, R; Higgins, J; Pratt, G; Williams, LN; Valentine, CC; Salk, JJ; Prichard, J; Radich, JP; Jabbour, E. Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Using Duplex Sequencing (DS) BLOOD. 2019.11; 134 ( DOI )

Jain, N; Keating, MJ; Thompson, PA; Ferrajoli, A; Burger, JA; Borthakur, GM; Takahashi, K; Estrov, ZE; Fowler, NH; Kadia, TM; Konopleva, MY; Alvarado, Y; Yilmaz, M; DiNardo, CD; Bose, P; Ohanian, M; Pemmaraju, N; Jabbour, E; Sasaki, K; Kanagal-Shamanna, R; Patel, K; Jorgensen, JL; Wang, SA; Garg, N; Wang, XM; Sondermann, K; Cruz, N; Wei, CJ; Ayala, A; Plunkett, W; Kantarjian, HM; Gandhi, V; Wierda, WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) BLOOD. 2019.11; 134 ( DOI )

Short, NJ; Kantarjian, HM; Ravandi, F; Huang, XL; Daver, NG; DiNardo, CD; Konopleva, MY; Pemmaraju, N; Wierda, WG; Garcia-Manero, G; Sasaki, K; Cortes, JE; Garris, R; Ward, M; Huang, BR; Encarnacion, C; Loiselle, C; Khoury, JD; Jorgensen, JL; Jain, N; Alvarez, J; Tippett, N; O'Brien, SM; Jabbour, E. Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia BLOOD. 2019.11; 134 ( DOI )

Montalban-Bravo, G; Jabbour, E; Class, C; Short, NJ; Kanagal-Shamanna, R; Kadia, TM; Borthakur, GM; Pemmaraju, N; Sasaki, K; Estrov, ZE; Cortes, JE; Ravandi, F; Alvarado, Y; Komrokji, RS; Sekeres, MA; Steensma, DP; DeZern, AE; Roboz, GJ; Yang, H; Kantarjian, HM; Garcia-Manero, G. Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes BLOOD. 2019.11; 134 ( DOI )

Perez, JMR; Kadia, TM; Montalban-Bravo, G; Benton, CB; Faderl, S; Sasaki, K; Naqvi, K; Cortes, JE; Daver, NG; DiNardo, CD; Jabbour, E; Borthakur, GM; Al Azzawi, H; Pemmaraju, N; Konopleva, MY; Pierce, SA; Jain, N; Ohanian, M; Garcia-Manero, G; Andreeff, M; Kantarjian, HM; Ravandi, F; Alvarado, Y. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) BLOOD. 2019.11; 134 ( DOI )

Jabbour, E; Roberts, KG; Sasaki, K; Zhao, YQ; Qu, CX; Gu, ZH; Jain, N; Patel, KP; Ravandi, F; Short, NJ; Garcia-Manero, G; Garris, R; Kornblau, S; Konopleva, MY; Mullighan, CG; Kantarjian, HM. Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) BLOOD. 2019.11; 134 ( DOI )

Jain, N; Thompson, PA; Burger, JA; Ferrajoli, A; Takahashi, K; Estrov, ZE; Borthakur, GM; Bose, P; Kadia, TM; Pemmaraju, N; Sasaki, K; Garg, N; Wang, XM; Kanagal-Shamanna, R; Patel, K; Jorgensen, JL; Wang, SA; Lopez, W; Ayala, A; Plunkett, W; Gandhi, V; Kantarjian, HM; O'Brien, S; Keating, MJ; Wierda, WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of <i>IGHV</i>-Mutated CLL and without Del(17p)/Mutated <i>TP53</i> BLOOD. 2019.11; 134 ( DOI )

Kanagal-Shamanna, R; Montalban-Bravo, G; Sasaki, K; Luthra, R; Phdmd, HY; Toruner, GA; Patel, KP; Mallampati, S; Kantarjian, HM; Bueso-Ramos, CE; Medeiros, LJ; Garcia-Manero, G. High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes BLOOD. 2019.11; 134 ( DOI )

Montalban-Bravo, G; Kanagal-Shamanna, R; Benton, CB; Class, C; Chien, KS; Sasaki, K; Naqvi, K; Alvarado, Y; Kadia, TM; Ravandi, F; Cortes, JE; Daver, NG; Takahashi, K; DiNardo, CD; Jabbour, E; Borthakur, GM; Pemmaraju, N; Konopleva, MY; Pierce, SA; Bueso-Ramos, CE; Andreeff, M; Patel, KP; Kantarjian, HM; Garcia-Manero, G. Genomic Context and <i>TP53</i> Allele Frequency Define Prognostic Subgroups and Response Outcomes in <i>TP53</i> Mutated Myelodysplastic Syndromes BLOOD. 2019.11; 134 ( DOI )

Kanagal-Shamanna, R; Montalban-Bravo, G; Class, C; Sasaki, K; Benton, CB; Soltysiak, K; Jabbour, E; Kadia, TM; Bueso-Ramos, CE; Patel, KP; Routbort, M; Ganan-Gomez, I; Wei, Y; Borthakur, GM; Ravandi, F; Do, KA; Medeiros, LJ; Kantarjian, HM; Garcia-Manero, G. Evolutionary Action (EA) Score of <i>TP53</i> Mutations Defines Prognostic Subsets within <i>TP53</i> Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia BLOOD. 2019.11; 134 ( DOI )

Cortes, J; Kantarjian, HM; Richard-Carpentier, G; Borthakur, GM; Ravandi, F; Naqvi, K; Sasaki, K; Kadia, TM; Verstovsek, S; Garcia-Manero, G; DiNardo, CD; Pemmaraju, N; Daver, NG; Bose, P; Pierce, SA; Dara, S; Jabbour, E; Cortes, JE. Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs) BLOOD. 2019.11; 134 ( DOI )

Samra, B; Kantarjian, HM; Sasaki, K; Konopleva, MY; Khouri, R; O'Brien, SM; Ferrajoli, A; Nunez, C; Kadia, TM; Jabbour, E. Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) BLOOD. 2019.11; 134 ( DOI )

Jain, N; Keating, MJ; Thompson, PA; Burger, JA; Ferrajoli, A; Estrov, ZE; Borthakur, GM; Takahashi, K; Bose, P; Fowler, NH; Kadia, TM; Daver, NG; Konopleva, MY; Alvarado, Y; Yilmaz, M; DiNardo, CD; Ohanian, M; Pemmaraju, N; Jabbour, E; Sasaki, K; Kanagal-Shamanna, R; Patel, K; Jorgensen, JL; Wang, SA; Garg, N; Wang, XM; Sondermann, K; Cruz, N; Wei, CJ; Ayala, A; Plunkett, W; Kantarjian, HM; Gandhi, V; Wierda, WG. Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) BLOOD. 2019.11; 134 ( DOI )

Sakhdari, A; Class, C; Montalban-Bravo, G; Sasaki, K; Bueso-Ramos, CE; Patel, KP; Khoury, JD; Kantarjian, HM; Garcia-Manero, G; Medeiros, LJ; Kanagal-Shamanna, R. Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with <i>EZH2</i> Mutation and Portends a Worse Outcome BLOOD. 2019.11; 134 ( DOI )

Maiti, A; DiNardo, CD; Rausch, CR; Cortes, JE; Pemmaraju, N; Daver, NG; Ravandi, F; Garcia-Manero, G; Borthakur, GM; Naqvi, K; Ohanian, MN; Short, NJ; Alvarado, Y; Benton, CB; Kadia, TM; Takahashi, K; Yilmaz, ME; Jain, N; Kornblau, SM; Sasaki, K; Andreeff, M; Bose, P; Ferrajoli, A; Issa, GC; Jabbour, E; Masarova, L; Rytting, ME; Thompson, PA; Wang, SA; Konoplev, S; Chen, ZN; Goswami, M; Maduike, R; Guerrero, JA; Zhang, Q; Cavazos, A; Ma, H; Bivins, CA; Wade, A; Adewale, SL; Tse, S; Thomas, R; Vaughan, K; Pierce, SA; Ning, J; Qiao, W; Welch, JS; Kantarjian, HM; Konopleva, MY. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial BLOOD. 2019.11; 134 ( DOI )

Alfayez, M; Richard-Carpentier, G; Jabbour, E; Vishnu, P; Naqvi, K; Sasaki, K; Cortes, J; Pemmaraju, N. Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia BRITISH JOURNAL OF HAEMATOLOGY. 2019.11; 187 (4): 543-545. ( PubMed, DOI )

Sasaki, K; Kantarjian, HM; Kadia, T; Patel, K; Loghavi, S; Garcia-Manero, G; Jabbour, EJ; DiNardo, C; Pemmaraju, N; Daver, N; Abou Dalle, I; Short, N; Yilmaz, M; Bose, P; Naqvi, K; Pierce, S; Yalniz, F; Cortes, JE; Ravandi, F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia CANCER. 2019.11; 125 (21): 3755-3766. ( PubMed, DOI )

Sasaki, K; Kantarjian, HM; Ravandi, F; Short, NJ; Kebriaei, P; Huang, XL; Rytting, ME; Jain, N; Konopleva, MY; Garcia-Manero, G; Champlin, RE; Kadia, TM; Cortes, JE; Estrov, ZE; Takahashi, K; Loiselle, C; Encarnacion, C; Rostykus, M; Khouri, R; Nasnas, P; Jacob, J; Kwari, M; Garris, R; Jabbour, E. Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse BLOOD. 2019.11; 134 ( DOI )

Sasaki, K; Kantarjian, HM; Jabbour, EJ. Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope? CANCER. 2019.11; 125 (21): 3891-3892. ( PubMed, DOI )

Sasaki, Y; Short, NJ; Kantarjian, HM; Garris, R; Jain, N; Sasaki, K; Ravandi, F; Konopleva, MY; Rytting, ME; Garcia-Manero, G; Little, L; Gumbs, C; Zhao, L; Futreal, PA; Wang, F; Takahashi, K; Jabbour, E. Prognostic Significance of <i>IKZF1</i>, <i>PAX5</i>, and <i>CDKN2A</i> Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib BLOOD. 2019.11; 134 ( DOI )

Sasaki, K; Kantarjian, HM; Samra, B; Short, NJ; Khoury, JD; Kanagal-Shamanna, R; Konopleva, MY; Jain, N; DiNardo, CD; Khouri, R; Garcia-Manero, G; Kadia, TM; Wierda, WG; Tippett, N; Garris, R; Jeanis, V; Daver, NG; Thompson, PA; Yilmaz, M; Cortes, JE; O'Brien, SM; Ravandi, F; Jabbour, E. Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs) BLOOD. 2019.11; 134 ( DOI )

Richard-Carpentier, G; DeZern, AE; Takahashi, K; Konopleva, MY; Loghavi, S; Masarova, L; Alvarado, Y; Ravandi, F; Bravo, GM; Naqvi, K; Sasaki, K; Delumpa, R; Kwari, M; Sekeres, MA; Nazha, A; Roboz, GJ; Kantarjian, HM; Garcia-Manero, G; DiNardo, CD. Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk <i>IDH2</i>-Mutated Myelodysplastic Syndromes (MDS) BLOOD. 2019.11; 134 ( DOI )

Richard-Carpentier, G; Kantarjian, HM; Konopleva, MY; Patel, KP; Roberts, KG; Gu, ZH; Ravandi, F; Jain, N; Short, NJ; Garcia-Manero, G; Schroeder, HM; Kwari, M; Garris, R; Khouri, R; Jones, M; Loiselle, C; Cortes, JE; Sasaki, K; Issa, GC; Kadia, TM; DiNardo, CD; Verstovsek, S; Daver, NG; Mullighan, CG; O'Brien, SM; Jabbour, E. Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) BLOOD. 2019.11; 134 ( DOI )

Masarova, L; Verstovsek, S; Bose, P; Pemmaraju, N; Cortes, JE; Jabbour, E; Ohanian, M; Zhou, LS; Pierce, SA; Gergis, R; Borthakur, GM; Kadia, TM; DiNardo, CD; Ravandi, F; Konopleva, MY; Naqvi, K; Sasaki, K; Estrov, ZE; Garcia-Manero, G; Bueso-Ramos, CE; Kantarjian, HM; Daver, NG. Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis BLOOD. 2019.11; 134 ( DOI )

Maiti, A; Rausch, CR; Cortes, JE; Pemmaraju, N; Daver, NG; Ravandi, F; Garcia-Manero, G; Borthakur, GM; Naqvi, K; Ohanian, M; Short, NJ; Alvarado, Y; Benton, CB; Benton, CB; Kadia, TM; Takahashi, K; Yilmaz, ME; Jain, N; Kornblau, SM; Bravo, GM; Sasaki, K; Andreeff, M; Bose, P; Ferrajoli, A; Issa, GC; Jabbour, E; Masarova, L; Rytting, ME; Thompson, PA; Wang, SA; Konoplev, S; Chen, ZN; Goswami, M; Maduike, R; Guerrero, JA; Zhang, Q; Cavazos, A; Ma, H; Bivins, CA; Wade, A; Adewale, SL; Tse, S; Thomas, R; Vaughan, K; Pierce, SA; Ning, J; Qiao, W; Welch, JS; Kantarjian, HM; Konopleva, MY; DiNardo, CD. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens BLOOD. 2019.11; 134 ( DOI )

Ahaneku, HO; Kantarjian, HM; González, GMN; Borthakur, GM; Verstovsek, S; Kadia, TM; Pemmaraju, N; Garcia-Manero, G; Konopleva, MY; DiNardo, CD; Naqvi, K; Sasaki, K; Issa, GC; Jabbour, E; Cortes, JE. Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet BLOOD. 2019.11; 134 2930. ( DOI )

Montalban-Bravo, G; Kanagal-Shamanna, R; Sasaki, K; Ravandi, F; Cortes, JE; Daver, NG; Takahashi, K; DiNardo, CD; Jabbour, E; Borthakur, GM; Naqvi, K; Konopleva, MY; Pierce, SA; Bueso-Ramos, CE; Patel, KP; Kantarjian, HM; Garcia-Manero, G; Kadia, TM. Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy BLOOD. 2019.11; 134 ( DOI )

Bravo, GM; Kanagal-Shamanna, R; Sasaki, K; Ravandi, F; Cortes, JE; Daver, NG; Takahashi, K; DiNardo, CD; Jabbour, E; Borthakur, GM; Naqvi, K; Konopleva, MY; Pierce, SA; Bueso-Ramos, CE; Patel, KP; Kantarjian, HM; Garcia-Manero, G; Kadia, TM. Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy BLOOD. 2019.11; 134 ( DOI )

Maiti, A; Rausch, CR; Cortes, JE; Pemmaraju, N; Daver, NG; Ravandi, F; Garcia-Manero, G; Borthakur, GM; Naqvi, K; Ohanian, M; Short, NJ; Alvarado, Y; Benton, CB; Kadia, TM; Takahashi, K; Yilmaz, M; Jain, N; Kornblau, SM; Sasaki, K; Andreeff, M; Bose, P; Ferrajoli, A; Issa, GC; Jabbour, E; Masarova, L; Rytting, ME; Thompson, PA; Wang, SA; Konoplev, S; Chen, ZN; Goswami, M; Maduike, R; Guerrero, JA; Zhang, Q; Cavazos, A; Ma, H; Bivins, CA; Wade, A; Adewale, SL; Tse, S; Thomas, R; Vaughan, K; Pierce, SA; Ning, J; Qiao, W; Welch, JS; Patel, KP; Kantarjian, HM; Konopleva, MY; DiNardo, CD. Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia BLOOD. 2019.11; 134 ( DOI )

Samra, B; Kantarjian, HM; Sasaki, K; Short, NJ; Khouri, R; Khoury, JD; Champlin, RE; Kebriaei, P; Cortes, JE; Jorgensen, JL; Wang, SA; Garcia-Manero, G; Kadia, TM; Borthakur, GM; Verstovsek, S; Daver, NG; Montalban-Bravo, G; Jain, N; Konopleva, MY; Yilmaz, ME; Naqvi, K; O'Brien, SM; Ravandi, F; Jabbour, E. Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR) BLOOD. 2019.11; 134 ( DOI )

Sasaki, K; Bravo, GM; Kanagal-Shamanna, R; Jabbour, E; Ravandi, F; Kadia, TM; Naqvi, K; Daver, NG; Pierce, SA; Takahashi, K; DiNardo, CD; González, GMN; Patel, K; Soltysiak, K; Sato, J; Cortes, JE; Kantarjian, HM; Garcia-Manero, G. Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome BLOOD. 2019.11; 134 ( DOI )

Yilmaz, M; Kantarjian, HM; Wang, XM; Khoury, JD; Ravandi, F; Jorgensen, JL; Short, NJ; Loghavi, S; Cortes, JE; Garcia-Manero, G; Kadia, TM; Sasaki, K; Konopleva, MY; Takahashi, K; Wierda, WG; Jain, N; Verstovsek, S; Estrov, ZE; Bose, P; Pierce, SA; Garris, R; O'Brien, SM; Jabbour, E. The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival BLOOD. 2019.11; 134 ( DOI )

Paul, S; Sasaki, K; Savoy, JM; Dipippo, A; Jammal, N; Marx, K; Kadia, TM; Garcia-Manero, G; Ravandi, F; Kantarjian, HM; Jabbour, E. Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia ( Ph)-Positive Acute Lymphocytic Leukemia (ALL) BLOOD. 2019.11; 134 ( DOI )

Sasaki, K; Kantarjian, HM; Jabbour, E; Ravandi, F; Konopleva, MY; Borthakur, GM; Wierda, WG; Daver, NG; Takahashi, K; Naqvi, K; DiNardo, CD; Bravo, GM; Kanagal-Shamanna, R; Pemmaraju, N; Issa, GC; Jain, P; Skinner, J; Rios, MB; Pierce, SA; Soltysiak, K; Sato, J; Garcia-Manero, G; Cortes, JE. The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) BLOOD. 2019.11; 134 ( DOI )

Sasaki, K; Ribera, JM; Figueroa, M; Ravandi, F; Short, NJ; Garcia-Manero, G; Daver, NG; Kadia, TM; Konopleva, MY; Jain, N; Issa, GC; Estrov, ZE; Garris, R; Khouri, R; Nasnas, P; DiNardo, CD; Naqvi, K; Kornblau, SM; Montalban-Bravo, G; Pemmaraju, N; Cortes, JE; O'Brien, SM; Chandra, J; Kantarjian, HM; Jabbour, E. The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI) BLOOD. 2019.11; 134 ( DOI )

Chien, KS; Kanagal-Shamanna, R; Naqvi, K; Sasaki, K; Alvarado, Y; Takahashi, K; Kadia, TM; Borthakur, GM; Jabbour, E; Routbort, M; Pierce, SA; Soltysiak, K; Kantarjian, HM; Garcia-Manero, G; Montalban-Bravo, G. The Impact of <i>PHF6</i> Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia BLOOD. 2019.11; 134 ( DOI )

The Detection of Minor Clones with Somatic KIT D816V Mutations Using Droplet Digital PCR in Pediatric De Novo AML: AML-05 Trial from the Japanese Pediatric Leukemia/Lymphoma Study Group 2019.11; 134 ( DOI )

Short, N; Kantarjian, H; Sasaki, K; Kanagal-Shamanna, R; Ravandi, F; Cortes, J; Konopleva, M; Issa, G; Kornblau, S; Garcia-Manero, G; Rivera, V; Garris, R; Salk, J; Prichard, J; Radich, J; Jabbour, E. Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S186.

Chien, K; Class, C; Bravo, GM; Sasaki, K; Naqvi, K; Gomez, IG; Wei, Y; Yang, H; Kanagal-Shamanna, R; Soltysiak, K; Kantarjian, H; Garcia-Manero, G. LILRB4 Expression in CMML and MDS Based on Response to Hypomethylating Agents CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S341. ( DOI )

Sasaki, K; Kantarjian, H; Richard-Carpentier, G; Short, N; Ravandi, F; Khouri, M; Garcia-Manero, G; Daver, N; Kadia, T; Konopleva, M; Jain, N; Issa, G; Jacob, J; Garris, R; Yilmaz, M; Thompson, P; Nasnas, P; Pemmaraju, N; Cortes, J; O'Brien, S; Jabbour, E. Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S181. ( DOI )

Yilmaz, M; Kantarjian, H; Ravandi, F; Thomas, D; Khouri, M; Garcia-Manero, G; Garris, R; Cortes, J; Short, N; Sasaki, K; Issa, G; Koller, P; Schroeder, H; Kadia, T; Verstovsek, S; Daver, N; Jain, N; Konopleva, M; O'Brien, S; Jabbour, E. Hyper-CVAD Plus Ofatumumab as Frontline Therapy for Adults with CD20 Positive Acute Lymphoblastic Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S185. ( DOI )

Sasaki, K; Kantarjian, H; Richard-Carpentier, G; Ravandi, F; Short, N; Garcia-Manero, G; Daver, N; Kadia, T; Konopleva, M; Jain, N; Issa, G; Jeanis, V; Alvarez, J; Khouri, M; Nasnas, P; Garris, R; Wierda, W; Thompson, P; Pemmaraju, N; Cortes, J; O'Brien, S; Jabbour, E. Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S180-S181.

Yalniz, F; Abou Dalle, I; Kantarjian, H; Borthakur, G; Kadia, T; Patel, K; Loghavi, S; Garcia-Manero, G; Sasaki, K; Daver, N; DiNardo, C; Pemmaraju, N; Short, NJ; Yilmaz, M; Bose, P; Naqvi, K; Pierce, S; Gonzalez, GMN; Konopleva, M; Andreeff, M; Cortes, J; Ravandi, F. Prognostic significance of baseline <i>FLT3</i>-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib AMERICAN JOURNAL OF HEMATOLOGY. 2019.09; 94 (9): 984-991. ( PubMed, DOI )

Yilmaz, M; Kantarjian, H; Wang, XM; Loghavi, S; Khoury, J; Jorgensen, J; Ravandi, F; Short, N; Cortes, J; Garcia-Manero, G; Kadia, T; Sasaki, K; Konopleva, M; Takahashi, K; Wierda, W; Khouri, M; Jain, N; Verstovsek, S; Estrov, Z; Bose, P; Pierce, S; Garris, R; O'Brien, S; Jabbour, E. The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia is a Strong Predictor for Survival CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S193-S194. ( DOI )

Short, N; Jabbour, E; Sasaki, K; Ravandi, F; Huang, XL; Kebriaei, P; Jain, N; Garcia-Manero, G; Kadia, T; Konopleva, M; Jacob, J; Garris, R; Cortes, J; O'Brien, S; Kantarjian, H. Reduced-Intensity Chemotherapy Plus Inotuzumab Ozogamicin, With or Without Sequential Blinatumomab, is Highly Effective as First Salvage Treatment in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S186-S187.

Sasaki, K; Kantarjian, H; Richard-Carpentier, G; Ravandi, F; Short, N; Garcia-Manero, G; Daver, N; Kadia, T; Konopleva, M; Jain, N; Issa, G; Estrov, Z; Garris, R; Khouri, M; Nasnas, P; Pemmaraju, N; Cortes, J; O'Brien, S; Jabbour, E. The Impact of Smoking on Relapse and Survival in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S180.

Jabbour, EJ; Sasaki, K; Ravandi, F; Short, NJ; Garcia-Manero, G; Daver, N; Kadia, T; Konopleva, M; Jain, N; Cortes, J; Issa, GC; Jacob, J; Kwari, M; Thompson, P; Garris, R; Pemmaraju, N; Yilmaz, M; O'Brien, SM; Kantarjian, HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis CANCER. 2019.08; 125 (15): 2579-2586. ( PubMed, DOI )

Naqvi, K; Sasaki, K; Montalban-Bravo, G; Pierola, AA; Yilmaz, M; Short, N; Assi, R; Jabbour, E; Ravandi, F; Kadia, T; Pierce, S; Takahashi, K; Gonzalez, GN; Kanagal-Shamanna, R; Patel, K; Soltysiak, KA; Kantarjian, HM; Garcia-Manero, G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome CANCER. 2019.07; 125 (13): 2233-2241. ( PubMed, DOI )

Alfayez, M; Abou Dalle, I; Abou Richard-Carpentier, G; Pak, D; Ning, J; Pierce, SA; Sasaki, K; Naqvi, K; Daver, NG; Cortes, JE; Ravandi, F; Pemmaraju, N; Ferrajoli, A; Garcia-Manero, G; Konopleva, M; Borthakur, G; Kantarjian, HM; Kadia, T; Dinardo, CD. Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY. 2019.05; 37 (15):

Jain, N; Keating, M; Thompson, P; Ferrajoli, A; Burger, J; Borthakur, G; Takahashi, K; Estrov, Z; Fowler, N; Kadia, T; Konopleva, M; Alvarado, Y; Yilmaz, M; DiNardo, C; Bose, P; Ohanian, M; Pemmaraju, N; Jabbour, E; Sasaki, K; Kanagal-Shamanna, R; Patel, K; Jorgensen, J; Garg, N; Wang, XM; Sondermann, K; Cruz, N; Wei, CJ; Ayala, A; Plunkett, W; Kantarjian, H; Gandhi, V; Wierda, W. Ibrutinib and Venetoclax for First-Line Treatment of CLL NEW ENGLAND JOURNAL OF MEDICINE. 2019.05; 380 (22): 2095-2103. ( PubMed, DOI )

Chien, KS; Class, CA; Montalban-Bravo, G; Sasaki, K; Naqvi, K; Gomez, IG; Wei, Y; Yang, H; Kanagal-Shamanna, R; Kantarjian, HM; Garcia-Manero, G. LILRB4 expression in CMML and MDS based on response to hypomethylating agents. JOURNAL OF CLINICAL ONCOLOGY. 2019.05; 37 (15):

Sasaki, K; Kantarjian, HM; O'Brien, S; Ravandi, F; Konopleva, M; Borthakur, G; Garcia-Manero, G; Wierda, WG; Daver, N; Ferrajoli, A; Takahashi, K; Jain, P; Rios, MB; Pierce, SA; Jabbour, EJ; Cortes, JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors INTERNATIONAL JOURNAL OF HEMATOLOGY. 2019.05; 109 (5): 545-552. ( PubMed, DOI )

Chien, KS; Benton, CB; Class, CA; Kadia, TM; Dinardo, CD; Konopleva, M; Andreeff, M; Sasaki, K; Naqvi, K; Gomez, IG; Wei, Y; Yang, H; Pierce, SA; Patel, KP; Kanagal-Shamanna, R; Kantarjian, HM; Garcia-Manero, G; Montalban-Bravo, G. Patterns of leukemic transformation in patients with <i>TP53</i>-mutant myelodysplastic syndromes. JOURNAL OF CLINICAL ONCOLOGY. 2019.05; 37 (15):

LILRB4 expression in CMML and MDS based on response to hypomethylating agents. 2019.05; 37 (15):

Patterns of leukemic transformation in patients with TP53-mutant myelodysplastic syndromes. 2019.05; 37 (15):

Montalban-Bravo, G; Kanagal-Shamanna, R; Sasaki, K; Patel, K; Ganan-Gomez, I; Jabbour, E; Kadia, T; Ravandi, F; Dinardo, C; Borthakur, G; Takahashi, K; Konopleva, M; Komrokji, RS; DeZern, A; Kuzmanovic, T; Maciejewski, J; Pierce, S; Colla, S; Sekeres, MA; Kantarjian, H; Bueso-Ramos, C; Garcia-Manero, G. <i>NPM1</i> mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy BLOOD ADVANCES. 2019.03; 3 (6): 922-933. ( PubMed, DOI )

Jain, P; Kantarjian, H; Boddu, PC; Nogueras-González, GM; Verstovsek, S; Garcia-Manero, G; Borthakur, G; Sasaki, K; Kadia, TM; Sam, P; Ahaneku, H; O'Brien, S; Estrov, Z; Ravandi, F; Jabbour, E; Cortes, JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs BLOOD ADVANCES. 2019.03; 3 (6): 851-861. ( PubMed, DOI )

Short, NJ; Jabbour, E; Naqvi, K; Patel, A; Ning, J; Sasaki, K; Nogueras-Gonzalez, GM; Bose, P; Kornblau, SM; Takahashi, K; Andreeff, M; Sanchez-Petitto, G; Estrov, Z; Dinardo, CD; Montalban-Bravo, G; Konopleva, M; Alvarado, Y; Bhalla, KN; Fiskus, W; Khouri, M; Islam, R; Kantarjian, H; Garcia-Manero, G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents AMERICAN JOURNAL OF HEMATOLOGY. 2019.01; 94 (1): 74-79. ( PubMed, DOI )

Hu, B; Thall, P; Milton, DR; Sasaki, K; Bashir, Q; Shah, N; Patel, K; Popat, U; Hosing, C; Nieto, Y; Lin, P; Delgado, R; Jorgensen, J; Manasanch, E; Weber, D; Thomas, S; Orlowski, RZ; Champlin, R; Qazilbash, MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes LEUKEMIA & LYMPHOMA. 2019.01; 60 (2): 442-452. ( PubMed, DOI )

Jabbour, E; Short, NJ; Ravandi, F; Huang, XL; Daver, N; DiNardo, CD; Konopleva, M; Pemmaraju, N; Wierda, W; Garcia-Manero, G; Sasaki, K; Cortes, J; Garris, R; Khoury, JD; Jorgensen, J; Jain, N; Alvarez, J; O'Brien, S; Kantarjian, H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study LANCET HAEMATOLOGY. 2018.12; 5 (12): E618-E627. ( PubMed, DOI )

Short, NJ; Kantarjian, HM; Sasaki, K; Ravandi, F; Cortes, JE; Konopleva, MY; Issa, GC; Kanagal-Shamanna, R; Kornblau, SM; Garcia-Manero, G; Rivera, V; Garris, RE; Salk, J; Prichard, J; Radich, JP; Jabbour, EJ. Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia BLOOD. 2018.11; 132 ( DOI )

Short, NJ; Jabbour, EJ; Ravandi, F; Huang, XL; Jain, N; Sasaki, K; Pemmaraju, N; Daver, NG; Khoury, JD; Jorgensen, JL; Alvarado, Y; Konopleva, MY; Garcia-Manero, G; Kadia, TM; Yilmaz, M; Borthakur, G; Burger, JA; Kornblau, SM; Wierda, WG; DiNardo, CD; Ferrajoli, A; Nasnas, P; Jacob, J; Garris, RE; O'Brien, SM; Kantarjian, HM. Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study BLOOD. 2018.11; 132 ( DOI )

Naqvi, K; Sasaki, K; Montalban-Bravo, G; Teach, MS; Pierce, SA; Kantarjian, HM; Garcia-Manero, G. Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis BLOOD. 2018.11; 132 ( DOI )

Richard-Carpentier, G; Kantarjian, HM; Short, NJ; Ravandi, F; Ferrajoli, A; Schroeder, HM; Khouri, M; Garcia-Manero, G; Bravo, GM; Cortes, JE; Jain, N; Konopleva, MY; Takahashi, K; Sasaki, K; Garris, RE; Jabbour, EJ. A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL) BLOOD. 2018.11; 132 ( DOI )

Garcia-Manero, G; Sasaki, K; Montalban-Bravo, G; Daver, NG; Jabbour, EJ; Alvarado, Y; DiNardo, CD; Ravandi, F; Borthakur, G; Bose, P; Pemmaraju, N; Naqvi, K; Cortes, JE; Kadia, TM; Konopleva, MY; Colla, S; Yang, H; Rausch, CR; Gasior, Y; Bueso-Ramos, CE; Kanagal-Shamanna, R; Patel, KP; Kantarjian, HM. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS) BLOOD. 2018.11; 132 ( DOI )

Rausch, CR; Paul, S; Kantarjian, HM; Ravandi, F; Short, NJ; Sasaki, K; Khouri, M; Jacob, J; Montalbano, KS; Thompson, PA; Jain, N; Yilmaz, M; Naqvi, K; Ohanian, MN; Nasnas, P; Estrov, ZE; O'Brien, SM; Jabbour, EJ. Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen BLOOD. 2018.11; 132 ( DOI )

Jain, N; Keating, MJ; Thompson, PA; Ferrajoli, A; Burger, JA; Borthakur, G; Takahashi, K; Estrov, ZE; Fowler, NH; Kadia, TM; Konopleva, MY; Alvarado, Y; Yilmaz, M; DiNardo, CD; Bose, P; Ohanian, MN; Pemmaraju, N; Jabbour, EJ; Sasaki, K; Kanagal-Shamanna, R; Patel, K; Jorgensen, JL; Garg, N; Wang, XM; Sondermann, K; Cruz, N; Wei, CJ; Ayala, A; Plunkett, W; Kantarjian, HM; Gandhi, V; Wierda, WG. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naive High-Risk Chronic Lymphocytic Leukemia (CLL) BLOOD. 2018.11; 132 ( DOI )

Aboudalle, I; Kantarjian, HM; Short, NJ; Ravandi, F; Sasaki, K; Garcia-Manero, G; Montalban-Bravo, G; Cortes, JE; Benton, CB; Issa, GC; Khouri, M; Nasnas, P; O'Brien, SM; Jabbour, EJ. Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia BLOOD. 2018.11; 132 4017. ( DOI )

Montalban-Bravo, G; Benton, CB; Kanagal-Shamanna, R; Sasaki, K; Assi, R; Kadia, TM; Ravandi, F; Ganan-Gomez, I; Cortes, JE; Daver, NG; Takahashi, K; DiNardo, CD; Jabbour, EJ; Borthakur, G; Pemmaraju, N; Konopleva, MY; Pierce, SA; Bueso-Ramos, CE; Kornblau, SM; Patel, K; Colla, S; Kantarjian, HM; Andreeff, M; Garcia-Manero, G. Landscape of <i>TP53</i> Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia BLOOD. 2018.11; 132 ( DOI )

Bose, P; McCue, D; Wiederhold, NP; Kadia, TM; Borthakur, G; Ravandi, F; Yilmaz, M; Takahashi, K; Thompson, PA; Pemmaraju, N; Daver, NG; Burger, JA; Cortes, JE; Garcia-Manero, G; Verstovsek, S; Konopleva, MY; Jain, N; DiNardo, CD; Alvarado, Y; Naqvi, K; Kornblau, SM; Ferrajoli, A; Wierda, WG; Estrov, ZE; Benton, CB; Masarova, L; Montalban-Bravo, G; Sasaki, K; Rausch, CR; Marx, K; Qiao, W; Huang, X; Bivins, CA; Pierce, SA; Kantarjian, HM; Kontoyiannis, DP. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label Prospective Study BLOOD. 2018.11; 132 ( DOI )

Maiti, A; DiNardo, CD; Cortes, JE; Borthakur, G; Pemmaraju, N; Benton, CB; Kadia, TM; Takahashi, K; Naqvi, K; Ravandi, F; Alvarado, Y; Short, NJ; Daver, NG; Sasaki, K; Ohanian, MN; Garcia-Manero, G; Thompson, PA; Kornblau, SM; Masarova, L; Jain, N; Jabbour, EJ; Andreeff, M; Maduike, R; Guerrero, JA; Zhang, Q; Cavazos, A; Ma, H; Rausch, CR; Bivins, CA; Vaughan, K; Pierce, SA; Ning, J; Qiao, W; Welch, JS; Kantarjian, HM; Konopleva, MY. Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome BLOOD. 2018.11; 132 ( DOI )

Sasaki, K; Kantarjian, HM; Short, NJ; Ravandi, F; Khouri, M; Garcia-Manero, G; Daver, NG; Kadia, TM; Konopleva, MY; Jain, N; Issa, GC; Jacob, J; Garris, RE; Yilmaz, M; Thompson, PA; Nasnas, P; Pemmaraju, N; Cortes, JE; O'Brien, SM; Jabbour, EJ. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis BLOOD. 2018.11; 132 ( DOI )

Naqvi, K; Sasaki, K; Montalban-Bravo, G; Alfonso, A; Yilmaz, M; Short, NJ; Assi, R; Jabbour, EJ; Ravandi, F; Kadia, TM; Pierce, SA; Takahashi, K; González, GMN; Kanagal-Shamanna, R; Patel, KP; Kantarjian, HM; Garcia-Manero, G. Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome BLOOD. 2018.11; 132 ( DOI )

Garcia-Manero, G; Sasaki, K; Montalban-Bravo, G; Bodden, KR; Bose, P; Alvarado, Y; Daver, NG; Borthakur, G; Ravandi, F; Takahashi, K; Cortes, JE; Jabbour, EJ; Naqvi, K; DiNardo, CD; Benton, CB; Pemmaraju, N; Kadia, TM; Ohanian, MN; Pierce, SA; Kantarjian, HM. Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) BLOOD. 2018.11; 132 ( DOI )

Kanagal-Shamanna, R; Sasaki, K; Bravo, GM; Benton, CB; Jabbour, EJ; Borthakur, G; Kadia, TM; Bueso-Ramos, CE; Patel, K; Ravandi, F; Kantarjian, HM; Garcia-Manero, G. Evolutionary Action Score of Missense <i>TP53</i> Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia BLOOD. 2018.11; 132 ( DOI )

Swaminathan, M; Kantarjian, HM; Sasaki, K; Ravandi, F; Borthakur, G; Kadia, TM; Garcia-Manero, G; DiNardo, CD; Konopleva, MY; Estrov, ZE; Pemmaraju, N; Daver, NG; Wierda, WG; Ferrajoli, A; Pierce, SA; Dellasala, MDE; Jabbour, EJ; Cortes, JE. Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia BLOOD. 2018.11; 132 ( DOI )

Sasaki, K; Jabbour, EJ; Ravandi, F; Short, NJ; Garcia-Manero, G; Daver, NG; Kadia, TM; Konopleva, MY; Jain, N; Issa, GC; Jeanis, V; Alvarez, J; Khouri, M; Nasnas, P; Garris, RE; Wierda, WG; Thompson, PA; Pemmaraju, N; Cortes, JE; O'Brien, SM; Kantarjian, HM. Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia BLOOD. 2018.11; 132 ( DOI )

Bravo, GM; Kanagal-Shamanna, R; Benton, CB; Colla, S; Ganan-Gomez, I; Sasaki, K; Ravandi, F; Kadia, TM; Cortes, JE; Daver, NG; Takahashi, K; DiNardo, CD; Jabbour, EJ; Borthakur, G; Naqvi, K; Konopleva, MY; Pierce, SA; Bueso-Ramos, CE; Patel, K; Kantarjian, HM; Garcia-Manero, G. Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes BLOOD. 2018.11; 132 ( DOI )

Jabbour, EJ; Sasaki, K; Ravandi, F; Short, NJ; Garcia-Manero, G; Daver, NG; Kadia, TM; Konopleva, MY; Jain, N; Issa, GC; Estrov, ZE; Garris, RE; Khouri, M; Nasnas, P; Pemmaraju, N; Cortes, JE; O'Brien, SM; Kantarjian, HM. Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI) BLOOD. 2018.11; 132 ( DOI )

Sasaki, K; Kantarjian, HM; Ravandi, F; Short, NJ; Kebriaei, P; Huang, XL; Rytting, ME; Jain, N; Konopleva, MY; Garcia-Manero, G; Champlin, RE; Kadia, TM; Cortes, JE; Estrov, ZE; Takahashi, K; Mace, M; Khouri, M; Nasnas, P; Jacob, J; Garris, RE; Jabbour, EJ. Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial BLOOD. 2018.11; 132 ( DOI )

Yalniz, F; Kantarjian, HM; Kadia, TM; Garcia-Manero, G; Patel, K; Loghavi, S; Sasaki, K; Daver, NG; DiNardo, CD; Pemmaraju, N; Short, NJ; Yilmaz, M; Bose, P; Naqvi, K; Pierce, SA; Cortes, JE; Ravandi, F. Prognostic Significance of Baseline <i>FLT3-</i>ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib BLOOD. 2018.11; 132 ( DOI )

Sasaki, K; Kanagal-Shamanna, R; Montalban-Bravo, G; Assi, R; Naqvi, K; Pierola, AA; Yilmaz, M; Short, NJ; Jabbour, EJ; Ravandi, F; Kadia, TM; Pierce, SA; Takahashi, K; DiNardo, CD; González, GMN; Abaza, Y; Devendra, KC; Chamoun, K; Sakurai, K; Patel, KP; Cortes, JE; Kantarjian, HM; Garcia-Manero, G. The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia BLOOD. 2018.11; 132 ( DOI )

Nakamura, Y; Ichikawa, M; Oda, H; Yamazaki, I; Sasaki, K; Mitani, K. <i>RUNX1</i>-<i>EVI1</i> induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice LEUKEMIA RESEARCH. 2018.11; 74 14-20. ( PubMed, DOI )

Jabbour, E; Sasaki, K; Ravandi, F; Huang, XL; Short, NJ; Khouri, M; Kebriaei, P; Burger, J; Khoury, J; Jorgensen, J; Jain, N; Konopleva, M; Garcia-Manero, G; Kadia, T; Cortes, J; Jacob, J; Montalbano, K; Garris, R; O'Brien, S; Kantarjian, HM. Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD, With or Without Blinatumomab, Is Highly Effective in Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage CANCER. 2018.10; 124 (20): 4044-4055. ( PubMed, DOI )

Kosho, T; Yue, F; Era, T; Nakayama, J; Yamaguchi, T; Miyake, N; Mizumoto, S; Yamada, S; Kawamura, R; Wakui, K; Yoshizawa, T; Takahashi, Y; Matsumoto, K; Hirose, T; Minaguchi, J; Takehana, K; Uehara, M; Takahashi, J; Ishikawa, M; Masuda, C; Shimazu, S; Nitahara-Kasahara, Y; Watanabe, A; Okada, T; Matsumoto, K; Hashimoto, A; Nomura, Y; Kakuta, Y; Hatamochi, A; Fukushima, Y; Sasaki, K. Pathophysiology of large subcutaneous hematomas in Musculocontractural EDS-<i>CHST14</i>: an iPS cells-based comprehensive investigation EUROPEAN JOURNAL OF HUMAN GENETICS. 2018.10; 26 237-238.

Kadia, TM; Cortes, J; Ravandi, F; Jabbour, E; Konopleva, M; Benton, CB; Burger, J; Sasaki, K; Borthakur, G; DiNardo, CD; Pemmaraju, N; Daver, N; Ferrajoli, A; Wang, XM; Patel, K; Jorgensen, JL; Wang, S; O'Brien, S; Pierce, S; Tuttle, C; Estrov, Z; Verstovsek, S; Garcia-Manero, G; Kantarjian, H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial LANCET HAEMATOLOGY. 2018.09; 5 (9): E411-E421. ( PubMed, DOI )

Morita, K; Kantarjian, HM; Wang, F; Yan, YQ; Bueso-Ramos, C; Sasaki, K; Issa, GC; Wang, S; Jorgensen, J; Song, XZ; Zhang, JH; Tippen, S; Thornton, R; Coyle, M; Little, L; Gumbs, C; Pemmaraju, N; Daver, N; DiNardo, CD; Konopleva, M; Andreeff, M; Ravandi, F; Cortes, JE; Kadia, T; Jabbour, E; Garcia-Manero, G; Patel, KP; Futreal, PA; Takahashi, K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia JOURNAL OF CLINICAL ONCOLOGY. 2018.06; 36 (18): 1788-+. ( PubMed, DOI )

Bazarbachi, AH; Yilmaz, M; Ravandi, F; Thomas, DA; Khouri, M; Garcia-Manero, G; Garris, RS; Cortes, JE; Short, NJ; Sasaki, K; Issa, GC; Koller, PB; Kadia, TM; Verstovsek, S; Daver, NG; Jain, N; Konopleva, M; O'Brien, SM; Jabbour, E; Kantarjian, HM. A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+acute lymphoblastic leukemia (ALL): Updated results. JOURNAL OF CLINICAL ONCOLOGY. 2018.05; 36 (15): ( DOI )

Ghorab, A; Kantarjian, HM; Jain, P; Kanagal-Shamanna, R; Jabbour, E; Sasaki, K; Kadia, TM; Garcia-Manero, G; Bose, P; Yilmaz, M; Naqvi, K; Wierda, WG; Verstovsek, S; Jain, N; Estrov, Z; Ravandi, F; O'Brien, SM; Cortes, JE. Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes. JOURNAL OF CLINICAL ONCOLOGY. 2018.05; 36 (15): ( DOI )

Sasaki, K; Kantarjian, H; O'Brien, S; Ravandi, F; Konopleva, M; Borthakur, G; Garcia-Manero, G; Wierda, W; Daver, N; Ferrajoli, A; Takahashi, K; Jain, P; Rios, MB; Pierce, S; Jabbour, E; Cortes, JE. Prediction for sustained deep molecular response of <i>BCR-ABL1</i> levels in patients with chronic myeloid leukemia in chronic phase CANCER. 2018.03; 124 (6): 1160-1168. ( PubMed, DOI )

Kantarjian, H; Ravandi, F; Short, NJ; Huang, XL; Jain, N; Sasaki, K; Daver, N; Pemmaraju, N; Khoury, JD; Jorgensen, J; Alvarado, Y; Konopleva, M; Garcia-Manero, G; Kadia, T; Yilmaz, M; Bortakhur, G; Burger, J; Kornblau, S; Wierda, W; DiNardo, C; Ferrajoli, A; Jacob, J; Garris, R; O'Brien, S; Jabbour, E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study LANCET ONCOLOGY. 2018.02; 19 (2): 240-248. ( PubMed, DOI )

Jabbour, E; Ravandi, F; Kebriaei, P; Huang, XL; Short, NJ; Thomas, D; Sasaki, K; Rytting, M; Jain, N; Konopleva, M; Garcia-Manero, G; Champlin, R; Marin, D; Kadia, T; Cortes, J; Estrov, Z; Takahashi, K; Patel, Y; Khouri, MR; Jacob, J; Garris, R; O'Brien, S; Kantarjian, H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Phase 2 Clinical Trial JAMA ONCOLOGY. 2018.02; 4 (2): 230-234. ( PubMed, DOI )

Short, NJ; Kantarjian, H; Ravandi, F; Huang, XL; Xiao, LC; Garcia-Manero, G; Plunkett, W; Gandhi, V; Sasaki, K; Pemmaraju, N; Daver, NG; Borthakur, G; Jain, N; Konopleva, M; Estrov, Z; Kadia, TM; Wierda, WG; DiNardo, CD; Brandt, M; O'Brien, SM; Cortes, JE; Jabbour, E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia LEUKEMIA & LYMPHOMA. 2018; 59 (4): 813-820. ( PubMed, DOI )

Assi, R; Kantarjian, HM; Khouri, R; Ravandi, F; Kebriaei, P; Short, NJ; Thomas, DA; Garcia-Manero, G; Champlin, RE; Kadia, T; Cortes, JE; Jain, N; Konopleva, M; Estrov, Z; Takahashi, K; Sasaki, K; Jacob, J; Manzoor, A; Garris, R; O'Brien, SM; Jabbour, EJ. Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) BLOOD. 2017.12; 130

Naqvi, K; Bravo, GM; Pierola, AA; Yilmaz, M; Sasaki, K; Short, NJ; Assi, R; Jabbour, EJ; Ravandi, F; Benton, CB; Kadia, T; Pierce, S; Borthakur, G; Daver, N; DiNardo, CD; Takahashi, K; Jain, N; Pemmaraju, N; González, GN; Kantarjian, HM; Garcia-Manero, G. Clonal Hematopoiesis of Indeterminate Potential - Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome BLOOD. 2017.12; 130

Short, NJ; Kantarjian, HM; Ravandi, F; Huang, X; Jain, N; Daver, N; Thomas, DA; Pemmaraju, N; Khouri, R; Khoury, JD; Jorgensen, JL; Alvarado, Y; Sasaki, K; Konopleva, M; Garcia-Manero, G; Kadia, T; Cortes, JE; Benton, CB; Borthakur, G; Burger, JA; Ohanian, M; Wierda, WG; Estrov, Z; Kornblau, S; DiNardo, CD; Ferrajoli, A; Jacob, J; Manzoor, A; Garris, R; O'Brien, SM; Jabbour, EJ. A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia BLOOD. 2017.12; 130

Sasaki, K; Nagasawa, F; Yoshida, K; Takeda, J; Shiraishi, Y; Chiba, K; Tanaka, H; Okada, A; Miyano, S; Ichikawa, M; Ogawa, S; Mitani, K. Contribution of <i>MIR9</i> on Disease Progression of Chronic Myelogenous Leukemia BLOOD. 2017.12; 130

Ghorab, A; Jain, P; Kantarjian, HM; Kanagal-Shamanna, R; Jabbour, EJ; Sasaki, K; Kadia, T; Garcia-Manero, G; Bose, P; Yilmaz, M; Naqvi, K; Wierda, WG; Verstovsek, S; Jain, N; Estrov, Z; Ravandi, F; O'Brien, SM; Cortes, JE. Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes BLOOD. 2017.12; 130

Sasaki, K; Kantarjian, HM; O'Brien, SM; Ravandi, F; Konopleva, M; Borthakur, G; Garcia-Manero, G; Wierda, WG; Daver, N; Ferrajoli, A; Takahashi, K; Jain, P; Rios, MB; Pierce, S; Jabbour, EJ; Cortes, JE. Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI) BLOOD. 2017.12; 130

Maiti, A; Kantarjian, HM; Ravandi, F; Khouri, M; Thomas, DA; Garcia-Manero, G; Garris, R; Cortes, JE; Short, NJ; Jain, N; Bose, P; Verstovsek, S; Konopleva, M; Sasaki, K; Issa, GC; Ghosn, M; Schroeder, HM; Kadia, T; Daver, N; O'Brien, SM; Jabbour, EJ. Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial BLOOD. 2017.12; 130

Yilmaz, M; Jabbour, EJ; Wang, XM; Loghavi, S; Khoury, JD; Jorgensen, JL; Ravandi, F; Short, NJ; Cortes, JE; Garcia-Manero, G; Kadia, T; Sasaki, K; Konopleva, M; Takahashi, K; Khouri, M; Jain, N; Verstovsek, S; Estrov, Z; Estrov, Z; Bose, P; Pierce, S; Garris, R; O'Brien, SM; Kantarjian, HM. Dynamics of Measurable Disease at Remission Determines Survival in Patients (Pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL) BLOOD. 2017.12; 130

Jain, P; Kanagal-Shamanna, R; Kantarjian, HM; Lucas, FAS; Ghorab, A; Jabbour, EJ; Ghayas, I; Sasaki, K; Kadia, T; Estrov, Z; Ravandi, F; Cortes, JE. Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML BLOOD. 2017.12; 130

Alqam, HM; Kantarjian, HM; Chihara, D; Sasaki, K; Jabbour, EJ; Cortes, JE. Survival Outcome of Secondary Solid Cancer in Patients with Chronic Myeloid Leukemia BLOOD. 2017.12; 130

Yilmaz, M; Kantarjian, HM; Wang, XM; Devendra, KC; Khoury, JD; Ravandi, F; Short, NJ; Cortes, JE; Garcia-Manero, G; Kadia, T; Sasaki, K; Konopleva, M; Wierda, WG; Khouri, M; Jain, N; Verstovsek, S; Estrov, Z; Bose, P; Pierce, S; Garris, R; O'Brien, SM; Jabbour, EJ. Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL) BLOOD. 2017.12; 130

Sasaki, K; Jabbour, EJ; Khouri, M; Thomas, DA; Garcia-Manero, G; Ravandi, F; Borthakur, G; Short, NJ; Issa, GC; Kadia, T; Jones, E; Garris, R; Cortes, JE; O'Brien, SM; Kantarjian, HM. Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) BLOOD. 2017.12; 130

Yilmaz, M; Devendra, KC; Akosile, MA; Khoury, JD; Short, NJ; Cortes, JE; Garcia-Manero, G; Ravandi, F; Kadia, T; Sasaki, K; Konopleva, M; Wierda, WG; Jain, N; Verstovsek, S; Estrov, Z; Pierce, S; O'Brien, SM; Jabbour, EJ; Kantarjian, HM. The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL) BLOOD. 2017.12; 130

A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia 2017.12; 130

Dynamics of Measurable Disease at Remission Determines Survival in Patients (Pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL) 2017.12; 130

Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial 2017.12; 130

Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI) 2017.12; 130

Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes 2017.12; 130

The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL) 2017.12; 130

Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML 2017.12; 130

Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL) 2017.12; 130

Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) 2017.12; 130

Jabbour, E; Short, NJ; Ravandi, F; Huang, XL; Xiao, LC; Garcia-Manero, G; Plunkett, W; Gandhi, V; Sasaki, K; Pemmaraju, N; Daver, NG; Borthakur, G; Jain, NT; Konopleva, M; Estrov, Z; Kadia, TM; Wierda, WG; DiNardo, CD; Brandt, M; O'Brien, SM; Cortes, JE; Kantarjian, H. A Randomized Phase 2 Study of Idarubicin and Cytarabine With Clofarabine or Fludarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia CANCER. 2017.11; 123 (22): 4430-4439. ( PubMed, DOI )

Issa, GC; Kantarjian, HM; Gonzalez, GN; Borthakur, G; Tang, GL; Wierda, W; Sasaki, K; Short, NJ; Ravandi, F; Kadia, T; Patel, K; Luthra, R; Ferrajoli, A; Garcia-Manero, G; Rios, MB; Dellasala, S; Jabbour, E; Cortes, JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment BLOOD. 2017.11; 130 (19): 2084-2091. ( PubMed, DOI )

Jain, P; Kantarjian, HM; Ghorab, A; Sasaki, K; Jabbour, EJ; Nogueras Gonzalez, G; Kanagal-Shamanna, R; Issa, GC; Garcia-Manero, G; Devendra, KC; Dellasala, S; Pierce, S; Konopleva, M; Wierda, WG; Verstovsek, S; Daver, NG; Kadia, TM; Borthakur, G; O'Brien, S; Estrov, Z; Ravandi, F; Cortes, JE. Prognostic Factors and Survival Outcomes in Patients With Chronic Myeloid Leukemia in Blast Phase in the Tyrosine Kinase Inhibitor Era: Cohort Study of 477 Patients CANCER. 2017.11; 123 (22): 4391-4402. ( PubMed, DOI )

Kanagal-Shamanna, R; Jain, P; Takahashi, K; Short, NJ; Tang, GL; Issa, GC; Ravandi, F; Garcia-Manero, G; Yin, CC; Luthra, R; Patel, KP; Khoury, JD; Montalban-Bravo, G; Sasaki, K; Kadia, TM; Borthakur, G; Konopleva, M; Jain, N; Garris, R; Pierce, S; Wierda, W; Estrov, Z; Cortes, J; O'Brien, S; Kantarjian, HM; Jabbour, E. <i>TP53</i> Mutation Does Not Confer a Poor Outcome in Adult Patients With Acute Lymphoblastic Leukemia Who Are Treated With Frontline Hyper-CVAD-Based Regimens CANCER. 2017.10; 123 (19): 3717-3724. ( PubMed, DOI )

Jain, P; Kantarjian, H; Jain, N; Short, NJ; Yin, CC; Kanagal-Shamanna, R; Khoury, J; Konopleva, M; Sasaki, K; Kadia, TM; Garris, R; Pierce, S; Estrov, Z; Wierda, W; Cortes, J; O'Brien, S; Ravandi, F; Jabbour, E. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens AMERICAN JOURNAL OF HEMATOLOGY. 2017.10; 92 (10): E595-E597. ( PubMed, DOI )

Arai, H; Ichikawa, M; Furuichi, S; Nagasawa, F; Takahashi, W; Handa, T; Nakamura, Y; Nakamura, Y; Sasaki, K; Mitani, K. Non-Hodgkin's lymphoma of the breast: a review of 6 cases including 3 patients with a history of autoimmune diseases ANNALS OF ONCOLOGY. 2017.10; 28

Assi, R; Kantarjian, H; Ravandi, F; O'Brien, SM; Kebriaei, P; Short, NJ; Thomas, DA; Garcia-Manero, G; Champlin, RE; Kadia, TM; Cortes, JE; Jain, N; Konopleva, M; Khouri, R; Estrov, Z; Takahashi, K; Sasaki, K; Jacob, J; Garris, R; Jabbour, E. A Phase II Trial of Inotuzumab Ozogamicin Combined with Mini-HyperCVD as Salvage Therapy for Relapsed/Refractory ALL CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2017.09; 17 S264-S265. ( DOI )

Maiti, A; Kantarjian, H; O'Brien, S; Ravandi, F; Short, N; Thomas, D; Garcia-Manero, G; Daver, N; Borthakur, G; Jain, N; Konopleva, M; Sasaki, K; Pemmaraju, N; Alvarado, Y; Jacob, J; Garris, R; Thompson, P; Cortes, J; Jabbour, E. Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2017.09; 17 S255-S256. ( DOI )

Maiti, A; Kantarjian, H; Ravandi, F; Short, N; Daver, N; Pemmaraju, N; Thomas, D; Yilmaz, M; Kadia, T; Sasaki, K; Garris, R; Garcia-Manero, G; DiNardo, C; Konopleva, M; Estrov, Z; Jain, N; Weirda, W; Jeanis, V; Cortes, J; O'Brien, S; Jabbour, E. Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2017.09; 17 S257-S258. ( DOI )

Maiti, A; Kantarjian, H; Ravandi, F; Thomas, D; Khouri, M; Garcia-Manero, G; Garris, R; Cortes, J; Short, N; Sasaki, K; Issa, G; Koller, P; Schroeder, H; Kadia, T; Verstovsek, S; Daver, N; Jain, N; Konopleva, M; O'Brien, S; Jabbour, E. Frontline Ofatumumab with Hyper-CVAD in CD20+Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2017.09; 17 S256-S257. ( DOI )

Sasaki, K; Jabbour, E; O'Brien, S; Thomas, D; Garcia-Manero, G; Ravandi, F; Borthakur, G; Short, N; Issa, G; Gachimova, E; Garris, R; Cortes, J; Kantarjian, H. Phase II study of hyper-CMAD with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2017.09; 17 S266. ( DOI )

Jabbour, E; Short, NJ; Montalban-Bravo, G; Huang, XL; Bueso-Ramos, C; Qiao, W; Yang, H; Zhao, C; Kadia, T; Borthakur, G; Pemmaraju, N; Sasaki, K; Estrov, Z; Cortes, J; Ravandi, F; Alvarado, Y; Komrokji, R; Sekeres, MA; Steensma, DP; DeZern, A; Roboz, G; Kantarjian, H; Garcia-Manero, G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN BLOOD. 2017.09; 130 (13): 1514-1522. ( PubMed, DOI )

Short, N; Kantarjian, H; Ravandi, F; Daver, N; Pemmaraju, N; Thomas, D; Yilmaz, M; Kadia, T; Sasaki, K; Garris, R; Garcia-Manero, G; DiNardo, C; Konopleva, M; Estrov, Z; Jain, N; Wierda, W; Jeanis, V; Cortes, J; O'Brien, S; Jabbour, E. UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA HAEMATOLOGICA. 2017.06; 102 198.

Short, N; Kantarjian, H; Ravandi, F; Huang, X; Xiao, L; Garcia-Manero, G; Plunkett, W; Gandhi, V; Sasaki, K; Pemmaraju, N; Daver, N; Borthakur, G; Jain, N; Konopleva, M; Estrov, Z; Kadia, T; Wierda, W; DiNardo, C; Brandt, M; O'Brien, S; Cortes, J; Jabbour, E. A RANDOMIZED PHASE II STUDY OF IDARUBICIN AND CYTARABINE WITH EITHER CLOFARABINE OR FLUDARABINE IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA HAEMATOLOGICA. 2017.06; 102 53.

Short, N; Kantarjian, H; O'Brien, S; Ravandi, F; Thomas, D; Garcia-Manero, G; Daver, N; Borthakur, G; Jain, N; Konopleva, M; Sasaki, K; Pemmaraju, N; Alvarado, Y; Jacob, J; Garris, R; Thompson, P; Cortes, J; Jabbour, E. INOTUZUMAB OZOGAMICIN IN COMBINATION WITH LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AS FRONTLINE THERAPY FOR OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE I/II TRIAL HAEMATOLOGICA. 2017.06; 102 34-35.

Short, NJ; Kantarjian, HM; O'Brien, SM; Ravandi, F; Thomas, DA; Garcia-Manero, G; Daver, NG; Borthakur, G; Jain, N; Konopleva, M; Sasaki, K; Pemmaraju, N; Alvarado, Y; Jacob, J; Garris, R; Thompson, PA; Cortes, JE; Jabbour, E. Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

Maiti, A; Kantarjian, HM; Ravandi, F; Thomas, DA; Khouri, M; Garcia-Manero, G; Garris, RS; Cortes, JE; Short, NJ; Sasaki, K; Issa, GC; Koller, PB; Schroeder, HM; Kadia, TM; Verstovsek, S; Daver, NG; Jain, N; Konopleva, M; O'Brien, SM; Jabbour, E. Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+acute lymphoblastic leukemia. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

Short, NJ; Kantarjian, HM; Ravandi, F; Daver, NG; Pemmaraju, N; Thomas, DA; Yilmaz, M; Kadia, TM; Sasaki, K; Garris, R; Garcia-Manero, G; Dinardo, CD; Konopleva, M; Estrov, Z; Jain, N; Wierda, WG; Jeanis, V; Cortes, JE; O'Brien, SM; Jabbour, E. Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Updated results of a phase II study. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

Assi, R; Kantarjian, HM; Ravandi, F; O'Brien, SM; Kebriaei, P; Thomas, DA; Garcia-Manero, G; Khouri, IF; Champlin, RE; Kadia, TM; Cortes, JE; Jain, N; Konopleva, M; Khouri, R; Estrov, Z; Takahashi, K; Sasaki, K; Jacob, J; Garris, R; Jabbour, E. Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

Gettys, SC; Gulbis, A; Wilhelm, K; Sasaki, K; Dinh, Y; Rondon, G; Qazilbash, MH. Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma EUROPEAN JOURNAL OF HAEMATOLOGY. 2017.04; 98 (4): 388-392. ( PubMed, DOI )

Short, NJ; Kantarjian, HM; Sasaki, K; Ravandi, F; Ko, H; Yin, CC; Garcia-Manero, G; Cortes, JE; Garris, R; O'Brien, SM; Patel, K; Khouri, M; Thomas, D; Jain, N; Kadia, TM; Daver, NG; Benton, CB; Issa, GC; Konopleva, M; Jabbour, E. Poor outcomes associated with+1der(22) t(9;22) and-9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor AMERICAN JOURNAL OF HEMATOLOGY. 2017.03; 92 (3): 238-243. ( PubMed, DOI )

Jabbour, E; Faderl, S; Sasaki, K; Kadia, T; Daver, N; Pemmaraju, N; Patel, K; Khoury, JD; Bueso-Ramos, C; Bohannan, Z; Ravandi, F; Borthakur, G; Verstovsek, S; Miller, D; Maduike, R; Hosing, C; Kantarjian, HM; Garcia-Manero, G. Phase 2 Study of Low-Dose Clofarabine Plus Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome Who Have Relapsed or Are Refractory to Hypomethylating Agents CANCER. 2017.02; 123 (4): 629-637. ( PubMed, DOI )

Issa, GC; Kantarjian, HM; Yin, CC; Qiao, W; Ravandi, F; Thomas, D; Short, NJ; Sasaki, K; Garcia-Manero, G; Kadia, TM; Cortes, JE; Daver, N; Borthakur, G; Jain, N; Konopleva, M; Khouri, I; Kebriaei, P; Champlin, RE; Pierce, S; O'Brien, SM; Jabbour, E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease CANCER. 2017.02; 123 (3): 459-467. ( PubMed, DOI )

Jabbour, E; Short, NJ; Jorgensen, JL; Yilmaz, M; Ravandi, F; Wang, SA; Thomas, DA; Khoury, J; Champlin, RE; Khouri, I; Kebriaei, P; O'Brien, SM; Garcia-Manero, G; Cortes, JE; Sasaki, K; Dinardo, CD; Kadia, TM; Jain, N; Konopleva, M; Garris, R; Kantarjian, HM. Differential Impact of Minimal Residual Disease Negativity According to the Salvage Status in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia CANCER. 2017.01; 123 (2): 294-302. ( PubMed, DOI )

Koji Sasaki, Elias J Jabbour, Farhad Ravandi, Nicholas J Short, Deborah A Thomas, Guillermo Garcia-Manero, Naval G Daver, Tapan M Kadia, Marina Y Konopleva, Nitin Jain, Ghayas C Issa, Vicki Jeanis, Haim G Moore, Rebecca S Garris, Naveen Pemmaraju, Jorge E Cortes, Susan M O'Brien, Hagop M Kantarjian. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016.12; 122 (23): 3650-3656. ( PubMed, DOI )

Jabbour, EJ; Short, NJ; Huang, X; Maiti, A; Kadia, TM; Daver, N; Borthakur, G; DiNardo, CD; Pemmaraju, N; Sasaki, K; Estrov, Z; Verstovsek, S; Ravandi, F; Alvarado, Y; Sekeres, MA; Komrokji, RS; Steensma, DP; DeZern, AE; Roboz, GJ; Miller, D; Dong, X; Kantarjian, HM; Garcia-Manero, G. A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium BLOOD. 2016.12; 128 (22): ( DOI )

Jabbour, EJ; Kantarjian, HM; Sasaki, K; Kadia, TM; Ravandi, F; Cortes, JE; Khoury, JD; Patel, KP; Bueso-Ramos, CE; Daver, NG; Borthakur, G; Jain, N; DiNardo, CD; Konopleva, M; Verstovsek, S; Pemmaraju, N; Estrov, Z; Miller, D; Maduike, R; Faderl, S; Garcia-Manero, G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy BLOOD. 2016.12; 128 (22): ( DOI )

Kanagal-Shamanna, R; Jain, P; Luthra, R; Patel, KP; Garcia-Manero, G; Takahashi, K; Ravandi, F; Sasaki, K; Kadia, TM; Borthakur, G; Konopleva, M; Jain, N; Garris, R; Pierce, S; Estrov, Z; Wierda, WG; O'Brien, SM; Cortes, JE; Kantarjian, HM; Jabbour, EJ. Clinical Implications of <i>TP53</i> Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens BLOOD. 2016.12; 128 (22): ( DOI )

Jain, P; Kantarjian, HM; Ravandi, F; Kanagal-Shamanna, R; Khoury, JD; Patel, KP; Garcia-Manero, G; Konopleva, M; Jain, N; Sasaki, K; Kadia, TM; Borthakur, G; Garris, R; Pierce, S; Estrov, Z; Wierda, WG; Cortes, JE; O'Brien, SM; Jabbour, EJ. Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens BLOOD. 2016.12; 128 (22): ( DOI )

Sasaki, K; Kantarjian, HM; Jabbour, EJ; O'Brien, S; Ravandi, F; Konopleva, M; Borthakur, G; Wierda, WG; Daver, N; Takahashi, K; Jain, P; Skinner, J; Rios, MB; Pierce, S; Garcia-Manero, G; Cortes, JE. Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase BLOOD. 2016.12; 128 (22): ( DOI )

Short, NJ; Jabbour, EJ; Sasaki, K; Ko, HD; Ravandi, F; Yin, CC; Khouri, MR; Cortes, JE; Garris, R; O'Brien, SM; Patel, KP; Garcia-Manero, G; Thomas, DA; Daver, N; Naqvi, K; Bose, P; Jain, N; Konopleva, M; Kantarjian, HM. Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality BLOOD. 2016.12; 128 (22): ( DOI )

Short, NJ; Kantarjian, HM; Jorgensen, JL; Ravandi, F; Yilmaz, M; Khouri, MR; Wang, S; Thomas, DA; Khoury, JD; Champlin, RE; Khouri, IF; Kebriaei, P; Marin, D; O'Brien, SM; Garcia-Manero, G; Cortes, JE; Sasaki, K; DiNardo, CD; Kadia, TM; Jain, N; Konopleva, M; Garris, R; Jabbour, EJ. Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment BLOOD. 2016.12; 128 (22): ( DOI )

Jain, P; Kantarjian, HM; Jabbour, EJ; Gonzalez, GN; Garcia-Manero, G; Kanagal-Shamanna, R; Patel, KP; Hu, SM; DellaSala, SE; Pierce, S; Sasaki, K; Konopleva, M; Wierda, WG; Daver, N; Kadia, TM; Borthakur, G; Estrov, Z; Ravandi, F; O'Brien, SM; Cortes, JE. Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients BLOOD. 2016.12; 128 (22): ( DOI )

Sasaki, K; Jabbour, EJ; O'Brien, SM; Ravandi, F; Thomas, DA; Garcia-Manero, G; Daver, N; Borthakur, G; Jain, N; Konopleva, M; Short, NJ; Pemmaraju, N; Alvarado, Y; Jacob, J; Garris, R; Thompson, PA; Cortes, JE; Kantarjian, HM. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial BLOOD. 2016.12; 128 (22): ( DOI )

Sasaki, K; Kantarjian, HM; Ravandi, F; Daver, N; Kadia, TM; Khouri, RB; Alvarado, Y; Burger, JA; Thomas, DA; Garcia-Manero, G; DiNardo, CD; Pemmaraju, N; Short, NJ; Schroeder, H; Garris, R; Bose, P; Jain, N; Naqvi, K; Wierda, WG; Verstovsek, S; Cortes, JE; Konopleva, M; O'Brien, SM; Jabbour, EJ. Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial BLOOD. 2016.12; 128 (22): ( DOI )

Patel, YB; Voit, KN; Sasaki, K; Ravandi, F; Thomas, DA; O'Brien, SM; Borthakur, G; Garcia-Manero, G; Cortes, JE; Konopleva, M; Jain, N; Ohanian, M; Garris, R; Jacob, J; Kantarjian, HM; Jabbour, EJ. Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen BLOOD. 2016.12; 128 (22):

Short, NJ; Kantarjian, HM; Sasaki, K; Cortes, JE; Ravandi, F; Thomas, DA; Garcia-Manero, G; Khouri, I; Kebriaei, P; Champlin, RE; Pierce, S; Issa, GC; Konopleva, M; Kadia, TM; Bueso-Ramos, C; Khoury, JD; Jain, N; O'Brien, SM; Jabbour, E. Prognostic Significance of Day 14 Bone Marrow Evaluation in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia CANCER. 2016.12; 122 (24): 3812-3820. ( PubMed, DOI )

Sasaki, K; Kantarjian, HM; O'Brien, S; Ravandi, F; Konopleva, M; Borthakur, G; Garcia-Manero, G; Wierda, WG; Daver, N; Ferrajoli, A; Takahashi, K; Jain, P; Rios, MB; Pierce, S; Jabbour, EJ; Cortes, JE. Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) BLOOD. 2016.12; 128 (22): ( DOI )

Sasaki, K; Jabbour, EJ; O'Brien, SM; Ravandi, F; Thomas, DA; Kadia, TM; Garcia-Manero, G; Burger, JA; Pemmaraju, N; Alvarado, Y; Daver, NG; Jain, N; Konopleva, M; Champlin, RE; Khouri, IF; Kebriaei, P; Marin, D; DiNardo, CD; Estrov, Z; Takahashi, K; Short, NJ; Khouri, MR; Jacob, J; Garris, R; Cortes, JE; Kantarjian, HM. Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) BLOOD. 2016.12; 128 (22): ( DOI )

Sasaki, K; Jabbour, EJ; Ravandi, F; Daver, NG; Pemmaraju, N; Thomas, DA; Khouri, RB; Yilmaz, M; Kadia, TM; Short, NJ; Garris, R; Garcia-Manero, G; DiNardo, CD; Konopleva, M; Estrov, Z; Jain, N; Wierda, WG; Jeanis, TV; Cortes, JE; O'Brien, SM; Kantarjian, HM. Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia BLOOD. 2016.12; 128 (22): ( DOI )

Sasaki, K; Jabbour, EJ; O'Brien, SM; Thomas, DA; Ravandi, F; Garcia-Manero, G; Cortes, JE; Short, NJ; Verstovsek, S; Yilmaz, M; Wierda, WG; Borthakur, G; Kadia, TM; Konopleva, M; Khouri, MR; Ferrajoli, A; Daver, NG; Pemmaraju, N; DiNardo, CD; Jain, N; Benton, CB; Takahashi, K; Naqvi, K; Bose, P; Kornblau, SM; Andreeff, M; Keating, MJ; Freireich, EJ; Kantarjian, HM. Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience BLOOD. 2016.12; 128 (22): ( DOI )

Koji Sasaki, Elias Jabbour, Jorge Cortes, Tapan Kadia, Guillermo Garcia-Manero, Gautam Borthakur, Preetesh Jain, Sherry Pierce, Naval Daver, Koichi Takahashi, Susan O'Brien, Hagop Kantarjian, Farhad Ravandi. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk. 2016.11; 16 (11): 616-624. ( PubMed, DOI )

Takahashi, K; Kantarjian, HM; Yang, YL; Sasaki, K; Jain, P; DellaSala, S; Ravandi, F; Kadia, T; Pemmaraju, N; Daver, N; Borthakur, G; Garcia-Manero, G; Jabbour, E; Cortes, JE. A Propensity Score Matching Analysis of Dasatinib and Nilotinib as a Frontline Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase CANCER. 2016.11; 122 (21): 3336-3343. ( PubMed, DOI )

Tamamyan, GN; Kantarjian, HM; Ning, J; Jain, P; Sasaki, K; McClain, KL; Allen, CE; Pierce, SA; Cortes, JE; Ravandi, F; Konopleva, MY; Garcia-Manero, G; Benton, CB; Chihara, D; Rytting, ME; Wang, S; Abdelall, W; Konoplev, SN; Daver, NG. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes CANCER. 2016.09; 122 (18): 2857-2866. ( PubMed, DOI )

Koji Sasaki, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Koichi Takahashi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia-Manero, William Wierda, Naval Daver, Preetesh Jain, Toshihisa Satta, Sherry Pierce, May Beth Rios, Jorge E Cortes. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica. 2016.08; 101 (8): e324-e327. ( PubMed, DOI )

Short, NJ; Jabbour, E; Sasaki, K; Patel, K; O'Brien, SM; Cortes, JE; Garris, R; Issa, GC; Garcia-Manero, G; Luthra, R; Thomas, D; Kantarjian, H; Ravandi, F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia BLOOD. 2016.07; 128 (4): 504-507. ( PubMed, DOI )

Sasaki, K; Kantarjian, HM; Ravandi, F; Thomas, DA; Cortes, JE; Pemmaraju, N; Kadia, TM; Short, NJ; Issa, GC; Garris, RS; Jeanis, V; Moore, HG; Garcia-Manero, G; Borthakur, G; Wierda, WG; Gachimova, E; O'Brien, SM; Jabbour, E. Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Short, NJ; Kantarjian, HM; Sasaki, K; Ravandi, F; Garcia-Manero, G; Thomas, DA; Pierce, S; Issa, GC; Cortes, JE; Kadia, TM; Jain, N; O'Brien, SM; Jabbour, E. xPrognostic significance of day 14 (D14) bone marrow (BM) assessment in adult patients receiving induction for Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Issa, GC; Kantarjian, HM; Ravandi, F; Thomas, DA; Khouri, M; Garcia-Manero, G; Garris, RS; Cortes, JE; Short, NJ; Sasaki, K; Schroeder, HM; Kadia, TM; Verstovsek, S; Daver, NG; Jain, N; Konopleva, M; O'Brien, SM; Jabbour, E. Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Hu, B; Sasaki, K; Bashir, Q; Shah, N; Patel, KK; Popat, UR; Hosing, C; Nieto, Y; Lin, P; Delgado, R; Jorgensen, JL; Shah, JJ; Manasanch, EE; Weber, DM; Thomas, SK; Orlowski, RZ; Champlin, RE; Qazilbash, MH. Depth of response post autologous hematopoietic stem cell transplantation (auto-HCT) to predict outcome in high risk multiple myeloma (MM). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Short, NJ; Jabbour, E; Cortes, JE; Garris, R; O'Brien, SM; Patel, K; Sasaki, K; Issa, GC; Garcia-Manero, G; Thomas, DA; Kantarjian, HM; Ravandi, F. Impact of complete molecular response (CMR) on survival in patients with Philadelphia chromosome positive (Ph plus ) acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Issa, GC; Kantarjian, HM; Yin, CC; Ravandi, F; Garcia-Manero, G; Thomas, DA; Cortes, JE; Short, NJ; Sasaki, K; Qiao, W; Takahashi, K; Pierce, S; Verstovsek, S; Kadia, TM; Borthakur, G; O'Brien, SM; Jabbour, E. Prognostic impact of pre-treatment cytogenetics in adult acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Sasaki, K; Kantarjian, HM; Ravandi, F; Thomas, DA; Daver, NG; Kadia, TM; Konopleva, M; Jain, N; Short, NJ; Issa, GC; Jeanis, V; Moore, HG; Garris, RS; Garcia-Manero, G; Cortes, JE; O'Brien, SM; Jabbour, E. Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) plus ponatinib vs. HCVAD plus dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

Jain, P; Kantarjian, H; Sasaki, K; Jabbour, E; Dasarathula, J; Gonzalez, GN; Verstovsek, S; Borthakur, G; Wierda, W; Kadia, T; Dellasala, S; Pierce, S; Ravandi, F; O'Brien, S; Cortes, J. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes BRITISH JOURNAL OF HAEMATOLOGY. 2016.04; 173 (1): 114-126. ( PubMed, DOI )

Ramlal, R; Sasaki, K; Cerrada, SL; Srour, SA; Chen, JLN; Rondon, RG; Rezvani, K; Oran, B; Olson, A; Shpall, EJ; Champlin, RE; Ciurea, SO. Viral Reactivation in Haploidentical Transplants Using Post-Transplantation Cyclophosphamide - a Single Institution Experience BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2016.03; 22 (3): S375-S376. ( DOI )

Sasaki, K; Lahoti, A; Jabbour, E; Jain, P; Pierce, S; Borthakur, G; Daver, N; Kadia, T; Pemmaraju, N; Ferrajoli, A; O'Brien, S; Kantarjian, H; Cortes, J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2016.03; 16 (3): 152-162. ( PubMed, DOI )

Jain, P; Kantarjian, H; Patel, KP; Gonzalez, GN; Luthra, R; Shamanna, RK; Sasaki, K; Jabbour, E; Romo, CG; Kadia, TM; Pemmaraju, N; Daver, N; Borthakur, G; Estrov, Z; Ravandi, F; O'Brien, S; Cortes, J. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors BLOOD. 2016.03; 127 (10): 1269-1275. ( PubMed, DOI )

Qazilbash, MH; Chen, J; Valdez, BC; Sasaki, K; Kawedia, JD; Bashir, Q; Hosing, C; Kebriaei, P; Nieto, Y; Shah, N; Patel, K; Shpall, EJ; Andersson, BS; Champlin, RE; Popat, U. Myeloablative Timed Sequential Busulfan Is Safe in Patients with Relapsed or High-Risk Multiple Myeloma BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2016.03; 22 (3): S228-S229. ( DOI )

Sasaki, K; Bashir, Q; Shah, N; Hosing, C; Popat, UR; Nieto, Y; Parmar, S; Shah, J; Weber, D; Thomas, S; Orlowski, RZ; Champlin, RE; Qazilbash, MH. Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2016.03; 22 (3): S231-S232. ( DOI )

Koji Sasaki, Hagop M Kantarjian, Preetesh Jain, Elias J Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Koichi Takahashi, Naveen Pemmaraju, Naval Daver, Sherry A Pierce, Susan M O'Brien, Jorge E Cortes. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016.01; 122 (2): 238-248. ( PubMed, DOI )

Jacobs, RW; Saliba, RM; Sasaki, K; Farhan, S; Armas, A; Shah, ND; Bashir, Q; Qureshi, S; Rondon, G; Hosing, C; Popat, U; Parmar, S; Shah, JJ; Wang, M; Weber, DM; Thomas, SK; Orlowski, RZ; Champlin, RE; Qazilbashi, MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2016.01; 16 (1): 36-42. ( PubMed, DOI )

Koji Sasaki, Sara S Strom, Susan O'Brien, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Preetesh Jain, Sherry Pierce, Hagop Kantarjian, Jorge E Cortes. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015.05; 2 (5): e186-e193. ( PubMed, DOI )

佐々木 宏治. CML治療と予後の最前線 臨床血液. 2020.09; 61 (9): 1179-1186. ( 医中誌 )

[Chronic myeloid leukemia: update on treatment and survival prediction]. 2020; 61 (9): 1179-1186. ( PubMed, DOI )

佐々木 宏治. 【急性白血病の薬物療法のupdate ～最新の診断・治療戦略～】ポナチニブ　国内承認(治療抵抗性Ph陽性ALL) 医薬ジャーナル. 2018.05; 54 (5): 1229-1233. ( 医中誌 )

山本 正英, 粂川 華恵, 佐々木 宏治, 村田 諭孝, 大木 学, 黒須 哲也, 福田 哲也, 新井 文子, 村上 直己, 三浦 修. 再生不良性貧血の経過中に薬疹に伴い生じた著明な反応性形質細胞増加 臨床血液. 2012.05; 53 (5): 526-530. ( 医中誌 )

粂川 華恵, 佐々木 宏治, 村田 諭孝, 山本 正英, 大木 学, 黒須 哲也, 福田 哲也, 新井 文子, 三浦 修, 村上 直巳. 再生不良性貧血の経過中に反応性形質細胞増加を合併した1例 臨床血液. 2010.03; 51 (3): 223-224. ( 医中誌 )

Niche-level immune evasion in <i>TP53</i> mutant AML residual disease revealed by spatial proteomics 2026.05; ( DOI )

Decitabine-cedazuridine in patients with MDS and TP53 mutations 2026.02; 10 (3): ( DOI )

Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia 2026.01; 10 (1): ( DOI )

MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia 2025.12; ( DOI )

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML 2025.11; 146 (21): ( DOI )

Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome 2025.11; ( DOI )

Mortality and relapse dynamics in AML after three years of complete remission 2025.11; ( DOI )

Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase 2025.10; ( DOI )

Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy 2025.09; ( DOI )

Nelarabine-related rhabdomyolysis in adult patients with T-cell lymphoblastic leukemia/lymphoma: a report of 6 patients 2025.09; ( DOI )

Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm. 2025.08; 26 (1): ( PubMed, DOI )

Treatment of RAS-associated leukoproliferative disease (RALD) and Rosai-Dorfman disease in a patient with KRAS mutation 2025.08; ( DOI )

Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. 2025.08; ( PubMed, DOI )

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML 2025.08; ( DOI )

Central nervous system relapse of core-binding factor acute myeloid leukemia 2025.07; ( DOI )

Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia. 2025.07; 9 (19): ( PubMed, DOI )

Management of chronic myeloid leukemia in 2025 2025.07; ( DOI )

PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes. 2025.07; 110 (12): ( PubMed, DOI )

Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with &lt;i&gt;BCR::ABL1&lt;/i&gt;-negative B-cell / myeloid mixed phenotype acute leukemia. 2025.06; 110 (12): ( PubMed, DOI )

Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. 2025.06; ( PubMed, DOI )

A Case of Cryptic CBFB::MYH11 Acute Myeloid Leukemia With Noncanonical Breakpoints Detected by Optical Genome Mapping. 2025.05; ( PubMed, DOI )

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results 2025.05; ( DOI )

Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. 2025.05; ( PubMed, DOI )

BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia. 2025.05; 146 (7): ( PubMed, DOI )

Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL. 2025.05; 9 (16): ( PubMed, DOI )

Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results: CHRONIC MYELOID LEUKEMIA 2025.04; ( DOI )

Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis. 2025.04; ( PubMed, DOI )

Dual MYC and GSPT1 Protein Degrader for MYC-Driven Cancers 2025.04; ( DOI )

Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research 2025.04; ( DOI )

Project EVOLVE: An international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. 2025.04; ( PubMed, DOI )

Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome. 2025.04; 153 ( PubMed, DOI )

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. 2025.04; 15 (1): ( PubMed, DOI )

Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasms. 2025.04; ( PubMed, DOI )

A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia 2025.03; ( DOI )

Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18). 2025.03; ( PubMed, DOI )

Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions. 2025.03; ( PubMed, DOI )

Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study 2025.03; 15 (1): ( DOI )

Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia 2025.03; ( DOI )

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. 2025.03; ( PubMed, DOI )

A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms 2025.02; 39 (2): 524-528. ( PubMed, DOI )

Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion. 2025.02; 150 ( PubMed, DOI )

Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy 2025.02; ( DOI )

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. 2025.02; ( PubMed, DOI )

Favorable transplantation outcome of patients with de novo chronic myeloid leukemia in blast phase (lymphoid and myeloid) 2025.01; 131 (1): ( PubMed, DOI )

Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. 2025.01; 100 (3): 402-407. ( PubMed, DOI )

ASXL1 mutations in AML are associated with a distinct epigenetic state that results in vulnerabilities to epigenetic-targeted agents 2025; ( DOI )

Novel therapeutic strategies targeting MECOM rearranged AMLs discovered by unbiased drug screen 2025; ( DOI )

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes 2025; ( DOI )

Artificial Intelligence Assessment of Chest Radiographs for COVID-19 2024.11; ( DOI )

Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. 2024.11; 131 (1): ( PubMed, DOI )

Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. 2024.11; 17 (1): ( PubMed, DOI )

Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase. 2024.11; 25 (4): 254-257. ( PubMed, DOI )

Current status and research directions in acute myeloid leukemia 2024.09; 14 (1): ( PubMed, DOI )

Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis. 2024.08; 144 ( PubMed, DOI )

Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. 2024.08; 38 (10): 2073-2084. ( PubMed, DOI )

Efficacy of Chemotherapy-Free Regimens in the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis 2024.06; 24 (10): e376-e384. ( PubMed, DOI )

Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia. 2024.06; 24 (11): 783-788. ( PubMed, DOI )

NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage 2024.06; 130 (20): 3452-3462. ( PubMed, DOI )

The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia 2024.06; 99 (6): 1175-1176. ( PubMed, DOI )

TP53 Y220C mutations in patients with myeloid malignancies (vol 10, pg 1, 2024) 2024.06; 65 (10): 1511-1515. ( PubMed, DOI )

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results 2024.05; 38 (7): 1522-1533. ( PubMed, DOI )

Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia 2024.05; 120 (2): 203-211. ( PubMed, DOI )

Outcomes and genetic dynamics of acute myeloid leukemia at first relapse 2024.05; 109 (11): 3543-3556. ( PubMed, DOI )

Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression 2024.04; 204 (6): 2259-2263. ( PubMed, DOI )

Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy 2024.04; 99 (7): 1423-1426. ( PubMed, DOI )

Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia 2024.04; 130 (15): 2652-2659. ( PubMed, DOI )

Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial 2024.04; 11 (4): e287-e298. ( PubMed, DOI )

Are there new relevant therapeutic endpoints in the modern era of the BCR:: ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? 2024.03; 38 (5): 1-4. ( PubMed, DOI )

Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm 2024.03; 8 (11): 2695-2706. ( PubMed, DOI )

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor 2024.02; 143 (20): blood-2023022832. ( PubMed, DOI )

Using Proton Pump Inhibitors is not Associated with Adverse Outcomes in Patients with Chronic Myeloid Leukemia Treated with Dasatinib 2024.02; 24 (7): 484-487. ( PubMed, DOI )

Outcome of Patients with Relapsed Acute Promyelocytic Leukemia 2024.02; 24 (6): 375-381. ( PubMed, DOI )

Comprehensive characterization of IFN$γ$ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies 2024.02; 15 (1): 1821. ( PubMed, DOI )

A Phase Ib/II Study of Ivosidenib with Venetoclax f Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update 2024; ( DOI )

Application of Next-Generation Cytogenetics in a Clinical Laboratory for Diagnostic Work-up of Myelodysplastic Syndromes/Neoplasms (MDS) 2024; ( DOI )

Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial 2024; ( DOI )

A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse 2024; ( DOI )

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome 2024; ( DOI )

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome 2024; ( PubMed, DOI )

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated with Upregulation of<i> HOX</i> Genes: Trial in Progress 2024; ( DOI )

Approximation of Glomerular Filtration Rate after 1 Year Using Annual Medical Examination Data 2024; ( DOI )

Choosing the Best Firstline Drug: Does Efficacy Make You Think About Cost? 2024;

Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia 2024; ( DOI )

Characteristics of Myelodysplastic Syndromes with Idiopathic Pulmonary Fibrosis 2024; ( DOI )

Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms 2024; 13 (5): ( PubMed, DOI )

Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker 2024; 145 (25): ( PubMed, DOI )

Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse 2024; ( DOI )

ASXLI Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents 2024; ( DOI )

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T3151-Mutated CML-CP: Final Analysis from a Phase 1 Trial 2024; ( DOI )

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10<SUP>-4</SUP> sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naive CLL 2024; ( DOI )

Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory 2024; ( DOI )

Genomic evolution of patients with myeloid neoplasms and known antecedent clonal hematopoiesis 2024;

Genomic Evolution of Patients With Myeloid Neoplasms and Known Antecedent Clonal Hematopoiesis 2024;

FLAG IDA Venetoclax in Newly Diagnosed Pediatric and AYA Patients with AML 2024; ( DOI )

Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia 2024; 148 (1): 105-110. ( PubMed, DOI )

Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph plus ALL Not Undergoing Allogeneic Transplant 2024; ( DOI )

Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome 2024; 24 (9): 629-633. ( PubMed, DOI )

Efficacy of Combinations of Targeted Agents Against Dependencies in Mecom Rearranged AML Identified By Unbiased Chemical and CRISPR Screens 2024; ( DOI )

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI) 2024; ( DOI )

Early Predictors of Treatment-Free Remission in Chronic Myeloid Leukemia 2024; ( DOI )

Identifying 'Druggable' Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1 2024; ( DOI )

Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update 2024; ( DOI )

Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia 2024; ( DOI )

Improved survival and unique mutational signatures in small cell lung cancer arising in patients with limited tobacco use 2024; 84 (6\_Supplement): 5061. ( DOI )

Impact of JAK2 allele burden on MF outcome in the era of ruxolitinib 2024;

Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy 2024; ( DOI )

Impact of complete cytogenetic response on survival in patients with myelodysplastic syndromes 2024;

Identifying novel therapies from unbiased screens in AML with MECOM re-arrangement 2024; 84 (6\_Supplement): 3351. ( DOI )

Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation 2024; 130 (19): 3333-3343. ( PubMed, DOI )

Oral Decitabine/Cedazuridine in Patients with MDS and <i>TP53</i> Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials 2024; ( DOI )

Nontuberculosis mycobacteria (NTM) infections in patients with leukemia: a single center case series 2024; 11 ( DOI )

Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds 2024; ( DOI )

Myelodysplastic Syndromes with Concomitant<i> SF381</i> Mutation and Deletion of the Long Arm of Chromosome 5 (SF381del5q): Outcomes and Response to Treatment 2024; ( DOI )

Myelodysplastic syndromes with concomitant SF3B1 mutation and deletion of the long arm of chromosome 5 2024;

Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions 2024;

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial 2024; ( DOI )

CNS Involvement in Adult Patients with B-Cell Acute Lymphoblastic Leukemia 2024; ( DOI )

Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission 2024; ( DOI )

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis 2024; ( DOI )

Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL 2024; ( DOI )

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease 2024; ( DOI )

Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) 2024; ( DOI )

Outcomes of Patients with Newly Diagnosed AML and Hyperleukocytosis 2024; 20 (12): 1637-1644. ( PubMed, DOI )

Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens 2024; ( DOI )

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax 2024; ( DOI )

Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms 2024; ( DOI )

Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL 2024; ( DOI )

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation 2024; ( DOI )

Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase 2024; 130 (19): 3344-3352. ( PubMed, DOI )

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML 2024; ( DOI )

Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML 2024; ( DOI )

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse 2024; ( DOI )

Clinical Outcomes Associated with<i> NPM1</i> Mutations in Newly Diagnosed AML 2024; ( DOI )

Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or<i> TP53</i>-Mutated Chronic Lymphocytic Leukemia 2024; ( DOI )

Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update 2024; ( DOI )

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies 2024; ( DOI )

Clinical Outcomes Using Frontline "Triplet" Regimens for Newly Diagnosed <i>IDH</i>-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials 2024; ( DOI )

Clinical Outcomes of Patients with AML Receiving Lower Intensity Chemotherapy with or without the Use of Granulocyte-Colony Stimulating Factor (GCSF) 2024; ( DOI )

Clinical Characteristics and Outcomes of NUP98 Rearrangement in Adults with Acute Leukemia 2024;

Risk Stratification in Hypomethylating Agent-Treated Patients With Myelodysplastic Syndromes: A Multivariate Model 2024;

Outcomes of patients with bone marrow fibrosis in de novo and secondary acute myeloid leukemia 2024;

Outcome of patients with chronic myeloid leukemia after more than 10 years of follow-up 2023.12; 1 (343): 070. ( DOI )

Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features 2023.11; 142 (Supplement 1): 1881. ( DOI )

Deeper Insight into Splicing Mutations in Myelofibrosis 2023.11; 142 (Supplement 1): 4580. ( DOI )

Protective Role of Oxaliplatin Among Platinum-Based Therapies in the Development of Therapy-Related Myeloid Neoplasms 2023.11; 142 (Supplement 1): 4220. ( DOI )

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs) 2023.11; 142 (Supplement 1): 4264. ( DOI )

Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort 2023.11; 142 (Supplement 1): 3237. ( DOI )

ASC2ESCALATE: A US, Phase II Open-Label, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Second-Line (2L) and First-Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) 2023.09; 23 S348-S349. ( DOI )

Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and <i>DDX41</i> Mutation 2023.09; 23 ( DOI )

Causes of Death in Patients With Myelodysplastic Syndrome and Spliceosome Mutations 2023.09; 23 S374-S375. ( DOI )

First-in-Human Phase I Study of ELVN-001, an Oral, Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients With Chronic Myeloid Leukemia Who Failed Prior Tyrosine Kinase Inhibitors 2023.09; 23 ( DOI )

MDS-208 Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation 2023.09; 23 S357-S358. ( DOI )

T-Cell Exhaustion and Immune Checkpoint VISTA Overexpression Are Associated With Suboptimal Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia (CML) 2023.09; 23 ( DOI )

P688: ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) 2023.08; 7 (S3):

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE 2023.08; 7 (S3): ( DOI )

P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS 2023.08; 7 (S3): ( DOI )

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS 2023.08; 7 (S3): ( DOI )

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE 2023.08; 7 (S3):

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS 2023.08; 7 (S3): ( DOI )

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX 2023.08; 7 (S3):

Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center. 2023.08; 7 (S3): ( DOI )

P485: Azacitidine, venetoclax and gilteritinib for patients with newly diagnosed flt3-mutated acute myeloid leukemia: A subgroup analysis from a phase ii study 2023.08; 7 (S3):

S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL 2023.08; 7 (S3): ( DOI )

P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA 2023.08; 7 (S3): ( DOI )

P672: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND T315I MUTATION AFTER FAILURE OF PRIOR THERAPIES 2023.08; 7 (S3): ( DOI )

P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND 2023.08; 7 (S3): ( DOI )

Supplementary Figure 2 from Integrative Prognostic Machine-Learning Models in Mantle Cell Lymphoma 2023.07; ( DOI )

Supplementary Table 2 from Integrative Prognostic Machine-Learning Models in Mantle Cell Lymphoma 2023.07; ( DOI )

Supplementary Table 1 from Integrative Prognostic Machine-Learning Models in Mantle Cell Lymphoma 2023.07; ( DOI )

Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center. 2023.06; 41 (16_suppl): ( DOI )

Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. 2023.03; 201 (3): e25-e29. ( PubMed, DOI )

A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph plus ) acute myeloid leukemia (AML) 2023;

Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results 2023; 142 233. ( DOI )

Actionable Findings from an Unbiased Drug Screen for Novel Single Agent and Combination Therapies Against AML with Mecom Re-Arrangement 2023; 142 1419. ( DOI )

Abstract A31: C-MYC Targeting by Degradation: Novel Dual c-MYC/GSPT1 Degrader GT19715 Induces TP53-independent Cell Death in MYC-amplified Acute Myeloid Leukemia and Lymphomas 2023; 4 (3\_Supplement): A31.

A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph plus ) acute myeloid leukemia (AML). 2023; ( DOI )

ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment 2023; 142 6389. ( DOI )

Dorsal Column Myelopathy Following Intrathecal Chemotherapy for Leukemia 2023; 117 (2): e486-e487.

Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and <i>DDX41</i> Mutation 2023; 23

Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study 2023; 142 2884. ( DOI )

Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia ChromosomePositive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph plus CMLCP/AP): Final Results from the Asciminib Phase 1 Study 2023; 142 868. ( DOI )

ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI). 2023; ( DOI )

ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI) 2023;

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab ( iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses 2023; 142 3267. ( DOI )

Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study. 2023; ( DOI )

Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study 2023;

Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia 2023; 142 (5): 4601. ( PubMed, DOI )

IFN. Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies 2023; 142 2796. ( DOI )

NPM1-Mutated Myeloid Neoplasms: Updated Outcomes with High-Intensive Chemotherapy Regardless of the Blast Percentage 2023; 142 957. ( DOI )

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Followup from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population 2023; ( DOI )

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after≥ 2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population 2023; 142 4536.

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria 2023; 142 3228. ( DOI )

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph plus CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study 2023; ( DOI )

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes 2023; 142 1857. ( DOI )

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study 2023; 142 450.

Outcomes of myeloid malignancies in patients previously treated with PARP inhibitors for solid malignancies: A single institution experience. 2023; ( DOI )

Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis 2023; 142 4282. ( DOI )

Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML) 2023; 142 870. ( DOI )

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results 2023; 142 2903. ( DOI )

Role and Prevalence of Risk Factors That Trigger Therapy Related Myeloid Neoplasms (TRMN) in Patients with Previous Treated Breast Cancer 2023; 142 4593. ( DOI )

Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms ( TRMN) 2023; 142 3224. ( DOI )

Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). 2023; ( DOI )

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update 2023; 142 968. ( DOI )

Comprehensive Characterization of Evolution of Genomic Complexity By Structural Variant and Mutational Profiling in Myelodysplastic Syndrome Patients with Hypomethylating Agent Failure 2023; 142 4612. ( DOI )

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data 2023; 142 4635. ( DOI )

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes 2023; 142 4616. ( DOI )

Clinical and transcriptomic analysis demonstrates improved survival and unique gene expression signatures among SCLC arising in patients with minimal tobacco use 2023; 83 (7\_Supplement): 1398. ( DOI )

Outcomes of myeloid malignancies in patients previously treated with PARP inhibitors for solid malignancies: A single institution experience 2023;

Severe RAS-Associated Lymphoproliferative Disease Case with Increasing αβ Double-Negative T Cells with Atypical Features 2023; ( DOI )

Porównanie asciminibu z bosutynibem w leczeniu pacjentów z przewlekłą białaczką szpikową w fazie przewlekłej leczonych wczésniej co najmniej dwoma inhibitorami kinazy tyrozynowej: dłuższa obserwacja ASCEMBL 2023; 3 (3-4): 119-133.

Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) 2023;

P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA 2023; 7 (S3):

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML 2022.11;

P695: Prognostic impact of ASXL1 mutations in chronic phase cml 2022.06; 6 590-591. ( DOI )

P769: MUTATION PROFILES AND RISK STRATIFICATION IN HYPOCELLULAR MYELODYSPLASTIC SYNDROME 2022.06; 6 664-665. ( DOI )

P767: CLINICAL SIGNIFICANCE OF ROUTINE HIGH-RESOLUTION STRUCURAL VARIANT PROFILING IN MYELODYSPLASTIC SYNDROMES 2022.06; 6 662-663. ( DOI )

P762: NONLINIEAR IMPACT OF CLINICAL FEATURES ON THE SURVIVAL OUTCOME OF MYELODYSPLASTIC SYNDROMES PATIENTS 2022.06; 6 ( DOI )

P703: ASSOCIATION BETWEEN BARIATRIC SURGERY AND OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH ORAL TYROSINE KINASE INHIBITORS 2022.06; 6 598-599. ( DOI )

P1590: OUTCOME OF HYPERBARIC OXYGEN THERAPY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES--A TERTIARY CANCER CENTER EXPERIENCE 2022.06; 6 1471-1472.

Targeting Oxidative Phosphorylation with a Mitochondrial Complex I Inhibitor is limited by Mechanism-based Toxicity 2022.04; ( DOI )

96-Week Update from the Phase 3 ASCEMBL Study for Evaluating the Safety and Efficacy of Asciminib versus Bosutinib in Patients with chronic phase chronic myeloid Leukemia after Pretreatment with 2 TKIs 2022;

AML-387 Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD) 2022; 22 S243. ( PubMed, DOI )

Effect of Early Caffeine Therapy on the Prevention of Severe Hyperkalemia in Preterm Infants 2022; 149 (1 Meeting Abstracts February 2022): 667.

HEALTH CARE RESOURCE UTILIZATION WITH ASCIMINIB AND BOSUTINIB AMONG ADULTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH=2 TYROSINE KINASE INHIBITORS: WEEK 48 AND WEEK 96 RESULTS FROM ASCEMBL TRIAL 2022;

Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis 2022; 138 631. ( DOI )

P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL 2022; 6 599-600.

CML-433 ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI) 2022; 22 S299. ( PubMed, DOI )

Phase II study of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia 2022; 33 ( DOI )

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia 2022; 140 (Supplement 1): 6170-6172. ( DOI )

Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib (Leukemia, (2022), 36, 5, (1253-1260), 10.1038/s41375-021-01496-8) 2022; 36 (5): 1448. ( PubMed, DOI )

P368: A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 2022; 6 268-269.

S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER≥ 2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE 2022; 6 56-57.

S149: Long term outcomes of iFCG regimen for firstline treatment of patients with CLL with mutated IGHV and without Del (17p)/TP53 mutation 2022; 6 50-51.

S114: ponatinib and blinatumomab for patients with philadelphia chromosome-positive acute lymphoblastic leukemia: updated results from a phase II study 2022; 6 15-16.

P541: OUTCOMES AND MANAGEMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PRESENTING WITH HYPERLEUKOCYTOSIS 2022; 6 440-441.

P496: CLINICAL CHARACTERISTICS OF SECONDARY MYELOID NEOPLASMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE 2022; 6 395-396.

P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB 2022; 6 272-273.

P371: hyper-CVAD with sequential blinatumomab, with or without inotuzumab ozogamicin, in adults with newly diagnosed philadelphia chromosome-negative B-cell acute lymphoblastic leukemia 2022; 6 271-272.

Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial 2021.09; 21 ( DOI )

Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer 2021.09; 144 (5): 585-590. ( PubMed, DOI )

Prognostic Value of CRh in Acute Myeloid Leukemia Treated with Venetoclax and Decitabine 2021.09; 21 S303-S304. ( DOI )

Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS) 2021.09; 21 ( DOI )

Efficacy and Safety Results From ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Previously Treated With ≥2 Tyrosine Kinase Inhibitors 2021;

Evolutionary action score identifies a subset of <i>TP53</i> mutated myelodysplastic syndrome with favorable prognosis 2021; 136 4-5. ( DOI )

Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors 2021; 138 1480.

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia 2021; 136 22-25. ( DOI )

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results 2021; 138 3720. ( DOI )

Contemporary outcomes for adults with AML requiring ICU admission. 2021; ( DOI )

Nakamura, F; Seo, S; Arai, H; Nakamura, Y; Handa, T; Takahashi, W; Furuichi, S; Nagasawa, F; Tadokoro, J; Tsurumi, S; Nakamura, Y; Sasaki, K; Ichikawa, M; Mitani, K. Outcomes and Prognostic Scoring System for Elderly Patients with Acute Myeloid Leukemia BLOOD. 2020.11; 136 31-32. ( DOI )

Md, YO; Mdphd, KY; Huang, YJ; Kuo, MC; Sasaki, K; Hosoya, N; Hiramoto, N; Bera, R; Nannya, Y; Shiozawa, Y; Takeda, J; Watatani, Y; Makishima, H; Shiraishi, Y; Chiba, K; Tanaka, H; Sanada, M; Ishikawa, T; Takaori-Kondo, A; Miyano, S; Mitani, K; Ogawa, S; Shih, LY. Prognostic Relevance of Genetic Abnormalities in Blastic Transformation of Chronic Myeloid Leukemia BLOOD. 2020.11; 136 ( DOI )

Evolutionary Action Score of TP53 Mutations: Integrated Clinico-pathologic And Protein Structural Analysis in Myelodysplastic Syndromes 2020; 2020-07.

Low-Dose Dasatinib 50 mg Daily Versus Standard-Dose Dasatinib 100 mg Daily in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis 2020; 20 ( DOI )

Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes 2020; 2020-09. ( DOI )

Ten-day decitabine with venetoclax in acute myeloid leukemia: a single-arm phase 2 trial 2020; 7 (10):

Outcomes and genetic dynamics of acute myeloid leukemia at first relapse 2020;

Outcomes of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Molecular Response at Three Months of Therapy 2020; 20 S164-S165. ( DOI )

Clarifying the structure of serious head and spine injury in youth Rugby Union players 2020; ( DOI )

Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma 2020; 136 25-26. ( DOI )

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia 2020; 136 54-56. ( PubMed, DOI )

CML 治療と予後の最前線 2020;

LILRB4 expression in CMML and MDS based on response to hypomethylating agents. 2019.05; 37 (15_suppl): ( DOI )

Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia. 2019;

Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 2019; 19 ( DOI )

Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 2019; 19 S180-S181. ( DOI )

The Impact of Smoking on Relapse and Survival in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor 2019; 19 ( DOI )

Reduced-Intensity Chemotherapy Plus Inotuzumab Ozogamicin, With or Without Sequential Blinatumomab, is Highly Effective as First Salvage Treatment in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia 2019; 19 S186-S187. ( DOI )

Double immune checkpoint inhibitor blockade with nivolumab and ipilimumab with or without azacitidine in patients with myelodysplastic syndrome (MDS) 2018.11; 132 (Supplement 1): 1831. ( DOI )

Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase 2018.11; 132 (Supplement 1): 3026. ( DOI )

Tomiyama, Y; Jang, JH; Lee, JW; Miyazaki, K; Nagafuji, K; Usuki, K; Uoshima, N; Fujisaki, T; Kosugi, H; Matsumura, I; Sasaki, K; Kizaki, M; Sawa, M; Hidaka, M; Kobayashi, N; Ichikawa, S; Yonemura, Y; Keta, H; Matsuda, A; Ozawa, K; Mitani, K; Nakao, S. Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial BLOOD. 2018.11; 132 ( DOI )

A RANDOMIZED PHASE II STUDY OF IDARUBICIN AND CYTARABINE WITH EITHER CLOFARABINE OR FLUDARABINE IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA 2017;

INOTUZUMAB OZOGAMICIN IN COMBINATION WITH LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AS FRONTLINE THERAPY FOR OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE I/II TRIAL 2017;

UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 2017;

Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) 2017; 130 (Supplement 1): 2597.

Survival Outcome of Secondary Solid Cancer in Patients with Chronic Myeloid Leukemia 2017; 130 1623.

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation. American Society of Hematology Annual Meeting 2024.12.01

Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission. American Society of Hematology Annual Meeting 2024.12.01

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update. American Society of Hematology Annual Meeting 2024.12.01

Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting 2024.12.01

Characteristics of Myelodysplastic Syndromes with Idiopathic Pulmonary Fibrosis. American Society of Hematology Annual Meeting 2024.12.01

Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker. American Society of Hematology Annual Meeting 2024.12.01

Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse. American Society of Hematology Annual Meeting 2024.12.01

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial. American Society of Hematology Annual Meeting 2024.12.01

Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial. American Society of Hematology Annual Meeting 2024.12.01

A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse. American Society of Hematology Annual Meeting 2024.12.01

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome. American Society of Hematology Annual Meeting 2024.12.01

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome. American Society of Hematology Annual Meeting 2024.12.01

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials. American Society of Hematology Annual Meeting 2024.12.01

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1del5q): Outcomes and Response to Treatment. American Society of Hematology Annual Meeting 2024.12.01

Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update. American Society of Hematology Annual Meeting 2024.12.01

Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy. American Society of Hematology Annual Meeting 2024.12.01

Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory. American Society of Hematology Annual Meeting 2024.12.01

FLAG IDA Venetoclax in Newly Diagnosed Pediatric and AYA Patients with AML. American Society of Hematology Annual Meeting 2024.12.01

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI). American Society of Hematology Annual Meeting 2024.12.01

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL. American Society of Hematology Annual Meeting 2024.12.01

Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms. American Society of Hematology Annual Meeting 2024.12.01

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies. American Society of Hematology Annual Meeting 2024.12.01

Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL. American Society of Hematology Annual Meeting 2024.12.01

Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). American Society of Hematology Annual Meeting 2024.12.01

CNS Involvement in Adult Patients with B-Cell Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting 2024.12.01

Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds. American Society of Hematology Annual Meeting 2024.12.01

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease. American Society of Hematology Annual Meeting 2024.12.01

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial. American Society of Hematology Annual Meeting 2024.12.01

Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia. American Society of Hematology Annual Meeting 2024.12.01

Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update. American Society of Hematology Annual Meeting 2024.12.01

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML. American Society of Hematology Annual Meeting 2024.12.01

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse. American Society of Hematology Annual Meeting 2024.12.01

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis. American Society of Hematology Annual Meeting 2024.12.01

Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens. American Society of Hematology Annual Meeting 2024.12.01

Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials. American Society of Hematology Annual Meeting 2024.12.01

Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL. American Society of Hematology Annual Meeting 2024.12.01

Choosing the Best Firstline Drug: Does Efficacy Make You Think About Cost?. Society of Hematologic Oncology Annual Meeting 2024.09.01

Clinical Characteristics and Outcomes of NUP98 Rearrangement in Adults with Acute Leukemia. Society of Hematologic Oncology Annual Meeting 2024.09.01

Genomic Evolution of Patients With Myeloid Neoplasms and Known Antecedent Clonal Hematopoiesis. Society of Hematologic Oncology Annual Meeting 2024.09.01

Myelodysplastic Syndromes With Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5. Society of Hematologic Oncology Annual Meeting 2024.09.01

Risk Stratification in Hypomethylating Agent-Treated Patients With Myelodysplastic Syndromes: A Multivariate Model. Society of Hematologic Oncology Annual Meeting 2024.09.01

A REAL-WORLD COMPARATIVE ANALYSIS OF FRONTLINE IDH1 MUTATED HIGHER-RISK MYELODYSPLASTIC SYNDROME TREATMENT RESPONSE: EVOLUTION FROM IWG 2006 TO IWG 2023 CRITERIA. European Hematology Association Annual Meeting 2024.06.01

CLINICAL CHARACTERISTICS OF RARE GENETIC ALTERATIONS ASSOCIATED WITH UPREGULATION OF HOXGENES IN ADULTS WITH ACUTE LEUKEMIA. European Hematology Association Annual Meeting 2024.06.01

CLINICAL CHARACTERISTICS OF ACUTE LEUKEMIA WITH PICALM::MLLT10 FUSION IN ADULTS. European Hematology Association Annual Meeting 2024.06.01

CLINICAL CHARACTERISTICS AND OUTCOMES OF NUP98 REARRANGEMENT IN ADULTS WITH ACUTE LEUKEMIA. European Hematology Association Annual Meeting 2024.06.01

CYTOGENETIC ANNOTATION AUTOMATION IN MYELODYSPLASTIC SYNDROME RESEARCH DATABASES. European Hematology Association Annual Meeting 2024.06.01

MUTATION PATTERNS AND PROGNOSTIC IMPLICATIONS IN ACUTE MYELOID LEUKEMIA WITH CHROMOSOMAL 7 DELETIONS. European Hematology Association Annual Meeting 2024.06.01

Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions. American Society of Clinical Oncology Annual Meeting 2024.06.01

Impact of JAK2 allele burden on MF outcome in the era of ruxolitinib.. American Society of Clinical Oncology Annual Meeting 2024.06.01

Impact of complete cytogenetic response on survival in patients with myelodysplastic syndromes. American Society of Clinical Oncology Annual Meeting 2024.06.01

IMPACT OF COMPLETE CYTOGENETIC RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES. European Hematology Association Annual Meeting 2024.06.01

GENOMIC EVOLUTION OF PATIENTS WITH MYELOID NEOPLASMS AND KNOWN ANTECEDENT CLONALHEMATOPOIESIS. European Hematology Association Annual Meeting 2024.06.01

Genomic evolution of patients with myeloid neoplasms and known antecedent clonal hematopoiesis. American Society of Clinical Oncology Annual Meeting 2024.06.01

FLAG-IDA + VENETOCLAX (VEN) IN NEWLY DIAGNOSED (ND) OR RELAPSED / REFRACTORY (RR) AML. European Hematology Association Annual Meeting 2024.06.01

MYELODYSPLASTIC SYNDROMES WITH CONCOMITANT SF3B1 MUTATION AND DELETION OF THE LONG ARMOF CHROMOSOME 5. European Hematology Association Annual Meeting 2024.06.01

SPECTRUM AND CLINICAL IMPLICATIONS OF EXTRAMEDULLARY MANIFESTATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA. European Hematology Association Annual Meeting 2024.06.01

RISK STRATIFICATION IN HYPOMETHYLATING AGENT-TREATED PATIENTS WITH MYELODYSPLASTICSYNDROMES: A MULTIVARIATE MODEL. European Hematology Association Annual Meeting 2024.06.01

RESULTS OF PONATINIB AS FRONTLINE THERAPY FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE. European Hematology Association Annual Meeting 2024.06.01

REDUCED VENETOCLAX EXPOSURE TO 7 DAYS VS STANDARD VENETOCLAX EXPOSURE WITH HYPOMETHYLATING AGENT IN OLDER/UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COMPARISON.. European Hematology Association Annual Meeting 2024.06.01

Outcomes of patients with bone marrow fibrosis in de novo and secondary acute myeloid leukemia.. American Society of Clinical Oncology Annual Meeting 2024.06.01

ORAL DECITABINE/CEDAZURIDINE WITH VENETOCLAX VERSUS ORAL DECITABINE/CEDAZURIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROME: A PROPENSITY SCORE MATCHED ANALYSIS. European Hematology Association Annual Meeting 2024.06.01

Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study. American Society of Hematology Annual Meeting 2023.12.01

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update. American Society of Hematology Annual Meeting 2023.12.01

Actionable Findings from an Unbiased Drug Screen for Novel Single Agent and Combination Therapies Against AML with Mecom Re-Arrangement. American Society of Hematology Annual Meeting 2023.12.01

Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort. American Society of Hematology Annual Meeting 2023.12.01

Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms (TRMN). American Society of Hematology Annual Meeting 2023.12.01

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs). American Society of Hematology Annual Meeting 2023.12.01

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results. American Society of Hematology Annual Meeting 2023.12.01

Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study. American Society of Hematology Annual Meeting 2023.12.01

Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results.. American Society of Hematology Annual Meeting 2023.12.01

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes. American Society of Hematology Annual Meeting 2023.12.01

Influence of Co-Mutational Patterns in Disease Phenotype and Clinical Outcomes of Chronic Myelomonocytic Leukemia. American Society of Hematology Annual Meeting 2023.12.01

IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies. American Society of Hematology Annual Meeting 2023.12.01

Deeper Insight into Splicing Mutations in Myelofibrosis. American Society of Hematology Annual Meeting 2023.12.01

Comprehensive Characterization of Evolution of Genomic Complexity By Structural Variant and Mutational Profiling in Myelodysplastic Syndrome Patients with Hypomethylating Agent Failure. American Society of Hematology Annual Meeting 2023.12.01

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data. American Society of Hematology Annual Meeting 2023.12.01

COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL. European Hematology Association Annual Meeting 2023.12.01

NPM1-Mutated Myeloid Neoplasms: Updated Outcomes with High-Intensive Chemotherapy Regardless of the Blast Percentage. American Society of Hematology Annual Meeting 2023.12.01

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/TP53 Mutation: Six-Year Follow-up Analyses. American Society of Hematology Annual Meeting 2023.12.01

Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features. American Society of Hematology Annual Meeting 2023.12.01

Role and Prevalence of Risk Factors That Trigger Therapy Related Myeloid Neoplasms (TRMN) in Patients with Previous Treated Breast Cancer. American Society of Hematology Annual Meeting 2023.12.01

Protective Role of Oxaliplatin Among Platinum-Based Therapies in the Development of Therapy-Related Myeloid Neoplasms. American Society of Hematology Annual Meeting 2023.12.01

Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML). American Society of Hematology Annual Meeting 2023.12.01

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes. American Society of Hematology Annual Meeting 2023.12.01

Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis.. American Society of Hematology Annual Meeting 2023.12.01

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria. American Society of Hematology Annual Meeting 2023.12.01

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study. American Society of Hematology Annual Meeting 2023.12.01

西田 有毅, スクラグス・ダラ , アユブ・ ドワード , オスターマン・ローレン , パトシレバス・タリー , ルボロ・ビビアン , マック・ポイー , カーター・ビン , ポッチャー・ステファン , マイティ・アビシェク , 佐々木 宏治, ジョウ・キャンジャン , ヤン・ジャオフィ , ヤン・ホンファ , マ・リャンドン , アンドレーフ・マイケル . 新規MYCタンパク分解薬GT19715はTP53非依存性にMYC依存性急性骨髄性白血病に有効である. 日本血液学会学術集会 2023.10.01

ASC2ESCALATE: A US, Phase II Open-Label, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Second-Line (2L) and First-Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Society of Hematologic Oncology Annual Meeting 2023.09.01

First-in-Human Phase I Study of ELVN-001, an Oral, Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients With Chronic Myeloid Leukemia Who Failed Prior Tyrosine Kinase Inhibitors. Society of Hematologic Oncology Annual Meeting 2023.09.01

Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and DDX41 Mutation. Society of Hematologic Oncology Annual Meeting 2023.09.01

Causes of Death in Patients With Myelodysplastic Syndrome and Spliceosome Mutations. POSTER: MDS-614. Society of Hematologic Oncology Annual Meeting 2023.09.01

MDS-208 Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation. Society of Hematologic Oncology Annual Meeting 2023.09.01

T-Cell Exhaustion and Immune Checkpoint VISTA Overexpression Are Associated With Suboptimal Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia (CML). Society of Hematologic Oncology Annual Meeting 2023.09.01

A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph+) acute myeloid leukemia (AML). American Society of Clinical Oncology, Annual Meeting 2023.06.01

ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI). American Society of Clinical Oncology Annual Meeting 2023.06.01

Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study. American Society of Clinical Oncology, Annual Meeting 2023.06.01

PB2481: OUTCOMES OF INDIVIDUALS WITH CLONAL HEMATOPOIESIS EVALUATED AT A CANCER CENTER. European Hematology Association Annual Meeting 2023.06.01

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE. European Hematology Association Annual Meeting 2023.06.01

P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS. European Hematology Association Annual Meeting 2023.06.01

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS. European Hematology Association Annual Meeting 2023.06.01

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE. European Hematology Association Annual Meeting 2023.06.01

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS. European Hematology Association Annual Meeting 2023.06.01

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX. European Hematology Association Annual Meeting 2023.06.01

P688: ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP). European Hematology Association Annual Meeting 2023.06.01

P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA. European Hematology Association Annual Meeting 2023.06.01

P672: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND T315I MUTATION AFTER FAILURE OF PRIOR THERAPIES. European Hematology Association Annual Meeting 2023.06.01

P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND. European Hematology Association Annual Meeting 2023.06.01

P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA. European Hematology Association Annual Meeting 2023.06.01

P485: AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY. European Hematology Association Annual Meeting 2023.06.01

Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center. American Society of Clinical Oncology Annual Meeting 2023.06.01

Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). American Society of Clinical Oncology, Annual Meeting 2023.06.01

A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies. American Society of Hematology Annual Meeting 2022.12.01

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure. American Society of Hematology Annual Meeting 2022.12.01

A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up. American Society of Hematology Annual Meeting 2022.12.01

Homologous Recombination DNA Repair Deficiency Score Is Independent Prognostic Variable in Myelodysplastic Syndrome/ Acute Myeloid Leukemia with Complex Karyotype. American Society of Hematology Annual Meeting 2022.12.01

Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results. American Society of Hematology Annual Meeting 2022.12.01

Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53. American Society of Hematology Annual Meeting 2022.12.01

Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1. American Society of Hematology Annual Meeting 2022.12.01

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients. American Society of Hematology Annual Meeting 2022.12.01

Combined Structural Variant and Mutation Profiling for Comprehensive Characterization of Chromoanagenesis and TP53 Mutations in Myelodysplastic Syndromes with Complex Karyotype.. American Society of Hematology Annual Meeting 2022.12.01

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data. American Society of Hematology Annual Meeting 2022.12.01

Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies. American Society of Hematology Annual Meeting 2022.12.01

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI).. American Society of Hematology Annual Meeting 2022.12.01

A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA. American Society of Hematology Annual Meeting 2022.12.01

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting 2022.12.01

Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS).. American Society of Hematology Annual Meeting 2022.12.01

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2022.12.01

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. American Society of Hematology Annual Meeting 2022.12.01

Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy. American Society of Hematology Annual Meeting 2022.12.01

Outcomes of Chronic Myeloid Leukemia with No Major Molecular Response within 2 Years of Tyrosine Kinase Inhibitor Therapy. American Society of Hematology Annual Meeting 2022.12.01

Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. American Society of Hematology Annual Meeting 2022.12.01

Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome. American Society of Hematology Annual Meeting 2022.12.01

More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia. American Society of Hematology Annual Meeting 2022.12.01

Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia. American Society of Hematology Annual Meeting 2022.12.01

Incidence of Central Nervous System Toxicity and Cytokine Release Syndrome in Leukemia Patients Treated with Blinatumomab. American Society of Hematology Annual Meeting 2022.12.01

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study. American Society of Hematology Annual Meeting 2022.12.01

Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression. American Society of Hematology Annual Meeting 2022.12.01

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). American Society of Hematology Annual Meeting 2022.12.01

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2022.12.01

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2022.12.01

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study. American Society of Hematology Annual Meeting 2022.12.01

Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2022.12.01

Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia.. American Society of Hematology Annual Meeting 2022.12.01

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study. American Society of Hematology Annual Meeting 2022.12.01

A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Society of Hematologic Oncology Annual Meeting 2022.09.01

Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update. Society of Hematologic Oncology Annual Meeting 2022.09.01

Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD).. Society of Hematologic Oncology Annual Meeting 2022.09.01

Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration. Society of Hematologic Oncology Annual Meeting 2022.09.01

Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial. Society of Hematologic Oncology Annual Meeting 2022.09.01

ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI).. Society of Hematologic Oncology Annual Meeting 2022.09.01

Acute Lymphoblastic Leukemia Following Multiple Myeloma Therapy: A Single-Center Experience With 9 Patients. Society of Hematologic Oncology Annual Meeting 2022.09.01

Impact of ASXL1 Mutations on Prognosis of Chronic Phase Chronic Myeloid Leukemia. Society of Hematologic Oncology Annual Meeting 2022.09.01

Prognostic Implication of the Molecular Profiles of Patients With Hypocellular Myelodysplastic Syndrome. Society of Hematologic Oncology Annual Meeting 2022.09.01

Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Society of Hematologic Oncology Annual Meeting 2022.09.01

The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T (6; 9)(P22; Q34).. Society of Hematologic Oncology Annual Meeting 2022.09.01

A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL). American Society of Clinical Oncology Annual Meeting 2022.06.01

HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. European Hematology Association Annual Meeting 2022.06.01

EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER .2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE. European Hematology Association Annual Meeting 2022.06.01

Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update. American Society of Clinical Oncology Annual Meeting 2022.06.01

DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB. European Hematology Association Annual Meeting 2022.06.01

CLINICAL SIGNIFICANCE OF ROUTINE HIGH-RESOLUTION STRUCURAL VARIANT PROFILING IN MYELODYSPLASTIC SYNDROMES. European Hematology Association Annual Meeting 2022.06.01

CLINICAL CHARACTERISTICS OF SECONDARY MYELOID NEOPLASMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. European Hematology Association Annual Meeting 2022.06.01

ASSOCIATION BETWEEN BARIATRIC SURGERY AND OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH ORAL TYROSINE KINASE INHIBITORS. European Hematology Association Annual Meeting 2022.06.01

ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL. European Hematology Association Annual Meeting 2022.06.01

Acute myeloid leukemia with KMT2Ar and association with risk of bleeding and early mortality.. American Society of Clinical Oncology Annual Meeting 2022.06.01

A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). American Society of Clinical Oncology Annual Meeting 2022.06.01

A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. European Hematology Association Annual Meeting 2022.06.01

LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION. European Hematology Association Annual Meeting 2022.06.01

Phase 2 study of azacitidine (AZA) and venetoclax (VEN) as maintenance therapy for acute myeloid leukemia (AML) patients in remission. American Society of Clinical Oncology Annual Meeting 2022.06.01

Outcomes of patients with newly diagnosed acute myeloid leukemia (AML) and hyperleukocytosis. American Society of Clinical Oncology Annual Meeting 2022.06.01

OUTCOMES AND MANAGEMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PRESENTING WITH HYPERLEUKOCYTOSIS. European Hematology Association Annual Meeting 2022.06.01

OUTCOME OF HYPERBARIC OXYGEN THERAPY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES -TERTIARY CANCER CENTER EXPERIENCE. European Hematology Association Annual Meeting 2022.06.01

NONLINIEAR IMPACT OF CLINICAL FEATURES ON THE SURVIVAL OUTCOME OF MYELODYSPLASTIC SYNDROMES PATIENTS. European Hematology Association Annual Meeting 2022.06.01

MUTATION PROFILES AND RISK STRATIFICATION IN HYPOCELLULAR MYELODYSPLASTIC SYNDROME. European Hematology Association Annual Meeting 2022.06.01

PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY. European Hematology Association Annual Meeting 2022.06.01

Treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) following the discontinuation of tyrosine kinase inhibitors. American Society of Clinical Oncology Annual Meeting 2022.06.01

PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN CHRONIC PHASE CML. European Hematology Association Annual Meeting 2022.06.01

Koji Sasaki. Artificial Intteligence in Hematology. 7th Taiwan-Japan Hematology Forum 2022.04.01

A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission. American Society of Hematology Annual meeting 2021.12.01

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks. American Society of Hematology Annual Meeting 2021.12.01

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results. American Society of Hematology Annual meeting 2021.12.01

Clinical and Pathological Characteristics of Hypocellular Myelodysplastic Syndrome: A Single-Center Retrospective Study. American Society of Hematology Annual meeting 2021.12.01

Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. American Society of Hematology Annual meeting 2021.12.01

Association between Bariatric Surgery and Outcomes in Patients with Chronic Myeloid Leukemia Treated with Oral Tyrosine Kinase Inhibitors. American Society of Hematology Annual meeting 2021.12.01

A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. American Society of Hematology Annual Meeting 2021.12.01

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. American Society of Hematology Annual meeting 2021.12.01

Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor “Triplet” Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML. American Society of Hematology Annual Meeting 2021.12.01

Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). American Society of Hematology Annual Meeting 2021.12.01

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. American Society of Hematology Annual Meeting 2021.12.01

Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents. American Society of Hematology Annual meeting 2021.12.01

Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy. American Society of Hematology Annual meeting 2021.12.01

NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML).. American Society of Hematology Annual meeting 2021.12.01

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. American Society of Hematology Annual meeting 2021.12.01

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). American Society of Hematology Annual meeting 2021.12.01

Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. American Society of Hematology Annual Meeting 2021.12.01

Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. American Society of Hematology Annual meeting 2021.12.01

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors. American Society of Hematology Annual meeting 2021.12.01

The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors. American Society of Hematology Annual meeting 2021.12.01

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. American Society of Hematology Annual meeting 2021.12.01

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton’s Tyrosine Kinase Inhibitor-Based Therapy. American Society of Hematology Annual Meeting 2021.12.01

Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2021.12.01

Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-line Tyrosine Kinase Inhibitors.. Japanese Society of Hematology Annual Meeting 2021.10.01

佐々木 宏治, Jabbour Elias, Issa Ghayas, Garciamanero Guillermo, Kadia Tapan, Wierda William, Yilmaz Musa, Dinardo Courtney, Skinner Jeffrey, Khouri Maria, Pemmaraju Naveen, Nasnas Patrice, Pierce Sherry, Cortes Jorge, Kantarjian Hagop. 慢性骨髄性白血病における三次治療としてのチロシンキナーゼ阻害薬の選択と予後(Optimal selection of third-line tyrosine kinase inhibitors in chronic myeloid leukemia). 日本血液学会学術集会 2021.09.01

CML-353: Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial. Society of Hematologic Oncology Annual Meeting 2021.09.01

Koji Sasaki. Treatment of lymphoid in blast phase. 23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy 2021.09.01

Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. American Society of Clinical Oncology Annual Meeting 2021.06.01

Contemporary outcomes for adults with AML requiring ICU admission. American Society of Clinical Oncology Annual Meeting 2021.06.01

PHASE II STUDY OF THE IDH2-INHIBITOR ENASIDENIB IN PATIENTS WITH HIGH-RISK IDH2-MUTATED MYELODYSPLASTIC SYNDROMES (MDS). European Hematology Association Annual Meeting 2021.06.01

Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS).. American Society of Clinical Oncology Annual Meeting 2021.06.01

A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS).. American Society of Hematology Annual Meeting 2020.12.01

Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS). American Society of Hematology Annual Meeting 2020.12.01

Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia. American Society of Hematology Annual Meeting 2020.12.01

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis.. American Society of Hematology Annual Meeting 2020.12.01

Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. American Society of Hematology Annual Meeting 2020.12.01

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. American Society of Hematology Annual Meeting 2020.12.01

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia.. American Society of Hematology Annual Meeting 2020.12.01

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia.. American Society of Hematology Annual Meeting 2020.12.01

Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma. American Society of Hematology Annual Meeting 2020.12.01

CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. American Society of Hematology Annual Meeting 2020.12.01

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. American Society of Hematology Annual Meeting 2020.12.01

Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation. American Society of Hematology Annual Meeting 2020.12.01

A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab.. American Society of Hematology Annual Meeting 2020.12.01

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. American Society of Hematology Annual Meeting 2020.12.01

Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors.. American Society of Hematology Annual Meeting 2020.12.01

Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure.. American Society of Hematology Annual Meeting 2020.12.01

Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression.. American Society of Hematology Annual Meeting 2020.12.01

Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib. American Society of Hematology Annual Meeting 2020.12.01

Only Hotspot SF3B1 K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes. American Society of Hematology Annual Meeting 2020.12.01

Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study. American Society of Hematology Annual Meeting 2020.12.01

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial. American Society of Hematology Annual Meeting 2020.12.01

Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS). American Society of Hematology Annual Meeting 2020.12.01

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). American Society of Hematology Annual Meeting 2020.12.01

Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2020.12.01

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. American Society of Hematology Annual Meeting 2020.12.01

Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors. American Society of Hematology Annual Meeting 2020.12.01

Impact of Hemoglobin Level As a Continuous Variable in Calculating Prognosis in MDS: Incorporation into LSC4 and IPSS-R. American Society of Hematology Annual Meeting 2020.12.01

Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). American Society of Hematology Annual Meeting 2020.12.01

Transcriptomic Features and Deregulation of Genes Involved in Monopoiesis Influence Outcomes of Patients with Chronic Myelomonocytic Leukemia. American Society of Hematology Annual Meeting 2020.12.01

The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. American Society of Hematology Annual Meeting 2020.12.01

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse. American Society of Hematology Annual Meeting 2020.12.01

Role of Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study. American Society of Hematology Annual Meeting 2020.12.01

Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Lymphoblastic Leukemia (ALL). American Society of Hematology Annual Meeting 2020.12.01

Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2020.12.01

Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib. American Society of Hematology Annual Meeting 2020.12.01

Predictors of Outcomes in Adult AML with MLL Rearrangements. American Society of Hematology Annual Meeting 2020.12.01

Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort. American Society of Hematology Annual Meeting 2020.12.01

Novel prognostic factor IKZF1 add for Ph+ B-ALL treated with hyper-CVAD plus dasatinib or ponatinib. Japanese Society of Hematology Annual Meeting 2020.10.01

The combination of intensive therapy with ponatinib for newly diagnosed Ph+ ALL. Japanese Society of Hematology Annual Meeting 2020.10.01

Low-dose Dasatinib 50 mg Daily versus Standard-dose Dasatinib 100 mg Daily in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. Society of Hematologic Oncology, Annual Meeting 2020.09.01

Outcomes of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Molecular Response at Three Months of Therapy. Society of Hematologic Oncology, Annual Meeting 2020.09.01

10-DAY DECITABINE AND VENETOCLAX (DEC10-VEN) VS. INTENSIVE CHEMOTHERAPY (IC) IN ACUTE MYELOID LEUKEMIA (AML): A PROPENSITY SCORE MATCHED ANALYSIS STRATIFIED BY RISK OF TREATMENT-RELATED MORTALITY. European Hematology Association Annual Meeting 2020.06.01

CHARACTERISTICS AND CLINICAL OUTCOMES OF MLL REARRANGEMENTS IN ADULTS WITH AML. European Hematology Association Annual Meeting 2020.06.01

EVOLUTIONARY ACTION SCORE OF MISSENSE TP53 MUTATIONS (EAP53) IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN MYELODYSPLASTIC SYNDROMES. European Hematology Association Annual Meeting 2020.06.01

Geographic disparity of outcome in patients with cancer over decades: The surveillance, epidemiology, and end results. American Society of Clinical Oncology Annual Meeting 2020.06.01

12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL). American Society of Hematology Annual Meeting 2019.12.01

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. American Society of Hematology Annual Meeting 2019.12.01

Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS). American Society of Hematology Annual Meeting 2019.12.01

Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm).. American Society of Hematology Annual Meeting 2019.12.01

A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). American Society of Hematology Annual Meeting 2019.12.01

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). American Society of Hematology Annual Meeting 2019.12.01

Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome. American Society of Hematology Annual Meeting 2019.12.01

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome. American Society of Hematology Annual Meeting 2019.12.01

Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting 2019.12.01

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes. American Society of Hematology Annual Meeting 2019.12.01

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). American Society of Hematology Annual Meeting 2019.12.01

Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL).. American Society of Hematology Annual Meeting 2019.12.01

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53. American Society of Hematology Annual Meeting 2019.12.01

Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes. American Society of Hematology Annual Meeting 2019.12.01

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2019.12.01

Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs). American Society of Hematology Annual Meeting 2019.12.01

Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). American Society of Hematology Annual Meeting 2019.12.01

Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). American Society of Hematology Annual Meeting 2019.12.01

Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR). American Society of Hematology Annual Meeting 2019.12.01

Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS).. American Society of Hematology Annual Meeting 2019.12.01

Guillermo Montalban-Bravo, Caleb Class, Irene Ganan-Gomez, Rashmi Kanagal-Shamanna, Koji Sasaki, Guillaume Richard-Carpentier, Kiran Naqvi, Yue Wei, Hui Yang, Kelly Soltysiak, Kelly S. Chien, Carlos E. Bueso-Ramos, Kim-Anh Do, Hagop M., Kantarjian, Guillermo Garcia-Manero. Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes. American Society of Hematology Annual Meeting 2019.12.01

The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). American Society of Hematology Annual Meeting 2019.12.01

The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI).. American Society of Hematology Annual Meeting 2019.12.01

The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2019.12.01

The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival. American Society of Hematology Annual Meeting 2019.12.01

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. American Society of Hematology Annual Meeting 2019.12.01

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse. American Society of Hematology Annual Meeting 2019.12.01

Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib. American Society of Hematology Annual Meeting 2019.12.01

Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs). American Society of Hematology Annual Meeting 2019.12.01

Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). American Society of Hematology Annual Meeting 2019.12.01

Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. American Society of Hematology Annual Meeting 2019.12.01

Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens. American Society of Hematology Annual Meeting 2019.12.01

Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet. American Society of Hematology Annual Meeting 2019.12.01

Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy. American Society of Hematology Annual Meeting 2019.12.01

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2019.12.01

Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). American Society of Hematology Annual Meeting 2019.12.01

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2019.12.01

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). American Society of Hematology Annual Meeting 2019.12.01

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting 2019.12.01

Frontline Inotuzumab with Low-Intensity vs. Intensive Therapy for Older Patients with Ph-neg ALL. Japanese Society of Hematology Annual Meeting 2019.10.01

Response prediction by machine learning in patients with newly diagnosed myelodysplastic syndrome.. Japanese Society of Hematology Annual Meeting 2019.10.01

Update Results of Hyper-CVAD with Ponatinib for Newly Diagnosed Ph+ ALL – Phase 2 Study. Japanese Society of Hematology Annual Meeting 2019.10.01

Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Society of Hematologic Oncology Annual Meeting 2019.09.01

Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Society of Hematologic Oncology Annual Meeting 2019.09.01

Hyper-CVAD Plus Ofatumumab as Frontline Therapy for Adults with CD20 Positive Acute Lymphoblastic Leukemia.. Society of Hematologic Oncology Annual Meeting 2019.09.01

Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Society of Hematologic Oncology Annual Meeting 2019.09.01

The Impact of Smoking on Relapse and Survival in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor. Society of Hematologic Oncology 2019 Annual Meeting 2019.09.01

Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia. American Society of Clinical Oncology Annual Meeting 2019.06.01

IDENTIFICATION AND TARGETING OF MOLECULAR SIGNATURES OF HYPOMETHYLATING AGENT RESISTANCE IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA. European Hematology Association Annual Meeting 2019.06.01

Patterns of leukemic transformation in patients with TP53-mutant myelodysplastic syndromes. American Society of Clinical Oncology Annual Meeting 2019.06.01

A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS).. American Society of Hematology Annual Meeting 2018.12.01

Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. American Society of Hematology Annual Meeting 2018.12.01

A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). American Society of Hematology Annual Meeting 2018.12.01

Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). American Society of Hematology Annual Meeting 2018.12.01

Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. American Society of Hematology Annual Meeting 2018.12.01

Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2018.12.01

Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. American Society of Hematology Annual Meeting 2018.12.01

Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. American Society of Hematology Annual Meeting 2018.12.01

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. American Society of Hematology Annual Meeting 2018.12.01

Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. American Society of Hematology Annual Meeting 2018.12.01

Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). American Society of Hematology Annual Meeting 2018.12.01

Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2018.12.01

Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia. American Society of Hematology Annual Meeting 2018.12.01

Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting 2018.12.01

Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase. American Society of Hematology Annual Meeting 2018.12.01

Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS).. American Society of Hematology Annual Meeting 2018.12.01

ng Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting 2018.12.01

Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting 2018.12.01

The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia. American Society of Hematology Annual Meeting 2018.12.01

Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI).. American Society of Hematology Annual Meeting 2018.12.01

Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial. American Society of Hematology Annual Meeting 2018.12.01

Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. American Society of Hematology Annual Meeting 2018.12.01

Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen. American Society of Hematology Annual Meeting 2018.12.01

Somatic mutations at remission serve as a minimal residual disease marker in acute myeloid leukemia. Japanese Society of Hematology Annual Meeting 2018.10.01

森田 聖美, Kantarjian Hagop, Wang Feng, Yan Yuanqing, Bueso-Ramos Carlos, 佐々木 宏治, Issa Ghayas, Wang Sa, Jorgensen Jeffrey, Song Xingzhi, Zhang Jianhua, Tippen Samantha, Thornton Rebecca, Coyle Marcus, Little Latasha, Gumbs Curtis, Pemmaraju Naveen, Daver Naval, Dinardo Courtney, Konopleva Marina, Andreeff Michael, Ravandi Farhad, Cortes Jorge, Kadia Tapan, Jabbour Elias, Garcia-Manero Guillermo, Patel Keyur, Futreal P. Andrew, 高橋 康一. 急性骨髄性白血病の寛解期に検出される遺伝子変異は微小残存病変として機能し予後予測に有効である(Somatic mutations at remission serve as a minimal residual disease marker in acute myeloid leukemia). 臨床血液 2018.09.01

佐々木 宏治, Jabbour Elias, Khouri Maria, Thomas Deborah, Garcia-Manero Guillermo, Ravandi Farhad, Borthakur Gautam, Short Nicholas, Issa Ghayas, Kadia Tapan, Jones Emily, Garris Rebecca, Cortes Jorge, Obrien Susan, Kantarjian Hagop. 新規発症急性リンパ性白血病に対するリポソーム封入ビンクリスチンを用いたHyper-CMAD療法による第II相試験(Hyper-CMAD with liposomal vincristine in patients with newly diagnosed acute lymphoblastic leukemia). 臨床血液 2018.09.01

佐々木 宏治, Kantarjian Hagop, Ravandi Farhad, Short Nicholas, Daver Naval, Pemmaraju Naveen, Thomas Deborah, Yilmaz Musa, Kadia Tapan, Garris Rebecca, Garcia-Manero Guillermo, Dinardo Courtney, Konopleva Marina, Estrov Zeev, Jain Nitin, Wierda William, Jeanis Vicki, Cortes Jorge, Obrien Susan, Jabbour Elias. 新規発症Ph陽性急性リンパ性白血病に対するポナチニブ併用Hyper-CVAD療法による第II相臨床試験(Hyper-CVAD with ponatinib for Philadelphia chromosome positive acute lymphoblastic leukemia). 臨床血液 2018.09.01

佐々木 宏治, Kantarjian Hagop, Ravandi Farhad, Daver Naval, Kadia Tapan, Khouri Rita Beatrice, Yesid Alvarado, Burger Jan, Thomas Deborah, Garcia-Manero Guillermo, Dinardo Courtney, Pemmaraju Naveen, Short Nicholas, Schroeder Heather, Garris Rebecca, Bose Prithviraj, Jain Nitin, Naqvi Kiran, Wierda William, Verstovsek Srdan, Cortes Jorge, Konopleva Marina, Obrien Susan, Jabbour Elias. 新規発症CD20陽性急性リンパ性白血病に対するオファツムマブ併用Hyper-CVAD療法による第II相臨床試験(A phase 2 trial of hyper-CVAD plus ofatumumab for newly diagnosed CD20+ acute lymphoblastic leukemia). 臨床血液 2018.09.01

Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase. ESH-iCMLf International Conference CHRONIC MYELOID LEUKEMIA: Biology and Therapy 2018.09.01

Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes.. American Society of Clinical Oncology Annual Meeting 2018.06.01

A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results. American Society of Clinical Oncology, Annual Meeting 2018.06.01

A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting 2017.12.01

Dynamics of Measurable Disease at Remission Determines Survival in Patients (pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL). American Society of Hematology Annual Meeting 2017.12.01

Clonal Hematopoiesis of Indeterminate Potential - Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. American Society of Hematology Annual Meeting 2017.12.01

Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL). American Society of Hematology Annual Meeting 2017.12.01

A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting 2017.12.01

The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL). American Society of Hematology Annual Meeting 2017.12.01

Survival Outcome of Secondary Solid Cancer in Patients with Chronic Myeloid Leukemia. American Society of Hematology Annual Meeting 2017.12.01

Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). American Society of Hematology Annual Meeting 2017.12.01

Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML. American Society of Hematology Annual Meeting 2017.12.01

Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes. American Society of Hematology Annual Meeting 2017.12.01

Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI). American Society of Hematology Annual Meeting 2017.12.01

Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial. American Society of Hematology Annual Meeting 2017.12.01

Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL).. American Society of Hematology Annual Meeting 2017.12.01

Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI). European School of Haematology: 19th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy Top Scoring Abstract 2017.09.01

Phase II study of hyper-CMAD with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Society of Hematologic Oncology Annual Meeting 2017.09.01

A RANDOMIZED PHASE II STUDY OF IDARUBICIN AND CYTARABINE WITH EITHER CLOFARABINE (CIA) OR FLUDARABINE (FIA) IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. European Society of Hematology Annual Meeting 2017.06.01

Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study. American Society of Clinical Oncology Annual Meeting 2017.06.01

Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL). American Society of Clinical Oncology Annual Meeting 2017.06.01

Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.. American Society of Clinical Oncology Annual Meeting 2017.06.01

UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA. European Hematology Association Annual Meeting 2017.06.01

Updated Results of Frontline Ofatumumab-Hyper-CVAD in Adults with CD20+ Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Annual Meeting 2017.06.01

甲田 祐樹, 山崎 あずさ, 市村 直也, 佐々木 宏治, 野上 彩子. 巨核球でより顕著な異形成を認めたGATA2欠損症を伴う骨髄系腫瘍の2症例. 日本検査血液学会雑誌 2026.05.01

川口 爽良, 甲田 祐樹, 服部 公美, 大久保 有希, 市村 直也, 佐々木 宏治, 野上 彩子. 血小板凝集能検査におけるコラーゲン凝集の低下を特徴とし,先天性血小板機能異常症が疑われる一例. 日本検査血液学会雑誌 2026.05.01

Phase II Study of Ponatinib and Blinatumomab in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. Japanese Society of Medical Oncology Annual Meeting Presidential Session 2022.02.01

A Phase 2 Trial of Hyper-CVAD plus Ofatumumab for Newly Diagnosed CD20+ Acute Lymphoblastic Leukemia. Japanese Society of Hematology Annual Meeting 2018.10.01

Hyper-CMAD with Liposomal Vincristine in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Japanese Society of Hematology Annual Meeting 2018.10.01

Hyper-CVAD with Ponatinib for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Japanese Society of Hematology Annual Meeting 2018.10.01

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population. American Society of Hematology Annual Meeting 2023.12.01

Outcomes of myeloid malignancies in patients previously treated with PARP inhibitors for solid malignancies: A single institution experience. American Society of Clinical Oncology, Annual Meeting 2023.06.01

Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL). American Society of Hematology Annual Meeting 2019.12.01

Reduced-Intensity Chemotherapy Plus Inotuzumab Ozogamicin, With or Without Sequential Blinatumomab, is Highly Effective as First Salvage Treatment in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Society of Hematologic Oncology Annual Meeting 2019.09.01

The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia is a Strong Predictor for Survival. Society of Hematologic Oncology Annual Meeting 2019.09.01